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Abstract 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
transcription factor family plays a key role in the regulation of the immune 
response and the transcriptional response to infection through transcriptional 
activation of genes involved in those processes. The NF-κB response is regulated 
in the nucleus by the balance between ubiquitination and deubiquitination 
processes. Ubiquitination of the p65 subunit of NF-κB terminates the NF-κB 
response by targeting p65 for proteasomal degradation. Nevertheless, the 
ubiquitin molecules can be removed from targeted proteins by the action of 
deubiquitinating enzymes (DUBs). Ubiquitin-specific protease 7 (USP7) is a 
deubiquitinase enzyme from the ubiquitin-specific protease (USP) family which 
deubiquitinates p65. Besides p65 deubiquitination, USP7 is involved in a huge 
variety of biological processes due to stabilisation or localisation of proteins 
involved in those processes. USP7 is a multidomain protein formed by an N-
terminal Meprin and tumour necrosis factor receptor-associated factor homology 
(MATH) / tumour necrosis factor receptor-associated factor (TRAF) domain, a 
catalytic domain (CD) and five ubiquitin-like domains (UBLs) in the C-terminal 
region. p65 recognition by USP7 takes place through the C-terminal region, but 
the molecular determinants involved in the interaction are still unknown. New 
therapeutic compound design strategies are based on interrupting the 
interaction interface between both proteins involved in the interaction. 
Therefore, in order to design a specific inhibitor of the deubiquitinase activity of 
USP7 on p65 we performed a peptide array and subsequent alanine scan 
followed by site directed mutagenesis experiments. We concluded that UBL2 of 
USP7 is necessary for the interaction with p65. UBL2 deletion completely 
abolishes the interaction and the deubiquitinase activity of USP7 on p65. 
Specificity of this mutant was tested by immunoprecipitation assays with 
different USP7 substrates. In silico modelling revealed a putative binding pocket 
in USP7 UBL2 that may be targeted to inhibit the interaction with p65. Together 
our data suggest that a binding pocket present on UBL2 composed by amino-
acids 627-ARSNGTK-633, 736-EEVKPNLTER-745 and 757-LDELMDGD-764 directs 
the interaction with p65, besides UBL2 when deleted inhibits the interaction 
with p65 and subsequently its deubiquitination in a substrate specific manner.  
10 
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 ERAD   Endoplasmic reticulum-associated degradation 
 ERK   Extracellular signal-regulated kinase 
F FBS   Fetal bovine serum 
 FDA   United States food and drug administration 
 FOXO4  Forkhead box protein O4 
 FT   Flow through 
G GMPS   Guanosine monophosphate synthetase 
 GRR   Glycine rich region 
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 Abbreviation Name  
G GSH   Glutathione 
 GSK   Glycogen synthase 
 GST   Glutathione S-transferase 
H HDAC   Histone deacetylase 
 HECT   Homology to E6-AP C-terminal  
 HEK293T  Human embryonic kidney 293T cells 
 HIV-1 TAT  TAT protein of human immunodeficiency virus 1 
 HP   High performance 
 HRP   Horseradish peroxidase 
 HSV-1   Herpes simplex virus 1 
 HUBL   HAUSP/USP7 UBLs 
I ICP0   HSV-1 infected cell protein 0 
 IκB   Inhibitor of κB 
 IKK   IκB kinase 
 IL-1   Interleukin 1 
 IL-1R   Interleukin 1 receptor 
 IMIDS   Immunomodulatory drugs 
 ING4   Inhibitor of growth family member 4 
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 Abbreviation Name  
I IPTG   Isopropyl β-D-1-thiogalactopyranoside 
J JAMM   JAB/MPN/Mov34  
 JNK   c-Jun N-terminal kinase 
 Josephins  Machado-Joseph diseases proteases 
L LB   Luria Bertani 
 LPS   Lipopolysaccharide  
 LTβR   Lymphotoxin β receptor 
 LZ   Leucine zipper 
M MATH   Meprin and tumour necrosis factor receptor-  
    associated factor homology 
 MD   Molecular dynamics 
 MDM2   Mouse double minute 2 
 MSK   Mitogen and stress-activated protein kinase 
 NAE   NEDD8 activating enzyme 
 NAK   Numb-associated kinase 
 NBD   NEMO binding domain 
 NEM   N-ethylmaleimide 
 NEMO   NF-κB essential modulator 
 NES   Nuclear export sequence 
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 Abbreviation Name 
N  NF-κB  Nuclear factor kappa-light-enhancer of activated B  
    cells 
 NIK   NF-κB inducing kinase 
 NLS   Nuclear localisation sequence 
 NMR   Nuclear magnetic resonance 
 NSD1   Nuclear receptor-SET domain-containing protein 1 
NTD   USP7 N-terminal domain 
O ODN   Decoy oligonucleotide 
 ORF73   LANA from human herpes virus 8 
 OTU   Ovarian tumour proteases 
 OTUB1  OTU ubiquitin aldehyde binding 1 
P PAGE   Polyacrylamide gel electrophoresis 
 PBS   Phosphate-buffered saline 
 PBS-T   PBS 0.05% tween 20 
 PCAF   p300/CBP-associated factor 
PCR   Polymerase chain reaction 
 PDLIM   PDZ and LIM domains protein 2 
 Peli-1    Pellino E3 ubiquitin ligase 1 
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Abbreviation Name  
P PAMP   Pathogen-associated molecular pattern 
Pim   Proviral integration site for moloney murine   
   leukaemia virus 
 PK   Protein kinase  
 PPARγ   Peroxisome proliferator-activated receptor γ 
 PTD   Protein transduction domain 
 PIAS3   Protein inhibitor of activated signal transducer and  
    activator of transcription 3 
PTEN   Phosphatase and tensin homolog 
 PTM   Posttranslational modification 
Q qPCR   Quantitative PCR 
R RANK   Receptor activator of nuclear factor κB 
 RBR   RING between RING 
 RHD   REL homology domain 
 RING   Really interesting new gene 
 RIP1   Receptor interacting protein 1 
 RIPA   Radioimmunoprecipitation assay 
 RITA   Reactivating p53 and inducing tumour apoptosis 
 RNA   Ribonucleic acid 
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Abbreviation Name 
R RSK   Ribosomal s6 kinase 
S SCF   Skp, cullin, F-box containing complex 
 SDM   Site directed mutagenesis 
 SDS   Sodium dodecyl sulphate 
 SET   Suppressor of variegation-enhancer of zeste-trithorax 
 SFM   Serum free media 
 siRNA   Small interfering RNA 
 SL   Sesquiterpene lactones 
 SOC   Super optimal broth with catabolite repressor 
 SOCS1   Suppressor of cytokine signalling 1 
 SPOT   Synthetic peptide arrays on membrane support 
 SUMO   Small ubiquitin-like modifier 
T TAB   TAK1 binding protein 
 TAD   Transcription activating domain 
 TAK1   TGFβ activated kinase 1 
 TAT   Transactivating transcription protein 
 TBK   TANK binding kinase 
 TBP   TATA binding protein 
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 Abbreviation Name 
T TBS   Tris-buffered saline  
TBS-T   TBS with 0.05% Tween 20 
 TCR   T cell receptor 
 TE   Tris, EDTA  
 TEMED  Tetramethylethylenediamine 
 TIR   Toll/Interleukin 1 receptor 
 TIRAP   TIR domain containing adaptor protein 
 TLR   Toll-like receptor  
 TNF   Tumour necrosis factor 
 TNF-RSC  TNFR1-associated signalling complex 
 TNFR   Tumour necrosis factor receptor 
 TRADD  Tumour necrosis factor receptor type 1-associated 
death domain protein 
 TRAF   Tumour necrosis factor receptor-associated factor 
U UBA1   Ubiquitin-like modifier activating enzyme 1 
 UBL   Ubiquitin-like domain 
 UBL12   USP7 ubiquitin-like domains 1 and 2 
 UBL123  USP7 ubiquitin-like domains 1, 2 and 3 
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 Abbreviation Name 
U UBL12345  USP7 ubiquitin-like domains 1, 2, 3, 4 and 5 
UBL125  USP7 ubiquitin-like domains 1, 2 and 5 
 UBL145  USP7 ubiquitin-like domains 1, 4 and 5 
UBL34   USP7 ubiquitin-like domains 3 and 4 
 UBL345  USP7 ubiquitin-like domains 3, 4 and 5 
 UBL45   USP7 ubiquitin-like domains 4 and 5 
 UCH   Ubiquitin carboxy-terminal hydrolases 
 UHRF1  Ubiquitin-like with PHD and RING finger domains 1 
 UPS   Ubiquitin proteasome system 
 USP   Ubiquitin-specific protease  
 USP7   Ubiquitin-specific protease 7 
 UV   Ultraviolet 
W WB   Western Blot 
 WT   Wild type 
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1 General introduction 
1.1 Overview 
As this study focussed on the regulation of the NF-κB transcription factor family 
by the ubiquitin proteasome system (UPS), the introduction of this thesis will 
provide a broad overview of the NF-κB transcription factor family and the UPS 
components regulating the NF-κB signalling pathway and activity and will 
include; i) reviewing the characteristics of NF-κB protein members, ii) describing 
the tight regulation of NF-κB activation, iii) exploring the role of the UPS on NF-
κB regulation, and lastly iv) a broad overview of USP7 and its role recognising 
and deubiquitinating p65 subunit of NF-κB.  
1.2 NF-κB transcription factor family 
NF-κB is an evolutionary conserved inducible transcription factor family [1–3]. 
Despite its discovery as a protein bound to 5’-GGGACTTTCC-3’ DNA sequence in 
the intronic enhancer of the  B-lymphocyte-specific immunoglobulin κ chain [4, 
5], it is ubiquitously expressed in all mammalian cell types [1, 2, 6]. A wide 
range of stimuli such as inflammatory cytokines (tumour necrosis factor (TNF) α, 
interleukin 1 (IL-1)), bacterial products (lipopolysaccharide (LPS), doubled 
stranded deoxyribonucleic acid (DNA)) and pro-apoptotic stimuli (ultraviolet (UV) 
light, γ irradiation and oxygen free radicals) [7–10] lead to the activation of NF-
κB. NF-κB has a fundamental role in a number of biological processes such as 
cell survival, proliferation, differentiation and apoptosis [2, 11, 12]; as well as a 
key role in the control of immunity by controlling the immune innate and 
adaptive responses and immune homeostasis [7, 13, 14]. NF-κB is involved in 
those processes through the transcriptional induction of genes involved in them, 
e.g. chemokines, cytokines, adhesion molecules [6, 7, 15, 16] (for a more 
precise description and list of NF-κB target genes see Boston University NF-κB 
transcription factors’ web page, http://www.bu.edu/nf-kb/) (see Figure 1-1).  
Due to such wide effects on physiology, its dysregulation is associated with 
numerous pathological states including (but not restricted to) cancer, 
autoimmune diseases, neurodegeneration and inflammatory diseases [12, 17, 
18].  
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Figure 1-1 Multifaceted roles of NF-κB. NF-κB response is activated upon a wide variety of 
stimuli (green boxes) which induces the expression of hundreds of genes involved in different 
cellular processes (blue boxes). For a full list see http://www.bu.edu/nf-kb webpage. *PAMP: 
Pathogen-associated molecular pattern. 
 
1.2.1 NF-κB members 
The NF-κB family is encoded by 5 genes; NFKB1, NFKB2, RELA, RELB and cREL 
[15, 19] which code for 7 proteins p105 (precursor protein of p50), p100 
(precursor protein of p52), p50, p52, p65 (RelA), RelB and c-Rel [15] that 
through the formation of homo- and heterodimers generate 15 NF-κB species 
[19, 20]. Each NF-κB protein or subunit carries out specific biological roles 
depending on their co-factors and dimer specific affinities for DNA binding 
sequences [1, 19]. Once the dimers are formed, they bind to κB sites in 
promoters or enhancers of their target genes regulating their transcription by 
the recruitment of transcriptional co-activators or transcriptional co-repressors 
[21]. NF-κB specifically recognises and binds κB DNA elements with a consensus 
sequence as follows 5’-GGGRNYYYCC-3’, where R is an unspecified purine, Y is 
an unspecified pyrimidine and N is any nucleotide [22].  
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All 5 NF-κB subunits share a 300 amino-acids length N-terminal REL homology 
domain (RHD) [1, 15]. The RHD domain is responsible of the dimerisation of NF-
κB subunits, DNA binding, and binding to the inhibitory inhibitor of κB (IκB) 
protein family [1, 7, 16, 23]. The C-terminal region of the RHD is composed of a 
series of positively charged amino-acids which form a nuclear localisation 
sequence (NLS) [1]; while the N-terminal region contains an immunoglobulin like 
domain which regulates the DNA binding selectivity for each κB site [23] (see 
Figure 1-2). 
NF-κB subunits are divided into two groups depending on their ability to activate 
transcription.  p65, RelB and c-Rel contain a C-terminal transcription activating 
domain (TAD) enriched in abundant serines, acidic and hydrophobic amino-acids, 
which when mutated reduce or inhibit the transcriptional activity of these 
subunits [24]. c-Rel transactivating activity is weaker than p65 activity, but 
when there are increased levels of c-Rel, p65 activity is attenuated [1]. RelB, 
besides the TAD domain, requires the presence of an N-terminal Leucine Zipper 
(LZ) domain for transactivation activity, and only binds the DNA in complex with 
p50 or p52 [1]. p50 and p52, which are generated by the limited proteasomal 
degradation of p105 and p100 respectively, lack the TAD domain [15, 19, 21], 
thereby they do not have transactivational activity when present as homodimers 
[19] (see Figure 1-2). p50 and p52 can act via 3 different ways: 1) by altering the 
IκB-site specificity when forming a heterodimer with p65, RelB or c-Rel, 2) by 
repressing the transcription when bound to κB sites as homodimers, or 3) by 
promoting transcription by the recruitment of other TAD-containing proteins to 
the κB sites [21]. Therefore, dimerisation of the NF-κB subunits generates 15 
possible dimers, from which 12 are able to bind the DNA and potentially activate 
transcription of target genes [25]. The most common dimer in physiological 
conditions is p50-p65 [2, 20, 22, 26] which controls the immune response and 
cellular growth and development [22]. All subunits can homodimerise or 
heterodimerise with each other except for RelB, which is only able to form 
stable heterodimers with p50 and p52 [7, 24] (see Figure 1-3). 
Besides its specific activity on κB promoter sites, NF-κB has different DNA 
binding specificity and affinity depending on the dimer composition [1, 14]. 
These differences on DNA binding and specificity to interact with other 
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neighbouring factors of homo- and heterodimers allow them to have distinct 
biological functions, being able to target selective genes depending on the 
stimuli [1, 14]. 
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Figure 1-2 Members of the NF-κB family of transcription factors. Schematic representation of 
the NF-κB family members indicating their structural domains. All NF-κB members share a RHD in 
their N-terminal region, composed by an N-terminal region in charge of DNA binding followed by a 
region controlling the dimerisation and a NLS in its C-terminal region. p65, c-Rel and RelB contain 
a TAD in their C-terminal region. The precursor proteins p100 and p105 contain a C-terminal 
glycine rich region (GRR), an ankyrin repeat domain and a death domain (DD). The limited 
proteolytic degradation occurs after the GRR region, generating p50 and p52. 
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Figure 1-3 Possible NF-κB homo- and heterodimers. NF-κB subunits are able to form dimers via 
their RHDs. Only p65, RelB and c-Rel contain transactivating activity, therefore homodimers and 
heterodimers containing any of these subunits contain transactivating ability (pale pink circles). On 
the other hand, p50 and p52 lack the TAD domain and are not able to activate transcription, thus 
p50-p52 heterodimer and p50 or p52 homodimers have no transactivating ability (blue circles). 
However, not all dimer combinations are found in vivo (grey circles), RelB is only known to dimerise 
with p50 and p52. 
 
1.2.2 NF-κB members structure 
The interest during the past decades of knowing how NF-κB members dimerise 
and bind to the DNA promoter of their target genes has resulted in a number of 
solved X-Ray structures. A number of these solved structures are formed by the 
dimerisation of the NF-κB members in complex with the DNA helix but there are 
as well, structures of the NF-κB members in complex with interacting partners. 
The majority of the structures present on the Protein Data Bank are truncated 
versions of the NF-κB members containing their RHD. However there are also 
two three dimensional (3D) structures of a partial TAD region of the p65 subunit 
[27, 28].  
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NF-κB members’ 3D structure is highly similar among them (see Figure 1-4). Each 
subunit is formed by an N-terminal β-barrel, folded into an immunoglobulin like 
module and linked by a flexible linker to a C-terminal β-barrel, folded into an 
immunoglobulin like module [22, 29–34]. There are a few structural differences 
within subunits. p50 and p52 share strong similarity [34] and differ with p65 
secondary structure by the presence of a second α-helix on the N-terminal 
region of p50 [22]. RelB linker’s conformation differs with the linker 
conformation of the other subunits. RelB linker’s helical conformation is more 
prominent than in the other subunits [31]. The N-terminal β-barrel regulates 
DNA binding, while the C-terminal β-barrel is the most invariant part of the NF-
κB sequence and controls NF-κB dimerisation [29]. The dimerisation interface is 
similar in all NF-κB members and is composed by a central hydrophobic core 
surrounded by hydrogen bonds [22, 30, 31]. Differences in dimers stability is due 
to slight differences in this interface [22, 30, 31]. NF-κB dimers differ in their 
relative orientation of the N-terminal and C-terminal regions of the RHDs [29, 
34–39], even when they bind κB sites with the same core sequence [29]. 
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Figure 1-4 RHD 3D structures of the NF-κB members. p65 subunit from 1VKX is coloured in 
blue (amino-acids 19-291 of the murine protein), c-Rel from 1GJI in green (amino-acids 7-281 from 
Gallus gallus), RelB from 3DO7 in grey (amino-acids 1-400 pf the murine protein), p50 from 1SVC 
in purple (amino-acids 2-366 from Homo sapiens) and p52 from 3DO7 in light blue (amino-acids 
35-341 from Mus musculus). 
 
1.2.2.1 p65 subunit structure 
The most common dimer in cells is p50-p65 heterodimer [22]. p50-p65-DNA 
complex structure is available on the Protein Data Bank (PDB: 1VKX) [22]. 1VKX 
PDB file is composed of the 3D structure of p50-p65 heterodimer bound to the κB 
DNA of the intronic enhancer of the immunoglobulin light chain gene [22]. 
Despite being able to solve the 3D structure of the complex; p65 and p50 
proteins are truncated and correspond to the murine sequence of these proteins. 
p65 truncated protein in 1VKX is formed by amino-acids 19-291 [22]. Amino-acids 
19-291 are located within the RHD; while the TAD of p65 is not present on the 
structure (amino-acids 428-551) (see Figure 1-5)  [40]. However, regions of the 
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p65 TAD 3D structure in complex with protein interactors are also available 
which were solved through nuclear magnetic resonance (NMR) experiments (see 
Figure 1-5) [27, 28]. p65 TAD is divided into two domains TAD1 and TAD2, which 
are required for full transcriptional activity of p65 [40]. TAD1 is located in the C-
terminal region of p65 TAD (amino-acids 521-551) and restores a 95% of the full 
transactivating potential of p65 [40]. TAD1 contains a highly conserved region in 
542-546 and a short transient helical conformation in 534-546. There is a 
conformational change between the unbound and the bound state of p65, 
because of which this helical conformation turns into a clear α-helix 
conformation in the bound state [28]. On the other hand, TAD2 is located in the 
preceding region (amino-acids 428-521) in an extended conformation containing 
an N-terminal α-helix, a dynamically disordered C-terminal α-helix and two 
additional helical turns (449-452 and 465-468) which regulate the electrostatic 
contacts with interacting proteins. The region prior to one of these helical turns, 
D444-D448, is highly acidic containing 4 out of 5 negatively charged residues 
[27], contributing to the interaction with different proteins. On the other hand, 
TAD2 restores a 30% of the full transactivation ability of p65 [40]. However, p65 
TAD is a highly flexible region [27], which may undergo conformational 
rearrangements upon substrate binding. p65 is known to undergo conformational 
rearrangements of the RHD domain upon IκBα binding [36]. The N-terminal 
region of the RHD rotates, due to the flexibility of the linker, from an open 
unbound conformation to a close conformation [41]. These rearrangements allow 
variability in the DNA sequence recognition [36]. The flexibility of p65 makes 
difficult to solve the full length p65 3D structure. 
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Figure 1-5 Available 3D structures of p65 protein. A) 1VKX 3D structure of the p50-p65 
heterodimer RHDs in complex with the DNA helix. p65 is coloured in blue, p50 in purple and the 
DNA helix in yellow and pink. B) 5U4K 3D structure of the TAD1 of p65. C) 2LWW 3D structure of 
the TAD2 of p65. All 3D structures were analysed with Maestro Schrodinger Software. 
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1.3 NF-κB regulation 
NF-κB activity is tightly regulated [2]. This regulation is performed through 
several posttranslational modifications (PTMs) which control the activity of the 
central components in the NF-κB signalling [12, 42] such as phosphorylation, 
ubiquitination, acetylation and SUMOylation [42]. Of these PTMs ubiquitination 
of NF-κB subunits is a critical factor in the termination of the NF-κB response 
and is a major limiting factor in the expression of pro-inflammatory genes [15]. 
One key protein family in the regulation of the NF-κB response is the IκB family 
[6, 8]. The IκB family is formed by three different groups of proteins, the 
classical IκB proteins, the NF-κB precursor proteins and the atypical IκB proteins 
[43]. The classical IκBs are IκBα, IκBβ and IκBε, which sequester NF-κB dimers in 
the cytoplasm [43]. The NF-κB precursor proteins are p105 and p100, which 
following a limited proteolytic degradation, form p50 and p52 subunits 
respectively [43]. And the atypical IκB proteins, localised in the nucleus, are B-
cell leukaemia 3 (Bcl-3), IκBNS and IκBζ [15, 19, 43], which function is to 
modulate transcription of NF-κB genes by acting as transcriptional co-activators 
[15, 21, 43]. These IκB members share a series of ankyrin repeats which regulate 
binding of NF-κB dimers through their RHD domains [43, 44]. 
1.3.1 NF-κB activation 
Several pathways lead to NF-κB activation as a consequence of changes in the 
intracellular microenvironment [12], the majority of which converge on the IκB 
kinase (IKK) complex activation, which is composed by two catalytic subunits 
(IKKα and IKKβ) and a regulatory subunit (IKKγ/NF-κB essential modulator 
(NEMO)) [15, 17, 20], and subsequent IκB degradation [12]. Different receptor 
signalling  such as TNF receptors (TNFR), Toll-like receptors (TLR), Interleukin 1 
receptor (IL-1R), T cell receptors (TCR), B cell receptors (BCR), receptor 
activator of nuclear factor κB (RANK) and B cell activating factor (BAFF) 
receptor (BAFFR) results in the activation of the NF-κB response [12]. Signalling 
intermediates upstream of the IKK complex are shared between different NF-κB 
pathways; however, differences between pathways are based on conformational 
changes, protein-protein interactions and assembly of large protein complexes 
at those early steps of the NF-κB signalling pathways [12]. 
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1.3.1.1 Signalling pathways 
NF-κB activation is generally considered to take place through either the 
canonical or the non-canonical pathways [45, 46] (see Figure 1-6). 
1.3.1.1.1 Canonical pathway 
Typically in resting cells, NF-κB dimers are bound to IκB proteins in the 
cytoplasm. Activation of receptors including TLRs, TNFR and IL-1R [20, 46, 47], 
through TNFα, IL-1β, LPS [20, 46, 47] stimuli, leads to the activation of the IKK 
complex [7–10, 15]. The active IKK complex phosphorylates IκB proteins, leading 
to its ubiquitination by the E3 ligase SCFβTrCP complex and consequent 
proteasomal degradation [7–10, 15, 48, 49]. Then, the NF-κB dimers are free to 
translocate to the nucleus by their NLS, where they bind to different promoters 
to induce the transcription of various genes such as pro-inflammatory cytokines 
and chemokines, and initiate the immune response. An important NF-κB target 
gene is IκBα, which binds to the NF-κB dimers sequestering them back to the 
cytoplasm through a nuclear export sequence (NES), in a negative feedback loop 
[7–10, 15]. See Figure 1-6. 
1.3.1.1.2 Non-canonical pathway 
This pathway is activated mainly through a small number of members of the TNF 
receptor superfamily; such as lymphotoxin β receptor (LTβR), CD40, BAFFR and 
RANK [6, 7, 22, 42]. In this pathway p100 acts as an IκB protein and binds the 
RelB subunit masking its NLS domain, thereby sequestering it in the cytoplasm 
[6, 7, 22, 42]. Activation requires p100 processing to form p52 by proteasomal 
partial degradation [6, 7, 22, 42]. IKKα phosphorylates p100 targeting it for 
ubiquitination by the E3 ligase SCFβTrCP complex and subsequent proteasomal 
degradation [6, 7, 22, 42, 50, 51]. This pathway controls genes important in the 
regulation of homeostatic processes like lymphoid organogenesis, bone 
metabolism and B cell survival [2]. See Figure 1-6. 
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Figure 1-6 NF-κB signalling pathways. A) Canonical pathway. In resting cells NF-κB dimers are 
sequestered in the cytoplasm by the IκB protein family. Once the cell receives a stimuli, such as 
TNFα, IL-1 or LPS; the IKK complex is activated and phosphorylates the IκB proteins, tagging them 
for ubiquitination by the SCF-βTrCP E3 ligase complex and subsequent proteasomal degradation. 
NF-κB dimers are then free to translocate to the nucleus where they bind to the promoter of their 
target genes transcribing them including genes involved in inflammation, cell survival and innate 
immunity. B) Non-canonical pathway. In resting cells, RelB is bound to p100 precursor protein. 
Upon stimuli such as CD40L, LTβ, RANK ligand (RANKL) and BAFF, NF-κB inducing kinase (NIK) 
is activated and subsequently the IKK complex. IKKα phosphorylates p100, tagging it for 
ubiquitination by the SCF-βTrCP E3 ligase complex and subsequent controlled proteolytic 
degradation by the proteasome. As a result, RelB-p52 dimers are free to translocate to the nucleus 
where they bind their target genes promoters including genes involved in the lymphoid 
organogenesis, adaptive immunity, anti-inflammatory properties, B-cell maturation and 
osteoclastogenesis, transcribing them. 
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1.3.2 Posttranslational modifications 
A number of PTMs of different components of the NF-κB signalling pathway, not 
only of NF-κB members, influences NF-κB activity at different levels. These PTMs 
include phosphorylation, acetylation, methylation, SUMOylation, glycosilation, 
nitrosilation and ubiquitination among others [52–54]. See Figure 1-7. 
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Figure 1-7 NF-κB members PTMs. Location of the different PTMs (SUMOylation, cysteine 
oxidation/modification, methylation, acetylation, phosphorylation, ubiquitination and glycosylation) 
described within the structural domains of each NF-κB member. The PTM data are taken from the 
PhosphoSite webpage and corresponds to the human proteins of the NF-κB family members. 
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1.3.2.1 Phosphorylation 
Regulation of the NF-κB members through phosphorylation has been extensively 
studied and it has a critical role on regulation of the NF-κB activity [55]. There 
are several phosphorylation sites in all NF-κB members (see Figure 1-7) and some 
of these sites regulate the transcriptional activity of NF-κB dimers in a gene 
specific manner [56–61]. These phosphorylations are either a consequence of 
signalling from upstream components or they work as a crosstalk within different 
signalling pathways [17].  
Phosphorylation of p65 induces a conformational change on p65 which has 
effects on protein ubiquitination and stability, and protein-protein interactions 
[62, 63]. It contains several phosphorylation sites within its whole sequence (see 
Table 1-1). S276 and S536 are the most studied phosphorylation sites but they 
are not the only ones. The different phosphorylations can enhance 
transactivation, promote the degradation of the subunit, regulate DNA binding 
specificity, stimulate dimerisation, inhibit the transactivation activity and 
facilitate other PTMs [57, 64–67] (see Table 1-1). 
Table 1-1 p65 phosphorylation sites. 
 
Site Kinase Effect Reference 
S42 Unknown Inhibition, regulation of molecular 
association 
[64, 68] 
S45 PKA Inhibition, regulation of molecular 
association 
[64, 68–70] 
T71 Unknown Unknown PhosphoSite 
S112 Unknown Unknown [64] 
S131 IKKβ Unknown [68] 
T136 IKKβ Unknown [68] 
S180 Unknown Unknown [64] 
S205 Unknown Transactivation [58] 
S238 PKA Unknown [64, 68, 70–73] 
T254 Unknown Prolyl isomerisation, transactivation [65] 
S261 Unknown Unknown [68] 
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Site Kinase Effect Reference 
S269 Unknown Unknown [68] 
S276 PKA-C, 
MSK1, 
MSK2, 
Pim-1, 
RSKp90, 
PKCζ 
Transactivation, K310 acetylation 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
[63, 66, 74] 
[75–77] 
[78] 
[79] 
[80] 
[81] 
S281 Unknown Transactivation [58, 82] 
T305 Unknown Unknown [83] 
Y306 Unknown Unknown PhosphoSite 
T308 Unknown Unknown [83] 
S311 PKCζ K310 acetylation, transactivation [84–87] 
S316 Unknown Transactivation [88] 
T435 Unknown Transactivation [89, 90] 
S468 GSK3β 
IKKε 
IKKβ 
Inhibition 
Transactivation 
Slight inhibition 
[67] 
[56] 
[91] 
S472 Unknown Unknown [68] 
T505 Chk 1 Transactivation [56, 92, 93] 
S529 CK2 Transactivation, K310 acetylation [94–97] 
S536 IKKε, 
IKKβ, 
IKKα, 
RSK1, 
NAK/TBK1 
Transactivation, K310 acetylation 
Unknown 
Unknown 
Unknown 
Unknown 
[57, 98–101] 
[57] 
[57, 98, 99] 
[57, 102] 
[57] 
S547 Unknown Unknown PhosphoSite 
*Protein kinase (PK), mitogen and stress-activated protein kinase (MSK), proviral integration site 
for moloney murine leukaemia virus (Pim), ribosomal s6 kinase (RSK), glycogen synthase kinase 
(GSK), C-terminal Src kinase (CSK)-homologous kinase (Chk), creatine kinase (CK), numb-
associated kinase (NAK)/TANK binding kinase (TBK). 
 
1.3.2.2 Acetylation 
Acetylation of p65 is a reversible process which takes place in the nucleus [103, 
104]. p65 subunit could be acetylated through a reversible process at seven 
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lysine residues (K122, K123, K218, K221, K310, K314 and K315) [103]. Acetylation 
of the majority of p65 acetylated lysines takes place through the activity of the 
p300/CREB-binding protein (CBP) acetyltransferases [103] and the effect 
depends on the lysine residues acetylated. Acetylation regulates the 
transcriptional activation of NF-κB, the DNA binding affinity, the subcellular 
localisation and the ability to associate with IκBα (see Table 1-2) [103–106]. 
Acetylation can be reversed by the action of histone deacetylases (HDACs). 
HDAC3 deacetylates the acetylated forms of p65 at K218 and K221 promoting its 
interaction with IκBα and subsequent cytoplasmic translocation, repressing the 
transactivating activity of NF-κB; while deacetylation of K122 and K123 increases 
the DNA binding of p65, activating the transcriptional activity of p65 [103, 104]. 
Table 1-2 p65 acetylation sites. 
 
Site Acetyltransferase Effect Reference 
K122 p300/CBP 
PCAF 
Reduces DNA binding [103] 
K123 p300/CBP 
PCAF 
Reduces DNA binding [103] 
K218 p300/CBP Impairs IκB association [103, 104] 
K221 p300/CBP Enhances DNA binding [103–105] 
K310 p300/CBP Transactivational activity [105] 
K314 p300/CBP Transactivational activity [103, 106] 
K315 p300/CBP Transactivational activity [103, 106] 
* p300/CBP-associated factor (PCAF) 
 
1.3.2.3 Methylation 
The functional result of NF-κB methylation varies depending on the methylated 
site and the methylation state (mono-, di- or trimethylation) [107–109]. Several 
methylation sites has been identified on p65 subunit such as, K37 [108], K218, 
K221 [107], K314 and K315 [109]. Some of these methylations induce the 
ubiquitination and degradation of p65 terminating the NF-κB response [109], 
while others enhance the transcriptional activity of NF-κB [107, 108]. However, 
as it happens for the phosphorylation and acetylation, methylation is also a 
reversible process by the action of histone demethylases [107]. See Table 1-3. 
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Table 1-3 p65 methylation sites. 
 
Site Methyltransferase Effect Reference 
K37 Set9 Transactivational activity [108] 
K218 NSD1 Transactivational activity [107] 
K221 NSD1 Transactivational activity [107] 
K314 Set9 Ubiquitination and degradation [109] 
K315 Set9 Ubiquitination and degradation [109] 
* Nuclear receptor-SET domain-containing protein 1 (NSD1), suppressor of variegation-enhancer 
of zeste-trithorax (SET). 
 
1.3.2.4 SUMOylation 
SUMOylation occurs through the activity of the small ubiquitin-like modifier 
(SUMO) family of proteins [110, 111]. SUMOylation requires the action of a set of 
enzymes, SUMO activating protein, SUMO conjugating protein UBC9 and SUMO 
ligases [112].  It affects protein stability and promotes the nuclear translocation 
of the cytoplasmic dimers [111]. For example, SUMOylation of RelB subunit 
reduces RelB activity while its DNA binding capacity is intact [112]. p65 
SUMOylation by the SUMO ligase protein inhibitor of activated signal transducer 
and activator of transcription 3 (PIAS3) acts also as a repression mechanism, it 
prefers DNA bound p65 and is induced by NF-κB activation [113]. 
1.3.2.5 Ubiquitination 
Ubiquitination is crucial not only for the activation of the NF-κB response but 
also for the termination of it. Ubiquitin direct proteasomal degradation is 
required in the cytoplasm to free the NF-κB dimers from the IκB proteins and 
activate the NF-κB response, but also in the nucleus to terminate the NF-κB 
response [2, 42]. However, non-proteolytic ubiquitination is also required 
upstream of the IKK complex for the recruitment of necessary proteins. The 
regulation of the NF-κB activity through ubiquitination will be further detailed in 
section 1.4. 
1.3.2.6 PTMs crosstalk 
Besides the regulation through different PTMs, there is a crosstalk among them 
[114, 115]. For example phosphorylation of certain p65 serines promotes binding 
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of p300/CBP and subsequently, acetylation of p65. Phosphorylation also 
mediates ubiquitination of different proteins, as for example IκB proteins. On 
the other hand, p65 acetylation at K310 inhibits p65 methylation of K314, K315 
[114]. Several lysines on p65 could be methylated, acetylated or ubiquitinated, 
the mechanism by which one or the other PTM occurs remains unclear [114]. 
1.3.3 NF-κB inhibitors 
Inhibition of the NF-κB signalling pathway has been broadly studied. Here we 
summarise the strategies developed to target the NF-κB signalling pathway and 
give some examples of inhibitors of each strategy. The majority of the inhibitors 
target upstream components of the NF-κB signalling pathway such as the IKK 
complex or IκB proteins degradation. NF-κB inhibitors encompass a variety of 
natural products, chemicals, peptide proteins, synthetic compounds and cell 
penetrating peptides (CPPs). The CPP strategy is based on the ability of certain 
peptidic sequences, formed by 5-30 amino-acid residues rich in basic amino-
acids, to cross the cellular membrane and enter into the cell [116–123]. These 
CPPs present a high transduction efficiency and low cytotoxicity [119, 120] and 
are able to deliver a large variety of cargoes into the cell [116, 120, 121, 124]. 
NF-κB inhibitors can be classified, according to at which level of the signalling 
pathway they act, into the following groups; upstream IKK complex, IKK complex 
or IκB phosphorylation, IκB degradation, nuclear translocation of NF-κB, DNA 
binding of NF-κB and NF-κB transactivation (see Figure 1-8, Table 1-4 and Table 
1-5). 
The IKK complex is the first common level for the integration of many NF-κB 
activating pathways [7]. The strategy of NF-κB inhibitors targeting upstream the 
IKK complex is to block a signal before it activates this first common level. The 
targets of these inhibitors are the receptors receiving the stimuli, the adaptor 
molecules recruited to the receptors or the kinases activating the IKK complex. 
For example, TNFR inhibition by antibodies or blocking agents leads to the 
inhibition of TNF induced NF-κB response [125]. Within the adaptor molecules 
recruited to TNFR, we find tumour necrosis factor receptor type 1-associated 
death domain protein (TRADD), TRAF2 and TRAF6 [126]. ARH1 compound binds 
to TRADD and inhibits TRADD-TRAF2 interaction, therefore the activation of the 
NF-κB response [127]. A dominant negative mutant of TRAF2 inhibits the CD40 
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and TNFα mediated NF-κB activation [128], while a dominant negative mutant of 
TRAF6 blocks the IL-1 induced NF-κB activation [129]. On the other hand, 
Toll/interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP) is 
recruited to TLR4 following LPS stimulation [130]; a CPP containing the sequence 
of TIRAP, antennapedia (AntP)-TIRAP has been described to inhibit LPS induced 
NF-κB response [130, 131]. Additionally, a kinase deficient mutant of NF-κB 
inducing kinase (NIK) has been reported [132, 133]. NIK phosphorylates IKKα 
leading to the activation of the non-canonical pathway [42, 134]; this kinase 
deficient mutant of NIK, inhibits IL-1 and TNFα induced NF-κB activation [132, 
133].  
The IKK complex and subsequent phosphorylation of IκB proteins is the prime 
target of NF-κB signalling pathway inhibitors. These inhibitors can be classified 
into five groups depending on their mechanism of action. The first group are 
gene based inhibitors; dominant negative forms of IKKα and IKKβ are shown to 
block the NF-κB response [135–141]. These dominant negative mutants can be 
created by mutations on the adenosine triphosphate (ATP) binding site or by 
mutations on the kinase activation loop [136–141]. The second group is formed 
by ATP analogues with some specificity to interact with IKK such as β-carboline 
and SC-839 [142, 143]. Both ATP analogues have a preference for IKKβ. The third 
group is composed by allosteric inhibitors of IKK like BMS-345541 [144]. These 
inhibitors bind to an allosteric site on both IKKα and IKKβ leading to 
conformational rearrangements of their structure [144]. The fourth group 
contains compounds that interact with C179 of IKKβ like thiol reactive 
compounds (parthenolide, arsenite, and some epoxyquinoids) [145–148]. C179 is 
located in the activation loop of IKKβ between S177 and S181 which 
phosphorylation is required for IKKβ activation [42, 134]. This interaction might 
interfere with IKKβ phosphorylation and subsequent activation. And lastly, the 
fifth group is formed by CPPs targeting the interaction of NEMO with IKKα and 
IKKβ. The most studied peptide inhibits the NEMO binding domain (NBD). NEMO 
is a scaffolding protein [149] which does not contain a catalytic domain but is 
critical for IKK activation [150]. Cells lacking NEMO fail to respond to any 
inducers of the canonical pathway [150]. NEMO associates with IKKα and IKKβ 
through the NBD which is formed by a hexa-peptide sequence (LDWSWL) within 
the C-terminal region of IKKα and IKKβ [150].  Disruption of the interaction 
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between NEMO and IKKβ blocks TNFα induced NF-κB activation in cells [150]. 
Several CPPs directly target NBD; AntP-NBD [151, 152], transactivating 
transcription (TAT)-NBD [152–155] and protein transduction domain (PTD) 5-NBD 
[152, 156]. They interact with IKKβ and IKKα, although the function on IKKα is 
still unknown and they have a higher preference for IKKβ [152]. These CPP 
inhibitors effectively block TNFα induced IKK and NF-κB activation specifically 
[152].  
Inhibitors of IκB ubiquitination and degradation consist of inhibitors of the 
ubiquitination step and inhibitors of the proteasomal degradation. The synthetic 
compound Ro196-9920, has been described to inhibit IκBα ubiquitination in 
mouse models, subsequently blocking the NF-κB response [157]. Some 
phosphopeptides corresponding to the IκBα phosphorylation sites have also been 
shown to inhibit NF-κB signalling [158]. These phosphopeptides act as 
competitive inhibitors for binding the E3 ligase of IκBα, thus blocking the NF-κB 
response [158]. CPPs mimicking serine to alanine mutations of the 
phosphorylation sites of IκBα S32 and S36 have also been reported. TAT-IκBα 
(S32A, S36A) is known as TAT super repressor [116]. Inhibitors of the proteasome 
system include compounds like Bortezomib [159–161] and will be described in 
section 1.4.1.3.  
The nuclear translocation step has an important role in NF-κB activation. Several 
CPPs have been shown to inhibit p50 translocation. The best described CPP 
inhibiting nuclear translocation is SN50 [162, 163]. SN50 contains the NLS of p50 
subunit and blocks p50 nuclear translocation by binding the importin complex. 
However, it also inhibits the nuclear translocation of other transcription factors 
which used this system [162, 163].  
Targeting the NF-κB DNA binding ability is a more specific strategy in order to 
inhibit the NF-κB response. Novel compounds from clary sage (Salvia Sclarea) 
[164] and triterpene derivatives [165] are competitive inhibitors of the NF-κB 
proteins by binding to κB sites. Decoy oligonucleotides (ODNs) used this 
mechanism of action; they usually have modifications to increase their stability 
and affinity for κB sites [166–168]. Their therapeutic potential has been 
demonstrated in a number of animal models of inflammation and cancer [166–
168]. On the other hand, several compounds have been described to impaired 
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NF-κB DNA binding ability by forming covalent bonds with the NF-κB proteins. 
For example, sesquiterpene lactones (SL) inhibit NF-κB binding ability by 
interaction with C38 of p65, which is located in the DNA binding loop of p65 
[169, 170]. Some SLs are able to interact with homologous C residues of c-Rel 
and p50 [148]. However some SL like parthenolide, inhibit IKKβ as well [146]. 
Dehydroxymethylepoxiquinomicin (DHMEQ) forms adducts with C38 of p65, C62 
of p50, C144 of RelB and C27 of c-Rel impairing their DNA binding ability, thus 
inhibiting the NF-κB response [171–174].   
The last step of the NF-κB signalling pathway that can be targeted is the 
transactivation of NF-κB proteins. PTMs of the NF-κB proteins have effects on 
their transactivating activity [52–54]. Therefore, there are some CPPs designed 
to inhibit NF-κB p65 subunit phosphorylation [175, 176]. Phosphorylation of 
S276, S529 and S536 of p65 are required for normal transactivating ability of p65 
[66, 96, 99]. AntP-peptide containing p65 S276 and AntP-peptide containing S529 
and S536 effectively block TNFα, LPS and IL-1 induced NF-κB activation [175, 
176].  
Besides the above inhibitors directly targeting specific steps of the NF-κB 
pathway, bacterial [177–179], fungal [180, 181] and viral proteins [182], 
antioxidants [183, 184] and anti-inflammatory [185, 186] and immunosuppressive 
agents [187–189] have been described to inhibit the NF-κB response through 
different mechanisms like inhibition of the IKK complex, impairing the DNA 
binding, blocking IκB degradation and inhibiting the transactivation of NF-κB 
proteins. Additionally some United States food and drug administration (FDA) 
approved drugs have been demonstrated to inhibit NF-κB activity for example 
aspirin [185] and Bortezomib [190]. On the other hand, several compounds like 
D609, R031-8220, SB203580 [191], wortmannin and LY294,002 [192, 193] have 
been shown to indirectly inhibit NF-κB transactivation ability. 
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Figure 1-8 NF-κB signalling pathway inhibitors targets. Inhibitors of the NF-κB signalling 
pathway target different levels of the signalling cascade. These inhibitors are classified into 
different groups depending on which level of the signalling pathway they target. The first group 
targets components upstream the IKK complex, second group targets directly the IKK complex or 
IκB phosphorylation, the third group targets the IκB ubiquitination and degradation, fourth group the 
nuclear translocation of the NF-κB dimers, fifth group the ability of NF-κB dimers to bind the DNA, 
and lastly the sixth group targets the transactivation of the NF-κB dimers. 
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Table 1-4 Mutations inhibiting the NF-κB signalling pathway 
 
Target Mutant Function Reference 
Upstream IKK 
complex 
TRAF2 dominant 
negative mutant 
Inhibits CD40 and TNFα 
induced NF-κB response 
at receptor associated 
proteins level 
[128] 
Upstream IKK 
complex 
TRAF6 dominant 
negative mutant 
Inhibits IL-1 induced 
NF-κB response at 
receptor associated 
proteins level 
[129] 
Upstream IKK 
complex 
NIK kinase deficient 
mutant 
Inhibits IKK activation 
by NIK 
[132, 133] 
IKK complex IKKα dominant 
negative mutant 
Inhibits IKKα kinase 
activity 
[135–141] 
IKK complex IKKβ dominant 
negative mutant 
Inhibits IKKβ kinase 
activity 
[135–141] 
 
Table 1-5 Compounds directly inhibiting components of the NF-κB signalling pathway 
 
Target Compound Function Reference 
Upstream IKK 
complex 
Anti-TNFR antibody 
or agent 
Inhibits TNFα signalling 
at receptor level 
[125] 
Upstream IKK 
complex 
AntP-TIRAP Inhibits TLR4 signalling 
at receptor associated 
proteins level 
[130, 131] 
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Target Compound Function Reference 
Upstream IKK 
complex 
ARH1 Inhibits TRADD-TRAF2 
interaction 
[127] 
IKK complex β-carboline ATP analogue of IKK [142, 143] 
IKK complex SC-839 ATP analogue of IKK [142, 143] 
IKK complex BMS-345541 Allosteric inhibitor of 
IKK 
[144] 
IKK complex Thiol reactive 
compounds 
Interaction with C179 of 
IKK, inhibiting IKK 
phosphorylation and 
activation 
[145–148] 
IKK complex AntP-NBD 
TAT-NBD 
PTD5-NBD 
Inhibits the interaction 
of IKKα and IKKβ with 
NEMO, thus its 
activation 
[151, 152] 
[152–155] 
[152, 156] 
IκB ubiquitination 
and degradation 
Ro196-9920 Inhibits IκBα 
ubiquitination 
[157] 
IκB ubiquitination 
and degradation 
Phosphopeptides Competitive inhibitors 
of IκBα E3 ligase, thus 
inhibiting IκBα 
ubiquitination 
[158] 
IκB ubiquitination 
and degradation 
TAT-IκBα(S32A, 
S36A) 
Inhibits IκBα 
phosphorylation and 
subsequent 
ubiquitination 
[194, 195] 
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Target Compound Function Reference 
NF-κB nuclear 
translocation 
SN50 Inhibits p50 nuclear 
translocation 
[162, 163] 
NF-κB DNA 
binding ability 
Compounds from 
Salvia Sclarea 
Competitive inhibitors 
of κB sites 
[164] 
NF-κB DNA 
binding ability 
Triterpene 
derivatives 
Competitive inhibitors 
of κB sites 
[165] 
NF-κB DNA 
binding ability 
Decoy 
oligonucleotides 
Competitive inhibitors 
of κB sites 
[166–168] 
NF-κB DNA 
binding ability 
Sesquiterpene 
lactones 
Covalent binding with C 
residue on the active 
loop of the DNA binding 
domain 
[148, 169, 
170] 
NF-κB DNA 
binding ability 
DHMEQ Covalent binding with C 
residue on the active 
loop of the DNA binding 
domain 
[171–174] 
NF-κB 
transactivation 
AntP- p65 S276 Inhibits p65 S276 
phosphorylation 
[175] 
NF-κB 
transactivation 
AntP- p65 S529 and 
S536 
Inhibits p65 S529 and 
S536 phosphorylations 
[175, 176] 
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However, most of these strategies are not totally NF-κB specific and have also 
effects on other signalling pathways. Some targets of these inhibitors are shared 
members of different signalling pathways. Inhibition of these shared members 
may inhibit NF-κB response as well as PKR, c-Jun N-terminal kinase (JNK) and 
extracellular signal-regulated kinase (ERK) 1/2 [196–198]. As for other inhibitors 
the mechanism of action is not completely elucidated, additional investigation 
of the potential effects is needed [152]. Further investigation on NF-κB specific 
inhibition is required to properly develop a new specific NF-κB inhibitory 
compound. 
1.4 Ubiquitination in the regulation of the NF-κB 
response 
Ubiquitination has a key role in the activation and termination of the NF-κB 
response.  
1.4.1 The ubiquitin proteasome system 
The UPS is key for most of the regulated proteolysis in the cells [199] but it also 
has non-degradative functions. Some of these functions are; regulation of the 
cell cycle [200]; cancer and cell survival [200]; immune response by the 
digestion of external or internal proteins into peptides which are presented by 
antigen presenting cells [201]; protein misfolding, it collaborates in the 
elimination of misfolded proteins [202]; endoplasmic reticulum (ER) associated 
degradation  (ERAD) by its involvement on the degradation of misfolded proteins 
[203, 204]; and inflammatory responses by its role on the NF-κB response [205] 
(see section 1.4.2). It has a huge variety of substrates and malfunction of the 
UPS is involved in several pathologies such as cancer [206, 207], cardiovascular 
disease [208], viral diseases [209] and neurodegenerative disorders [210] among 
them. 
Proteins targeted for proteasomal degradation by the proteasome are tagged by 
the addition of ubiquitin molecules [211, 212]. Ubiquitin is a small molecule of 
76 amino-acids which is covalently attached to the target proteins by an 
isopeptide bond between the carboxy terminal of the C-terminal glycine (G76) 
and the primary amine of a lysine of the target protein or the ubiquitin itself 
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[213, 214]. Ubiquitin contains 7 lysines (K6, K11, K27, K29, K33, K48 and K63) 
and the N-terminal methionine (M1) which can serve as an additional 
ubiquitination site [215–217]. The different polyubiquitin chain linkages lead to 
different structural conformations and different biological roles [215–217] (see 
Table 1-6). K11 and K48 linkages promote proteasomal degradation of target 
proteins [218–221]. The other K-linked polyubiquitin chains are involved in non-
proteolytic functions; such as, DNA damage response (K6, K27, K63) [222–226], 
adenosine monophosphate (AMP)-activated protein kinase (AMPK) related kinase 
signalling (K29, K33) [227], mitochondrial biology (K6, K27) [228–231], 
endocytosis (K63) [232] and NF-κB signalling (K63, M1) [226, 233–238] among 
others. 
Table 1-6 Polyubiquitin chains function in cells 
 
K-linkage Function Reference 
M1 NF-κB activation [233–238] 
K6 DNA damage response 
Parkin mediated mitophagy 
[222, 223] 
[228, 229] 
K11 Cell cycle regulation 
Proteasomal degradation 
ERAD 
Wnt/β-catenin signalling 
[239] 
[221] 
[240–242] 
[243] 
K27 PKC signalling pathway 
DNA damage response 
Parkin mediated mitophagy 
Differentiation and tolerance of T cells 
[244] 
[224] 
[230, 231] 
[245] 
K29 Differentiation and tolerance of T cells 
AMPK-related kinases regulation 
Wnt/β-catenin signalling 
[246] 
[227] 
[243] 
K33 Differentiation and tolerance of T cells 
AMPK-related kinases regulation 
Post-Golgi trafficking 
[247] 
[227] 
[248] 
K48 Proteasomal degradation 
Lysosomal degradation 
[218–220] 
[249] 
K63 
 
DNA damage response 
Stress response 
[225, 226] 
[250] 
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K-linkage Function Reference 
K63 
 
NF-κB signalling 
Endocytosis 
Lysosomal targeting 
[226] 
[232] 
[249] 
 
The ubiquitination process is regulated by a three step enzymatic cascade that 
involves the ubiquitin activating enzyme E1, a ubiquitin conjugating enzyme E2 
and a ubiquitin protein ligase E3 [211, 214]. The first step requires the 
activation of the ubiquitin molecule in an ATP dependent manner. This activated 
ubiquitin molecule is bound to the E1 enzyme by the formation of a thioester 
bond and is passed onto one E2 conjugating enzyme as an activated moiety. 
Lastly, the E2-ubiquitin binds the E3 ligase bound to the target substrate forming 
a complex and the ubiquitin molecule is then transferred onto the target protein 
[212, 214, 251]. In order to mark these target proteins for proteasomal 
degradation addition of several ubiquitin molecules by a K48-linkage occurs 
[212, 251]. See Figure 1-9. 
Polyubiquitinated substrates are delivered to the proteasome [251]. The 
proteasome is a ~2.5MDa multimeric subunit composed by two components, the 
20S core particle and the 19S regulatory particle [213, 214, 251, 252]. The 20S is 
organised in a barrel structure formed by 4 heptameric rings. The inner two are 
the β-rings formed by β type subunits, and the outer two are the α-rings formed 
by α type subunits. The active site is in the centre of the barrel and located in 
the β-rings, while the α-rings are more conserved forming a selective barrier 
between the catalytic site and the cytoplasm or nucleus of the cell [213, 214, 
252]. This active site contains different catalytic activities, trypsin like, 
chemotrypsin like and peptidyl-glutamyl-peptide bond hydrolysing activities 
[213]. This barrel is capped at either sides or single end by the regulatory 
particle 19S [213, 214, 252]. The 19S regulates the gate opening for substrate 
proteasomal degradation. It contains several enzymatic activities and ubiquitin 
receptors promoting deubiquitination of substrates, unfolding of the target 
proteins and translocation into the 20S interior [213, 214, 252]. The 
deubiquitination of tagged substrates support the ubiquitin recycling within the 
cell [214]. This deubiquitination of the target protein takes place through the 
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activity of several DUBs such as RPN11, USP14 and UCH37 [253–256]. Once the 
target protein is in the interior of the 20S particle, is cleaved and degraded 
[213, 214, 252]. See Figure 1-9. 
However, ubiquitination is a reversible process, ubiquitin molecules can be 
removed by DUBs [257, 258] (see Figure 1-9). There is a balance between 
ubiquitination and deubiquitination; and depending on which activity level is 
higher, the result will be the ubiquitination of target proteins and subsequent 
proteasomal degradation or maintenance of the target protein [257, 259]. Thus, 
the importance of E3 ligases and DUBs in NF-κB response.  
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Figure 1-9 Schematic of the UPS system. The protein ubiquitination process is regulated by a 
three step enzymatic cascade that involves the ubiquitin activating enzyme E1, a ubiquitin 
conjugating enzyme E2 and a ubiquitin protein ligase E3. Firstly the ubiquitin molecule is activated 
in an ATP dependent manner and is subsequenty bound to the E1 enzyme. Secondly, the active 
ubiquitin is transferred to the E2 enzyme. And lastly, the ubiquitin molecule is transferred onto the 
target prtein via two different ways depending on the E3 ligase transferring the ubiquitin. RING and 
Ubox E3 ligases bind to the E2 enzyme and to the substrate directly transferring the ubiquitin from 
the E2 to the substrate. While for HECT and RBR E3 ligases the ubiquitin is firstly transferred from 
the E2 enzyme to the E3 ligase and then onto the target protein. Subsequently, addition of several 
ubiquitin molecules could occur. This protein ubiquitination could lead to proteasomal degradation 
prior ubiquitin molecules removal, cellular signalling or the ubiquitin molecule could be removed by 
DUBs rescuing the tagged protein from degradation. 
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1.4.1.1 E3 ligases 
Protein degradation selectivity by the UPS is controlled by E3 ligases [214]. 
While there are only two E1 enzymes, there are around 40 E2 enzymes and more 
than 600 E3 ligases; hence, substrate recognition and specificity is determined 
by E3 ligases [214], proving the important role of E3 ligases within the UPS 
system. There are four different subfamilies of E3 ligases; Really interesting new 
gene (RING) E3 ligases, Homology to E6-AP C-terminal (HECT) E3 ligases, Ubox E3 
ligases and RING between RING (RBR) E3 ligases [260–264]. These subfamilies 
differ in their E2 binding domains and substrate recognition domains, 
determining the specificity of the UPS action [260–264]. E3 ligases are helped by 
co-factors which modify E3 ligases’ intracellular localisation and subsequently 
localisation of the ubiquitinating activity [260–264]. The transfer of ubiquitin 
from the E2 enzyme to the substrate occurs via two different mechanisms [214, 
252]. RING and Ubox subfamilies bind to both, E2 and substrate, at the same 
time catalysing the transfer of ubiquitin directly from the E2 to the substrate 
[214, 252]. While HECT and RBR subfamilies require a two-step reaction process. 
Firstly, the ubiquitin is transferred from the E2 to the active cysteine of the E3 
and subsequently transferred from the E3 ligase to the substrate  [214, 252]. 
1.4.1.2 Deubiquitinase enzymes 
Ubiquitin can be removed from target proteins by the action of deubiquitinating 
enzymes [257, 258]. It is an essential mechanism in ubiquitin-mediated signalling 
networks [258]. For many proteins addition of a ubiquitin molecule supposes a 
decrease in their stability [259]; however, protein stability is restored by the 
removal of the ubiquitin molecule by DUBs [257]; hence, it is not only important 
the ubiquitination process but also the deubiquitination process. DUBs 
specifically cleave the isopeptide bond at the c-terminus of ubiquitin [265–267]. 
By this reaction, DUBs add an additional posttranslational regulation level. The 
cleavage of the isopeptide bond is made by a nucleophilic attack to the carbonyl 
group of the isopeptide bond, resulting in the hydrolysis of the bond linking the 
ubiquitin to the target protein or to itself [268, 269]. As a consequence of the 
reaction, a polyubiquitin chain or monoubiquitin chain and a non-ubiquitinated 
target protein are obtained. 
 60 
 
There are 95 putative DUBs encoded in the human genome, from which only 79 
are functional [270]. DUBs are divided into five families according to their 
protease domain. The majority of them are cysteine proteases but there is a 
small group which are zinc metalloproteases. The five cysteine protease families 
are; ubiquitin carboxy-terminal hydrolases (UCHs), USPs, ovarian tumour 
proteases (OTUs), Machado-Joseph diseases proteases (Josephins) and the MIU-
containing novel DUB family (MINDY); and the zinc metalloprotease family is 
formed by the JAB1/MPN/Mov34 (JAMMs) [258, 266, 267, 269, 271]. 
The purposes of DUBs’ activity are; processing of the ubiquitin precursors [272] 
and recycling of attached ubiquitin from molecules committed to degradation 
and consequently generating free ubiquitin, maintaining the ubiquitin 
homeostasis [273–275]; rescuing ubiquitinated proteins from proteasomal  and 
lysosomal degradation [276, 277]; controlling protein trafficking [278, 279]; 
increasing target protein expression [280]; editing the ubiquitin chains [265] and 
regulating intracellular processes such as, cell cycle progression [281], apoptosis 
[268, 282], reproduction [283], gene transcription [268], DNA damage and repair 
[281] and immunity [284–288]. DUBs carry out their function by; interaction and 
co-regulation of E3 ligases; hydrolysis and re-organisation of poly- and 
monoubiquitinated proteins; being active at certain localisations in the cell and 
facilitating or inhibiting proteolysis [269]. In order to act in the correct 
localisation and recognise the specific substrate, the activity of these DUBs has 
to be strictly regulated [266]. Therefore, action of DUBs is tissue specific and 
context-dependent [282]. Apart from substrate protein specificity, DUBs are able 
to distinguish between different ubiquitination chains and linkages [267, 289], 
adding an extra regulatory level of their activity. 
The mechanisms regulating DUBs deubiquitinating activity are; PTMs [290, 291]; 
protein interaction and allosteric activation [290, 292, 293]; redox regulation by 
reactive oxygen species [294]; specific subcellular localisation [295–298]; and in 
final instance, reactivity and conformation of their active site residues´ [299–
301]. 
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1.4.1.3 UPS inhibitors  
The ubiquitin and proteasome system has been an interesting subject for 
research in order to find novel therapeutic drugs. Several steps can be targeted 
within the proteasomal degradation pathway [302, 303] (see Figure 1-10). The 
proteasome itself can be directly inhibited. MG132 is the best known proteasome 
inhibitor and it is frequently used in research. MG132, also called carbobenzoxy-
L-leucyl-Leucyl-L-leucin, is a peptide aldehyde proteasome inhibitor [304] able 
to inhibit different types of proteases [304]. It covalently binds the active site of 
the β subunits of the proteasome effectively blocking the proteolytic activity of 
the 26S proteasome complex [305]. It has never been clinically tested due to 
rapid oxidation, but is a valuable tool in research [302]. Due to the proteasome 
being key in the cellular function, blocking its activity leads to cellular toxicity 
and cell death after prolonged treatment or high concentrations [306, 307]. 
However, only two proteasome inhibitors have been approved by the FDA; 
Bortezomib [159, 308–310] and Carfilzomib [311–314], both of them approved for 
the treatment of cancer. Several drugs have been discovered but due to toxicity, 
poor specificity or drug activity, none have been approved by the FDA yet, 
although some are currently in clinical trials [306, 307, 315].  
Components of the three enzymatic steps in the ubiquitination process can be 
targeted. Several E1 inhibitors have been developed. PYR-41 is an irreversible 
inhibitor of ubiquitin-like modifier activating enzyme 1 (UBA1) blocking its 
catalytic cysteine [316]. But it can also partially inhibit HECT E3 ligases activity 
[316]. PYDZ-4409 is also a UBA1 inhibitor [317]. JS-K is a nitric oxide producing 
prodrug which inhibits the ubiquitin binding to E1 enzymes [318]. Finally, 
MLN4924 inhibits the E1 NEDD8 activating enzyme (NAE) [319, 320]. NEDD8 is 
required for the activation of Cullin RING ligases (CRL) an E3 ligases subfamily 
[321–323]. MLN4924 inhibitor binds to the binding pocket of NEDD on NAE and 
subsequently all the CRL E3 enzymes stay in their inactive conformation [324]. 
Drugs targeting different E2 enzymes have also been developed, which is a more 
specific strategy than targeting E1 enzymes [325]. Different strategies have been 
used, either directly inhibiting E2 enzymes or blocking the transfer of ubiquitin 
to substrates [326–328]. As an example, CC0651 is an allosteric inhibitor of cell 
division cycle 34 (CDC34) E2 enzyme [326]. It binds into a pocket far from its 
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catalytic domain inducing conformational rearrangements which make it unable 
to transfer the ubiquitin into the target protein [326]. On the other hand, two 
different compounds have been designed to inhibit UBE2N-UBE2V1 E2 enzyme 
activity [327, 328]. UBE2N is the active subunit and the target for these two 
compounds [327–329]. NSC607923 is a small molecule compound which inhibits 
the UBE2N-ubiquitin binding [328]. BAY 117082 covalently modifies the reactive 
cysteine of UBE2N and possibly of several other E2 enzymes [327].  
Inhibitors of the ubiquitin ligation step target E3 ligases or their interaction with 
their target proteins. These include inhibitors of the Skp, cullin, F-box 
containing complex (SCF)SKP2 E3 ligase complex, by the disruption of the 
interaction between its components [330–332]. Three inhibitors of Cereblon 
(CRBN), an E3 ligase enzyme component of the complex CRL4
PDB1 have been 
approved by the FDA for multiple myeloma cancer treatment [333–335]. 
Thalidomide, Lenalidomide and Pomalidomide alter CRBN substrate preference 
and are called immunomodulatory drugs (IMIDS) [333–335]. Inhibitors of the 
mouse double minute 2 (MDM2) E3 ligase and p53 complex include Nutlins [336], 
MI219 [337] and reactivating p53 and inducing tumour apoptosis (RITA) [338]. 
RITA binds to p53 inhibiting its interaction with MDM2 [338], while Nutlins and 
MI219 bind to MDM2 inhibiting its interaction with p53 [336, 337]. Ubiquitin 
chains are also target of some inhibitory compounds [306, 339]. Ubistatins are 
small molecules which specifically bind to K48 linked ubiquitin chains changing 
the conformation of ubiquitin and impairing its recognition by polyubiquitin 
receptors of the proteasome [339]. 
DUBs have also been the subject of research in the field of UPS inhibitors [302, 
303]. All patented deubiquitinating enzyme inhibitors are largely reviewed in 
Deubiquitinases (DUBs) and DUB inhibitors: a patent review (Farshi et al, 2016). 
DUB enzymes inhibition shifts the ubiquitination-deubiquitination equilibrium 
towards ubiquitination and subsequent proteasomal degradation of the substrate 
proteins [302]. 
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Figure 1-10 Schematic of the UPS system inhibitors. Inhibitors blocking different steps of the 
ubiquitination process. PYR-41, PYDZ-4409 and MLN4924 compounds inhibit E1 enzymes activity 
while JS-K compound inhibits the binding of E1 enzyme to the active ubiquitin molecule. Similarly, 
CC0651 and BAY117082 inhibit E2 enzymes activity while NSC607923 inhibits the binding of the 
ubiquitin molecule to the E2 enzyme. IMIDS directly inhibit CRBN E3 ligase, however there are 
compounds inhibiting the E3-substrate interaction such as MI219, RITA and Nutlins which inhibit 
MDM2-p53 interaction. Ubistatins, on the other hand, inhibit the recognition of polyubiquitin chains. 
And lastly, Bortezomib, Carfilzomib and MG132 compounds inhibit the proteasome activity. 
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1.4.2 Ubiquitination in the NF-κB signalling pathways 
Ubiquitination of different components of the NF-κB signalling pathway is 
required for NF-κB activation. Different polyubiquitin chains play an important 
role in the activation and termination of the NF-κB activity. K48 polyubiquitin 
chains are essential for the activation of the NF-κB response in the canonical 
pathway but they also play an inhibitory role in the non-canonical pathway. 
Processing of the p100 and p105 proteins is required for p52 and p50 formation 
respectively [43]. p100 and p105 precursor proteins phosphorylation by the IKK 
complex is recognised by the E3 ligase complex SCFβTrCP. SCFβTrCP 
polyubiquitinates, with K48-linked polyubiquitin chains, p100 and p105 leading 
to their partial degradation and subsequent p52 and p50 formation respectively 
[42, 340, 341]. In the canonical pathway, ubiquitination and subsequent 
proteasomal degradation of the IκB proteins is required to free the NF-κB dimers 
leading to their nuclear translocation [7–10, 15]. Phosphorylation of IκBs by the 
IKK complex is also recognised by SCFβTrCP, which K48 polyubiquitinates the IκB 
proteins leading to their proteasomal degradation [341]. In this way, K48 
polyubiquitination is exerting its NF-κB signalling pathway activator role. 
Besides, the K48 polyubiquitination plays a positive role in the activation of the 
non-canonical pathway as well. In CD40 signalling, cellular inhibitor of apoptosis 
protein (cIAP) 1/2, which are recruited to CD40, ubiquitinate proteins associated 
to CD40 like TRAF2 and TRAF3, which leads to their proteasomal degradation 
and subsequent activation of the NF-κB activity [342]. See Figure 1-11. However, 
in the absence of a stimulus K48 polyubiquitination restricts the constitutive 
activation of NF-κB non-canonical pathway. In this case cIAP1/2 ubiquitinate 
NIK, leading to its proteasomal degradation and inhibiting the NF-κB constitutive 
activation [343–345]. See Figure 1-12. 
Addition of non-proteolytic polyubiquitin chains is also crucial for activation 
and/or termination of the NF-κB response. In the TNFR signalling, components of 
the TNFR1-associated signalling complex (TNF-RSC) undergo K63 and linear 
ubiquitination. The TNF-RSC is composed of proteins such as receptor interacting 
protein 1 (RIP1), cIAP1/2, TGFβ activated kinase 1 (TAK1) [346]. K63- and linear 
polyubiquitination of RIP1 by cIAP1/2 recruits TAK1 binding protein (TAB)-TAK1 
complex and activates its kinase activity phosphorylating and activating the IKK 
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complex, subsequently activating the NF-κB response [346–351]. Besides cIAP1/2 
ubiquitination, RIP1 could be linearly ubiquitinated by the LUBAC complex [352]. 
In the same way, K63-polyubiquitination by TRAF6 and linear polyubiquitination 
by LUBAC of NEMO promotes IKK activation [233, 351–358]. However, these 
linkages also play a role in the termination of the NF-κB response by the 
recruitment of negative regulators of NF-κB activity leading to its inhibition 
[359–361]. It has also been described that TNFα stimulation leads to K11 
polyubiquitination of RIP1 by cIAP1 leading to IKK activation and subsequent NF-
κB activation [236, 362]. K6- and K27-polyubiquitination of NEMO activates the 
NF-κB pathway in response to TNFα stimulation or virus infection respectively 
[363, 364]. K33-linked polyubiquitination of PKCζ inhibits the TCR signalling, 
thus inhibiting the NF-κB response [247]. Moreover, mixed polyubiquitin chains 
have been discovered, which can carry multiple recognition signals [365]. See 
Figure 1-13.  
Ubiquitination of NF-κB subunits is also critical in the termination of the NF-κB 
response and is a major limiting factor in the expression of pro-inflammatory 
genes [366, 367].  NF-κB ubiquitination and deubiquitination are DNA binding 
dependent [287, 366, 368]. DNA has a role as an allosteric regulator of NF-κB, 
inducing a conformational change in NF-κB structure [369, 370]. This change is 
recognised by the proteins of the ubiquitination apparatus, that differentially 
interact with DNA-bound versus nucleoplasmic NF-κB [369, 370]. This will be 
further described in section 1.4.2. See Figure 1-14. 
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Figure 1-11 K48-linked polyubiquitin chains positive role in NF-κB activation. During the NF-
κB signalling cascade, K48 ubiquitination and subsequent proteasomal degradation of proteins is 
required (highlighted in red boxes). In the canonical pathway, IκB proteins sequester NF-κB dimers 
in the cytoplasm, but K48 ubiquitination by the SCF-βTrCP E3 ligase complex and subsequent 
proteasomal degradation of these IκB proteins leads to translocation of the dimers into the nucleus. 
In the non-canonical pathway, receptor associated protein cIAP1/2 K48 ubiquitinates other receptor 
associated proteins such as TRAF2 and TRAF3 leading to their proteasomal degradation and 
subsequent NF-κB activation. Besides, K48 polyubiquitination by the SCF-βTrCP E3 ligase 
complex and controlled proteasomal degradation of p100 leads to the formation of RelB-p52 
dimers able to translocate to the nucleus and activate the NF-κB response. 
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Figure 1-12  K48-linked polyubiquitin chains negative role in NF-κB activation. In the non-
canonical pathway in the absence of a stimulus the receptor associated protein cIAP1/2 K48 
polyubiquitinates NIK leading to its proteasomal degradation and subsequent restriction of the NF-
κB constitutive activation (highlighted in the red box).  
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Figure 1-13 Non-proteolytic ubiquitination of the NF-κB signalling pathway. Receptor 
associated RIP1 protein could be K63 and K11 polyubiquitinated by cIAP1/2 and M1 
polyubiquitinated by cIAP1/2 and LUBAC. K11 polyubiquitination of RIP1 activates the IKK 
complex. K63 and M1 polyubiquitination of RIP1 recruits NEMO and subsequently activates the 
IKK complex, and TAB-TAK1 complex which phosphorylates and activates the IKK complex. 
NEMO protein, component of the IKK complex, could be M1 polyubiquitinated by LUBAC and K63 
polyubiquitinated by TRAF6 which leads to IKK activation. M1 polyubiquitin chains are coloured in 
grey, K11 polyubiquitin chains in blue, K48 polyubiquitin chains in yellow and K63 polyubiquitin 
chains in light purple. Non-proteolytic ubiquitination within the NF-κB signalling pathway is 
highlighted in the red box. 
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Figure 1-14 Nuclear NF-κB regulation by the ubiquitination/deubiquitination balance. NF-κB 
response is regulated in the nucleus by the ubiquitination/deubiquitination balance. Once the cell 
receives an stimuli it activates the NF-κB response, NF-κB dimers are free in the cytoplasm and 
translocate to the nucleus where they bind to their target gene promoters and transcribed them. In 
the nucleus, NF-κB dimers can be ubiquitinated by E3 ligases and subsequently degraded by the 
proteasome, terminating the NF-κB response. This ubiquitin process is reversible and ubiquitin 
molecules can be removed from target proteins by the action of DUBs. Removal of the ubiquitin 
molecules maintains an active NF-κB response. 
 
1.4.2.1 E3 ligases  
E3 ligases have an important role inducing NF-κB degradation. Almost all NF-κB 
subunits are known to be ubiquitinated and subsequently degraded by the 
proteasome system but the main focus is on p65 ubiquitination. The mechanism 
of action and the specific E3 ligase ubiquitinating each ubiquitination site on 
p50, p52, c-Rel and RelB are poorly understood.  
p52 is known to be ubiquitinated at K153, K229, K319 but no further information 
of the ubiquitination process on p52 is available [71, 371, 372]. p50 
ubiquitination is induced in response to TLR and TNFR activation and it requires 
p50 DNA binding [368]. Two ubiquitination sites have been identified K243 and 
K251 [71, 372, 373]. Herpes simplex virus 1 (HSV-1) infected cell protein 0 (ICP0)  
and it has been identified to interact with p50 and deubiquitinate it [374]. 
However the specific p50 ubiquitinating mechanism is still unknown. RelB 
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ubiquitination promotes transcriptional activity and it consists on different K-
linkages of polyubiquitin chains [375–377]. This suggests that RelB ubiquitination 
does not have a proteolytic role, although the different polyubiquitination chain 
types may have different functions. c-Rel ubiquitination sites have not yet been 
identified, although two E3 ligases interacting with c-Rel have been identified, 
pellino E3 ubiquitin ligase 1 (Peli-1) [378] and cIAP [344, 379]. Both proteins 
when overexpressed induce c-Rel ubiquitination, however, no evidence of direct 
ubiquitination of c-Rel by Peli-1 and cIAP has yet been reported [344, 378, 379].  
p65 protein is known to be ubiquitinated by several E3 ligases such as 
peroxisome proliferator-activated receptor γ (PPARγ) [380], inhibitor of growth 
family member 4 (ING4) [381–383], suppressor of cytokine signalling 1 (SOCS1) 
[384], ORF73 (LANA from human herpesvirus 8) [385], PDZ and LIM domains 
protein 2 (PDLIM2) [386] and HERC3-Ubiquilin1 [387], at several ubiquitination 
sites including K28, K56, K62, K79, K122, K123, K195, K310, K314 and K315 [380–
383] (see Table 1-7). HERC3 E3 ligase overexpression leads to p65 ubiquitination 
and degradation. However, this p65 ubiquitination requires the action of a 
second E3 ligase, ubiquilin1 [387]. PDLIM2 is a member of the actinin associated 
LIM protein family which interacts and promotes p65 ubiquitination, although in 
vitro p65 ubiquitination ability has yet not been demonstrated [386]. ORF73 is a 
cullin-5-RING ubiquitin ligase (ECS) type ligase complex which increases p65 
ubiquitination and subsequent degradation [385]. SOCS1 is also and E3 ligase 
forming part of a multisubunit ECS complex, ECSSOCS1 [384]. It was the first NF-κB 
E3 ligase identified, binding and ubiquitinating p65 promoting its proteasomal 
degradation [384]. PPARγ is a member of the superfamily of nuclear hormone 
factors which contains a RING finger domain acting as an E3 ligase inducing 
ubiquitination and degradation of p65 at K28 [380]. ING4 is a member of the ING 
family of chromatin modifying proteins which together with E2 enzyme UbcH3, 
induces K48-linked polyubiquitination of p65 at K62 [381–383]. 
Existence of several ubiquitin sites may be explained by the different binding 
requirements of distinct E3 ligases. Various p65 E3 ligases have been identified 
and although the ubiquitination site of all the identified E3 ligases has not been 
determined, the established ones do not overlap [380–383]. This suggests 
specificity of E3 ligases for p65 ubiquitination sites. 
 71 
 
Table 1-7 List of lysines ubiquitinated on p65 
 
Amino acid Enzyme Function Reference 
K28 PPARγ Degradation [380] 
K56 Unknown Unknown [381, 382] 
K62 ING4 Degradation [381–383] 
K79 Unknown Unknown [381, 382] 
K122 Unknown Unknown [381] 
K123 Unknown Unknown [381, 382] 
K195 Unknown Degradation [381, 388] 
K310 Unknown Unknown [381, 382] 
K314 Unknown Unknown [381] 
K315 Unknown Unknown [381, 382] 
 
1.4.2.2 Deubiquitinating enzymes 
Several DUBs are indirectly involved in NF-κB regulation by deubiquitination of 
different molecules upstream the NF-κB signalling pathway leading to activation 
or inactivation of the NF-κB response; such as deubiquitinase cylindromatosis 
protein (CYLD) [284, 389, 390], A20 [391–393], cellular zinc finger anti NF-κB 
(Cezanne) [286, 394], USP2 [395], USP11 [396, 397], USP14 [398], USP15 [399], 
USP18 [398], USP21 [400], USP22 [398] and USP35 [401]. In addition USP7 [287] 
and USP31 [402] deubiquitinate the p65 NF-κB subunit. p65 deubiquitination 
increases protein stability [287, 402]. The action of USP7 [287] and USP31 [402] 
is a mechanism for the control of transcription through the active recycling of 
ubiquitinated NF-κB. 
USP31, later called USP48, was discovered in 2004 [403]. This protein contains a 
conserved ubiquitin hydrolase region, a ubiquitin protease region and a 
ubiquitin-like domain [402, 403]. This enzyme inhibits TNFα-induced 
ubiquitination of p65 acting downstream of IKKβ [404]. It is located in the 
nucleus [402, 404] where it indirectly interacts with the p65 subunit of NF-κB 
through COP9 signalosome (CSN) association [402]. Inhibition of USP31 decreases 
NF-κB target gene expression while p65 expression is intact [402]. It 
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preferentially trims long ubiquitin chains and is selectively activated through 
association with K48-linked ubiquitin [402]. 
1.4.3 USP7 
USP7 (previously called HAUSP) was discovered in 1997 [405]. USP7 is a cysteine 
protease [406–408] that is located in the nucleus [409]. USP7 has a family 
conserved CD shared with the rest of USPs [406, 410, 411]. This conserved CD 
shares homology in its amino-acid sequence surrounding the catalytic triad, but 
also shares structural homology arranged in three architecture domains 
resembling the palm, fingers and thumb of a hand [406, 410–412]. While areas 
outside the CD are very divergent in their sequence and structure, leading to 
substrate specificity of each protein within the USPs [406, 411, 412]. USP7 
preferentially cleaves substrate-attached monoubiquitin and short polyubiquitin 
chains [413]. 
USP7 interacts with different subunits of NF-κB transcription factor; c-Rel, p50, 
p52, p65 and RelB subunits [287]. Interaction between USP7 and NF-κB is DNA 
dependent [282, 287]. USP7 binds p65 at the promoter of NF-κB target genes, 
regulating p65 ubiquitination and its stability at sites of transcription [282, 287]. 
The interaction with p65 is through the C-terminal region of USP7 [287]. Because 
of this, USP7 deubiquitinating activity is critical in determining the duration and 
strength of the NF-κB transcriptional response by opposing promoter associated 
ubiquitin activities [282, 287]. 
1.4.3.1 Structure 
There has been a huge effort elucidating the 3D structure of USP7, and USP7-
substrates complexes. USP7 is a 1103 amino-acid multidomain protein. USP7 is 
formed by an N-terminal MATH/TRAF domain, a CD containing the amino-acids 
forming the catalytic triad (Cys223, His 464, Asp 481), and a C-terminal region 
composed of five ubiquitin like domains (UBLs) and referred as HAUSP (USP7) 
ubiquitin-like domains (HUBL) (see Figure 1-15) [267, 414–417]. The MATH/TRAF 
domain is involved in substrate recognition, [414, 415, 417–419]. The UBLs 
present in the C-terminal region have two different functions. UBL 1, 2 and 3 
(UBL123) are involved in substrate recognition [41, 406, 408, 420, 421]. While 
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UBL 4 and 5 (UBL45) are essential, along with the C-terminal 20 amino-acids 
peptide (CTP), for full USP7 deubiquitinase activity [299, 408]. These structural 
domains are arranged in a way in which the fingers, palm and thumb [269, 411], 
create the ubiquitin binding pocket [408, 411]. 
 
Figure 1-15 USP7 protein structural domains. USP7 is a multidomain protein composed of an N-
terminal MATH/TRAF domain, a catalytic domain in charge of the deubiquitinase activity of USP7 
and 5 UBLs located in the C-terminal region, which is called HUBL. 
 
When looking for USP7 3D structure on the Protein Data Bank server, there are 
around 50 available structures. But none of them is formed by the full length 
USP7 protein. Recent studies have modelled a USP7 full length molecule [299].  
Unluckily this model is not available on the PDB server. This lack of a full size 
USP7 X-Ray structure is probably due to the size of USP7 (130KDa). Within all the 
available USP7 structures the whole USP7 is covered. For example; USP7 N-
terminal domain (NTD) and CD (PDB: 2F1Z); CD and CTP (PDB: 5JTJ); CD and 
UBL123 (PDB: 5J7T); and UBL domains 1, 2, 3, 4 and 5 (UBL12345) (PDB: 4YOC).  
On the other hand, USP7 is a flexible molecule, which is known to undergo 
conformational rearrangements when binding its substrates [299–301, 408]. The 
catalytic triad of USP7 is misaligned in the apo conformation of the protein; that 
is, when USP7 is not bound to its substrate. The loops close to the catalytic triad 
are in such  conformation that the ubiquitin binding is not possible due to steric 
impediments [299–301]. When ubiquitin is covalently bound to USP7, USP7 
undergoes conformational rearrangements leading to its active state [299–301]. 
In this active state the catalytic triad is aligned and there are no steric obstacles 
for ubiquitin binding [299–301]. The loop hindering the catalytic triad undergoes 
these conformational rearrangements making ubiquitin binding possible; this 
loop is called the switching loop [300, 408] and it is in charge of the active and 
inactive state of USP7. The conformational rearrangement of the switching loop 
results in the creation of an active cleft in which the CTP binds, stabilising the 
active conformation [299, 300]. The conformational rearrangements to mediate 
the shift between the apo and the active conformation are partly mediated by 
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the HUBL. The HUBL is formed by three modules; UBL 1 and 2 (UBL12) dimer, 
UBL3 and UBL45 dimer [300, 418, 422]. These modules are connected through 
flexible regions [300, 418, 422]. HUBL are also connected to the CD through a 
flexible α-helix [300]. Flexibility of these areas allows the appropriate position 
of UBL domains in order to be able to position the CTP on the active cleft and 
activate USP7. Flexibility of molecules is important in the regulation of substrate 
recognition and protein complexes formation, therefore the importance of a 
whole picture of the protein structure.  
1.4.3.2 Function and substrates 
USP7 acts on a variety of substrates, such as the p65 subunit of NF-κB [287], 
MDM2 [417], p53 [417], phosphatase and tensin homolog (PTEN) [423, 424], DAAX 
[423], claspin [425], forkhead box protein O4 (FOXO4) [426], DNA (cytosine-5)-
methyltransferase 1 (DNMT1) [420], ICP0 [41], ubiquitin-like with PHD and RING 
finger domains 1 (UHRF1) [427], N-Myc proto-oncogene protein [428] and 
Epstein–Barr nuclear antigen 1 (EBNA1) [429, 430]. In this way, USP7 has an 
effect in different biological processes such as apoptosis and senescence [300, 
418, 422, 431, 432], stress response [432, 433], DNA repair [300, 407, 418, 432, 
434, 435], epigenetic regulation [407, 422, 431], viral infection [407], 
tumourigenesis [407, 422, 431, 435], cell cycle control [431, 433], cell survival 
[422, 431, 432] and inflammatory response [407]. The ability of USP7 to control 
such a range of different processes relies on the variety of different substrates 
which targets. See Figure 1-16. 
USP7 targets a series of viral proteins such as ICP0 from HSV-1, EBNA1 from 
Epstein-Barr virus (EBV), vIRF4 and ORF73 from human herpes virus 8, UL35 from 
cytomegalovirus (CMV) and E1B-55K from adenovirus [435]. From these proteins, 
the most studied ones are ICP0 and EBNA1. USP7 was firstly discovered bound to 
ICP0 [405, 429]. ICP0 is crucial for effective lytic infection through the 
activation of viral genes during early stages of infection and alteration of the 
cellular levels of different proteins in the host [41]. On the other hand, EBNA1 
regulates viral gene transcription maintaining EBV in latently proliferating cells 
[436]. p53 is the best studied substrate of USP7 [407, 418, 422, 435]. However, it 
is not the only member of the p53 pathway which interacts with USP7. MDM2 E3 
ligase ubiquitinates p53 protein but is also a USP7 substrate [407, 418, 422, 435]. 
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The p53 pathway is involved in apoptosis and senescence, the stress response, 
DNA repair process, tumourigenesis and cell survival [431, 437, 438]. USP7 
effects on these processes are mainly through its activity on p53 and MDM2. In 
addition, DAXX, which is involved in apoptosis, cell survival and tumourigenesis 
processes [439, 440], is also a USP7 substrate [441]. Besides its activity on 
tumourigenesis through p53, MDM2 and DAXX it is also involved in 
neuroblastomas through its interaction with N-Myc [428]. USP7’s role in 
chromatin modification is through the action of substrates such as DNMT1 [41, 
300, 422, 433] and UHRF1 [41, 422]. DNMT1 is essential for the maintenance of 
methylation patterns in the genome [420, 442], while UHRF1 is an E3 ligase 
which recognises hemi-methylated DNA and recruits DNMT1 [41, 443]. In 
addition, UHRF1 [443], claspin [407] and p53 [431] are also involved in cell cycle 
control. Claspin controls the DNA damage checkpoint [407], while UHRF1 is 
required for the G1/S phase transition [443]. Finally, USP7 is involved in the 
inflammatory response by interaction with all NF-κB members [287]. USP7 is able 
to interact with all subunits of the NF-κB family but its deubiquitinase activity 
has only been studied on p65 subunit [287].  
 
Figure 1-16 Multifaceted USP7 role in cells. USP7 interacts with a broad variety of substrates 
(green box) and thus, it acts in a variety of biological processes (blue box). 
 
The importance of USP7 in various biological processes in the cell is reflected in 
the lethality of USP7 knockout mice [444]. USP7 is essential for early embryonic 
development in mice, USP7 knockout mice show deficiency in cell proliferation, 
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due to a failure of its blastocyst to proliferate [444]. Homozygous embryos at 
E6.5 are smaller and contain disorganised cells with no pro-amniotic cavity 
formation; at E7.5 they do not contained a recognisable structure and embryonic 
cells were reduced in number. USP7 knockout embryos dye between E6.5 and 
E7.5 [444]. Therefore, USP7 plays a crucial role within cellular biological 
processes. 
The crucial role of USP7 within different cellular biological processes makes it an 
interesting target for new therapeutic drugs. Although the main focus at the 
moment is at p53 pathway inhibition for different cancer treatments [445], the 
fact that is able to interact with such different proteins as EBNA1, ICP0, DNMT1, 
UHRF1 and NF-κB members, has increased its therapeutic potential for 
treatment of different diseases e.g. arthritis, infectious diseases and epigenetic 
disorders among others. 
1.4.3.3 USP7 inhibitors 
One of the first USP7 inhibitors developed is HBX 19,818 which forms a covalent 
bond with Cys223 in the catalytic site, blocking USP7 in a non-substrate specific 
manner [446]. More USP7 inhibitors were developed including P22077 [447], P509 
[448] and HBX 41,108 [446, 449]. These four inhibitors show similar effects on 
cells, on stability of p53, on transcription of p53 target genes and on p21 protein 
levels [446–449]. However, these inhibitors are not USP7 specific, having a 
broader effect on different cysteine protease DUBs such as USP9, USP5, OTU 
ubiquitin aldehyde binding 1 (OTUB1), UCH-L3, UCH-L1, USP8, USP14 and USP15 
[450–452]. Four recent studies developed specific inhibitors of USP7 [445, 453–
455]. The studies performed by Turnbull et al. and by Lamberto et al. are based 
on the conformational rearrangements underwent by the switching loop of USP7 
after ubiquitinated substrate binding [445, 454]. USP7 has a switching loop 
located in close proximity to the catalytic triad which has an active and an 
inactive state. The inhibitors XL-188, FT671 and FT827 bind into a pocket 
located in that switching loop in its inactive conformation, inhibiting the binding 
of USP7 to the ubiquitin molecule present in its substrate and keeping its 
enzymatic activity off [445, 454].  On the other hand GNE-6640 and GNE-6776 
non-covalently bind USP7 in close proximity to the catalytic triad attenuating 
the ubiquitin binding to the catalytic triad [453]. Similarly, oxadiazole 
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compounds recognize a binding pocket overlapping the catalytic pocket and 
therefore inhibiting substrate binding; and aminopyridine compounds bind to a 
functional site on the palm of USP7 CD impeding the binding of the target 
protein to the catalytic site [455]. These more selective inhibitors have similar 
in vivo effects to those less selective inhibitors. FT671 increases p53 level and 
MDM2 degradation leading to induction of p53 target genes, and promotes 
degradation of UHRF1 and DNMT1 in colorectal carcinoma HCT116 and bone 
osteosarcoma U20S cell lines [445]. It also stabilises p53 levels on human 
neuroblastoma IMR-32 cell line and MM.1S multiple myeloma cell line [445]. 
FT671 shows a dose-dependent inhibition of tumour growth on MM.1S cell line 
[445]. GNE-6776 and GNE-6640 have similar effects in vivo, they stabilise p53, 
promote MDM2 ubiquitination, upregulate p21, and decrease proliferation and 
caspase activation on TP53 wild type (WT) cell lines [453]. XL-188 increase p53 
and p21 proteins level and promotes HDM2 loss in MCF7 cells and MM.1S 
myeloma cells [454]. Oxadiazole and aminopyridine compounds increase p53 
level on SJSA osteosarcoma cells and reduce cell viability by cell cycle arrest on 
EOL-1, increasing the caspase activity [455]. See Figure 1-17. 
 
Figure 1-17 Schematic of the USP7 inhibitors. Chemical compounds developed to inhibit the 
deubiquitinase activity of USP7. HBX19,818, HBX41,108, P22077 and P509 inhibitors directly 
inhibit the catalytic activity of USP7 by the direct binding to the catalytic triad. GNE-6640, GNE-
6776, oxadiazole compounds and aminopyridine compounds by to a site in close proximity to the 
active site impeding the binding of the ubiquitin molecule to the catalytic triad. However, FT671, 
FT827 and XL-188 inhibitors bind to the switching loop in the apo conformation blocking the active 
state of USP7. 
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These approaches are USP7 specific but not substrate specific and would be 
expected to promote the ubiquitination of all USP7 substrates equally. These 
inhibitors inhibit the deubiquitinase activity equally in all its substrates; 
therefore, USP7 is not able to specifically deubiquitinate p53, MDM2, EBNA1, 
DAXX, DNMT1, UHRF1, p65 among other substrates. 
1.4.3.4 Substrate specificity and binding pockets 
Some of the crystallised USP7 components are solved in complex with USP7 
substrates, such as DNMT1 (4YOC), UHRF1 (5C6D), MDM2 (2F1X) p53 (2FOO) and 
ICP0 (5C56) among others. There is an increasing interest to discover the 
molecular determinants of USP7 involved in the recognition of its substrates. As 
USP7 is involved in a variety of biological processes, information on the specific 
residues involved in substrate recognition provides a unique target for each of 
USP7 substrates. USP7 substrates can be divided into two groups depending on 
the region of USP7 required for the interaction, the N-terminal or C-terminal 
region. p65 protein is known to be recognised by the C-terminal region of USP7 
(see Figure 1-18) [287].  
 
Figure 1-18 USP7 substrate binding specificity. Substrate recognition is performed by two 
different regions of USP7, the MATH/TRAF domain and the C-terminal HUBL. Several of its 
substrates are recognised by the N-terminal MATH/TRAF domain as it is the case of MDM2, 
EBNA1 and p53. On the other hand, the C-terminal HUBL is in charge of recognition of substrates 
such as p65, DNMT1, ICP0 and UHRF1. There are still several substrates which binding specificity 
has not been elucidated. 
 
ICP0 was the first USP7 substrate discovered and it is recognised by the C-
terminal region of USP7 [41]. Using a peptide binding technique, Pfoh et al, 
narrowed the interacting amino-acids involved in the sequence of USP7 [41]. 
They discovered that the peptidic sequence of ICP0 binds in a predominantly 
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negatively charged region of USP7 located on UBL2. This region of USP7 is 758-
DELMDGD-764, and the peptidic sequences used from ICP0 contain two lysines 
which interact with the negatively charged aspartate residues of USP7. Mutation 
of USP7 D762 and D764 decrease the interaction with ICP0 and also with 
guanosine monophosphate synthetase (GMPS) and UHRF1, two other known 
substrates of USP7 [41]. Following this advance on discovering the amino-acids of 
USP7 involved in the recognition of its substrates by the C-terminal region, Kim 
and Sixma analysed the pattern motif recognised by USP7 [418]. They used 
peptidic sequences of each substrate (DNMT1, GMPS, ICP0, UHRF1) and co-
crystallised them with USP7 UBL12 for substrates recognised by the C-terminal 
region [418]. They used the same approach to co-crystallised substrates 
recognised by the N-terminal region (MDM2, p53, EBNA1) with USP7 MATH/TRAF 
domain [418]. They identified the amino-acid motifs recognised by USP7. In the 
N-terminal region the consensus motif is formed by P/A/ExxS [418]. A region 
containing that motif in substrates recognised by USP7 is more likely to be part 
of the binding interface. While for the C-terminal region of USP7, the motif 
recognised on the substrates is a positively charged motif K/RxKxxxK [418]. This 
positively charged motif is recognised by a region located on UBL2 of USP7 
containing the 758-DELMDGD-764 area identified by Pfoh et al as an important 
region involved in the interaction with ICP0, UHRF1 and GMPS [41, 418]. While 
characterisation of the binding interface of these substrates has been identified, 
there are still substrates whose binding sites are still unknown.  
1.4.3.5 p65 interaction and deubiquitination 
USP7 has been identified as an NF-κB deubiquitinase, critical for NF-κB 
transcriptional activity [287]. Inhibition of the deubiquitinating activity of USP7, 
blocks the pro-inflammatory effectors transcription induced by the NF-κB 
response [287]. USP7 recognises p65 subunit through its C-terminal region and 
deubiquitinates it, but the specific molecular determinants involved in the 
binding interface are still unknown [287]. 
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1.5 Thesis aims 
 Identification of the molecular determinants involved on USP7-p65 
interaction.  
 Investigation of the interaction mechanism of USP7-p65 by the elaboration 
of a USP7-p65 structural model. 
 Identification of possible inhibitory peptides of USP7 deubiquitinase 
activity on p65.  
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2 Material and Methods 
2.1 Cell biology techniques 
2.1.1 Mice 
C57BL/6 WT mice were used for extraction of bone marrow (BM). All animals 
were housed within the Biological Central Research Facility at Glasgow 
University. Animals had access to food and water ad libitum. All experiments 
received ethical approval and were performed under the auspices of a UK Office 
License.  
2.1.2 Cell culture 
2.1.2.1 Maintenance 
Human embryonic kidney 293T (HEK293T) and RAW 264.7 (murine macrophages) 
cell lines were cultured in high glucose Dulbecco’s Modified Eagle Medium 
(DMEM) (Sigma, D6429) containing 10% heat inactivated fetal bovine serum (FBS) 
(Gibco 10500-064), 2mM glutamine (Sigma, G7513), and 100U/ml 
penicillin/streptomycin (Sigma, P0781). All cells were maintained at 37°C in a 
humidified environment with 5% CO2. Cells were sub-cultured three times per 
week following mechanical (RAW 264.7 cells) or enzymatic detachment 
(HEK293T) with 0.05% Trypsin ethylenediaminetetraacetic acid (EDTA) solution 
(Gibco, 25300-054). 
2.1.2.2 Bone marrow derived macrophages  
2.1.2.2.1 Bone marrow isolation 
BM was isolated from C57BL/6 mice for generation of primary bone marrow 
derived macrophages (BMDM) in vitro. Mice were sacrificed by CO2 asphyxiation 
and cervical dislocation. Hind legs were removed at the hip joint and excess 
tissue removed from the femur and tibia bones. In sterile culture conditions, 
bones were cleaned in sterile DMEM. Bones were then cut at each extremity and 
the BM was flushed with DMEM using a 21-gauge needle and a 10ml syringe. 
Isolated BM was collected and resuspended in sterile DMEM and filtered through 
a 40μm cell strainer to generate a single cell suspension. The BM suspension was 
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centrifuged for 5 minutes at 400g and resuspended in DMEM 10% FBS 
supplemented with glutamine and penicillin/streptomycin or freezing media 
(10% dimethyl sulfoxide (DMSO), FBS) for cryopreservation. 
2.1.2.2.2 BMDM differentiation and stimulation experiments 
Following isolation or cryopreservation, bone marrow was cultured in DMEM 10% 
FBS supplemented with glutamine, penicillin/streptomycin and 30% L929 
conditioned media (BMDM differentiation media) in sterile petri dishes, for seven 
days. Differentiation media was replaced on day 3 and any non-adherent cells 
were removed. By day 7, adherent monocytes/macrophage progenitors were 
differentiated into BMDMs. BMDMs were removed from petri dishes by incubating 
them with 5mM EDTA in sterile phosphate-buffered saline (PBS) at 37°C for 2 
minutes. Cells were washed in DMEM 10% FBS supplemented with glutamine and 
penicillin/streptomycin by centrifugation at 300rpm for 5 minutes and 
resuspended in DMEM 10% FBS supplemented with glutamine and 
penicillin/streptomycin. BMDMs were replated overnight in tissue culture treated 
dishes for subsequent experiments. 
2.1.2.3 Cryopreservation 
Cells were centrifuged for 5 minutes at 300rpm and pellets were resuspended in 
FBS containing 10% DMSO. Resuspended cells were frozen at -80°C for one day 
and then stored in liquid nitrogen. 
2.1.2.4 Plating conditions 
The number of cells plated in each tissue culture plate or dish depends on the 
cellular type cultured (see Table 2-1). 
Table 2-1 Cell plating conditions 
 
Plate/Dish Media volume No.HEK293T No. RAW 264.7 No. BMDM 
24 well 500μl 0.1 x106 0.2 x106 1 x106/ml 
12 well 1ml 0.25 x106 0.5 x106 1 x106/ml 
6 cm 5ml 2 x106 4 x106 1 x106/ml 
10 cm 10ml 5 x106 10 x106 1 x106/ml 
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2.2 Molecular biology techniques 
2.2.1 DNA transformation for routine plasmid preparation 
XL-1 Blue Competent cells (Agilent technologies, 200249) were used for 
transformation of DNA for routine plasmid preparation. 10ng of the desired DNA 
was added to 20μl of cells and incubated for 30 minutes on ice. Cells were 
subjected to a heat shock, 45 seconds at 42°C, and recovered from it for 2 
minutes on ice before the addition of 300μl of super optimal broth with 
catabolite repressor (SOC) media (Invitrogen, 5544-034, P/N 46-0700) for 1 hour 
at 37°C. Cells were plated in Luria-Bertani (LB) agar plates supplemented with 
their corresponding antibiotic (ampicillin 100μg/ml –Sigma Aldrich, A9518- and 
Kanamycin 50μg/ml –Melford, K0126-), and incubated overnight at 37°C. 
2.2.2 Plasmid preparation 
2.2.2.1 Midiprep 
A single bacterial colony was picked and inoculated into 5ml LB-Broth media 
supplemented with the corresponding antibiotic as explained above for a starter 
culture. The starter culture was incubated for several hours at 37°C shaking at 
150rpm. Afterwards, the starter culture was added to a 100ml culture 
supplemented with the respective antibiotic and incubated at 37°C shaking at 
150rpm overnight. Plasmid DNA was prepared following the Pure Yield Plasmid 
Midiprep System kit (Promega, A2495) protocol. Plasmid concentration was 
measured using a NanoDrop spectrophotometer. 
2.2.2.2 Miniprep 
5ml of LB-Broth media supplemented with the respective antibiotic was 
inoculated with a single colony and incubated overnight at 37°C shaking at 
150rpm. DNA was extracted using Qiaprep Spin Miniprep kit (Qiagen, 27104) 
following manufacturer’s instructions.  
2.2.3 Transfection 
HEK293T cells were transiently transfected using Turbofect transfection reagent 
(Thermo Scientific, R0531). Plasmids were incubated with serum free media 
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(SFM) and turbofect for 15 minutes at room temperature and added dropwise to 
the cells. The transfection ratios are as follows; 100:1:2 (SFM (µl): DNA (µg): 
Turbofect (µl)) (see Table 2-2). Within each experiment total plasmid 
concentrations were kept constant between samples by the addition of an empty 
expression vector. For a list of used plasmids see Table 2-11. 
Table 2-2 HEK293T cells transfection conditions 
 
Dish size #Cells SFM DNA Turbofect 
10cm 5 x10
6 400µl 4µg 8µl 
6cm 2 x10
6 300µl 3µg 6µl 
 
2.2.4 Gene expression analysis (qPCR) 
For real time polymerase chain reaction (PCR) or quantitative PCR (qPCR) 
analysis, ribonucleic acid (RNA) was extracted using RNeasy kit (Qiagen, 74104), 
QiaShreders (Qiagen, 79654) and RNase Free DNase Set (Qiagen, 79254) following 
manufacturer’s instructions. The RNA was reversed transcribed to 
complementary DNA (cDNA) using nanoScript RT Kit (Primer Design, RT 
nanoscript) following its protocol. qPCR was performed with Perfecta SYBR 
Green FastMix Rox (Quanta Bioscience, 95073-012) using QuantiTect Primer 
Assays (Qiagen) in a 384 well plate using QuantStudio 7 Flex (Applied Biosystems 
by Life Technologies) with the running conditions as described in Table 2-3. 
Data was normalised to TATA binding protein (TBP) and gene expression changes 
calculated using the 2-ΔΔCT method [456]. 
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Table 2-3 qPCR running conditions  
Stage Cycle Rate Temperature Time 
Hold  1  (1.6°C/s) 
(1.6°C/s) 
50°C 
95°C 
2 minutes 
10 minutes 
PCR  40 (1.6°C/s) 
(1.6°C/s) 
95°C 
60°C 
15 seconds 
1 minute 
Melt Curve 1 (1.6°C/s) 
(1.6°C/s) 
(1.6°C/s) 
95°C 
60°C 
95°C 
15 seconds 
1 minute 
15 seconds 
 
TBP primers were resuspended in Tris, EDTA (TE) buffer (Tris/HCl 1M pH8, EDTA 
0.5M pH8, H2O). Sequences and/or catalogue numbers of each primer are listed 
in Table 2-12. 
2.2.5 Synthetic peptide arrays on membrane support (SPOT)- 
synthesis of peptides and overlay Analysis 
SPOT-synthesis of peptides was performed by Dr. Kiely, (University of Limerick, 
Limerick, Ireland). Arrays were activated by incubation in 100% ethanol for 5 
minutes. The excess of ethanol was cleaned with tris-buffered saline (TBS) with 
0.05% Tween-20 (TBS-T) for 5 minutes. Arrays were then equilibrated in TBS-T 
for 10 minutes and blocked with 5% non-fat milk (Marvel) in TBS-T for 1 hour at 
room temperature. The interaction of glutathione S-transferase (GST) and GST-
p65 proteins with the peptide array was investigated by overlying the cellulose 
membrane with 10μg/ml of each protein in 1% milk/TBS-T overnight at 4°C. 
Arrays were washed three times for 5 minutes in TBS-T before immunoblotting 
with anti-GST primary antibody (Sigma G7781) for 2 hours at 1:2,000 dilution in 
5% Milk TBS-T. Arrays were washed as previously described and incubated for 1 
hour with anti-Rabbit horseradish peroxidase (HRP) conjugated secondary 
antibody (GE Healthcare NA934V). Arrays were washed as previously described 
and bound protein was detected with Western Bright ECL chemiluminescense 
substrate (Advansta K-12045-D50). Arrays were incubated in peptide array 
stripping buffer (buffer composition listed in Table 2-20) for 30 minutes at 70°C 
and washed twice for 10 minutes with TBS-T. Arrays were developed in the dark 
room and scanned on the Li-cor c-Digit machine to detect bound protein. 
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2.2.6 Site directed mutagenesis 
Site directed mutagenesis (SDM) of USP7 was performed using Quick Change 
Lightning Site Directed Mutagenesis Kit (Agilent Technologies, 210518-5) and Q5 
Site Directed Mutagenesis Kit (New England Biolabs, E05545) as per instructions. 
SDM primers were designed using NEBase Changer online tool 
(https://nebasechanger.neb.com/) from NEB and PrimerX online bioinformatic 
tool (http://www.bioinformatics.org/primerx/). 
High-performance liquid chromatography (HPLC) grade oligonucleotides were 
purchased from IDT Integrated DNA Technologies. 
Oligonucleotides sequences are displayed in Table 2-13. 
2.2.7 Cloning 
To remove and insert different epitope tags from previous plasmids from the 
group, human p65 WT, mouse p65 WT and mutants were sub-cloned into pCDNA 
3.1 vector (kindly donated by Graham Milligan’s Lab). Proteins’ cDNA was 
amplified from existing plasmids following the PCR amplification conditions 
describe in Table 2-4 and Table 2-5. See Table 2-14 for a list of used primers. 
Table 2-4 Cloning PCR components 
 
Product Concentration Volume Supplier Catalogue 
Number 
DNA 100ng/μl 1μl N/A N/A 
Primer F 100μM 5μl N/A N/A 
Primer R 100μM 5μl N/A N/A 
Q5 High Fidelity 
2X Master Mix  
2X 12.5μl NEB M0492S 
H2O N/A 1.5μl Qiagen 1039480 
Total N/A 25μl N/A N/A 
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Table 2-5 Cloning PCR running conditions 
 
Cycles Temperature Time 
1 98°C 30 seconds 
35 98°C 
Tm 
72°C 
10 seconds 
30 seconds 
1 minute 
1 72°C 2 minutes 
1 4°C ∞ 
 
Amplification products were run in a 1% agarose gel, with the addition of 
1/10,000 gel red (PAGE Gel Red Nucleic Acid, Biotium, 41008). Samples were 
loaded on loading buffer (10X Blue Juice Gel Loading Buffer, Invitrogen, 10816-
015) and their size was measured by the addition of a 1Kb DNA Ladder (Promega, 
G571A). Proteins were extracted from the gel with Pure Link Quick Gel 
Extraction Kit, according to manufacturer’s conditions (Invitrogen by Thermo 
Fisher Scientific, K210012).  
Purified proteins were digested overnight at 37°C, using the corresponding 
restriction enzymes following the conditions described in Table 2-6. 
Table 2-6 Cloning digestion components 
 
Product Volume Supplier Catalogue 
Number 
CutSmart Buffer  2μl NEB B7204S 
Restriction Enzyme 1 
HindIII 
1μl  
NEB 
 
R0104S 
Restriction Enzyme 2 
XbaI  
1μl  
NEB 
 
R0145S 
Purified protein // 
// Purified Vector  
16μl 
10μl + 6μl H2O 
N/A N/A 
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Digested products were run on an agarose gel and extracted from the gel as 
previously described. 
Purified digested products were ligated overnight at 16°C following the 
conditions described in Table 2-7. 
Table 2-7 Cloning ligation components 
 
Product Volume Supplier Catalogue 
Number 
Construct 6μl N/A N/A 
pCDNA3.1 2μl N/A N/A 
10X Buffer for T4 DNA ligase with 10mM ATP  1μl NEB B0202S 
T4 DNA ligase  1μl NEB M0202S 
Total 10μl N/A N/A 
 
20μl of XL-1 Blue Competent cells were transformed with 2μl of the ligation 
product following the protocol explained in section 2.2.1. 
12 colonies of each ligation product bacterial transformation were picked for 
colony PCR amplification following the conditions in Table 2-8 and Table 2-9. 
 
Table 2-8 Cloning colony PCR components 
 
Product Concentration Volume Supplier Catalogue 
Number 
DNA N/A Colony N/A N/A 
Primer F 10μM 1μl N/A N/A 
Primer R 10μM 1μl N/A N/A 
Q5 High Fidelity 2X Master Mix  2X 10μl NEB M0492S 
H2O N/A 8μl N/A N/A 
Total N/A 20μl N/A N/A 
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Table 2-9 Cloning colony PCR running conditions 
 
Cycles Temperature Time 
1 98°C 30 seconds 
35 98°C 
Tm 
72°C 
10 seconds 
30 seconds 
1 minute 
1 72°C 2 minutes 
1 4°C ∞ 
 
From the positively amplified colonies, 5 were selected for subsequent miniprep 
preparation (as explained in section 2.2.2.2), and sent for sequencing to ensure 
the success of the cloning. 
2.2.8 DNA sequencing 
Plasmid DNA sequencing was performed by GATC-Biotech LTD (Germany), using 
on site primers or specifically designed primers by GATC-Biotech LTD (Germany). 
See list of primers on Table 2-15. Sequencing results were analysed using 
Geneious Molecular Biology and NGS Analysis Tools (Biomatters LTD, New 
Zealand). 
2.3 Protein methodologies 
2.3.1 Glutathione S-transferase (GST) - protein purification 
BL21 DE3 cells (Agilent Technologies, 200131) were transformed with GST-p65 
mouse pET-42a(+) (GenScript, Lot.552515 S-2 S26776) by the addition of 150ng 
of DNA to the cells. Cells were incubated on ice for 30 minutes, and then 
exposed to a heat shock (45 seconds at 42°C), followed by incubation on ice for 
2 minutes and the addition of 100μl SOC medium (Invitrogen, 5544-034, P/N 46-
0700) for an hour at 37°C and shaking at 150rpm. Cells were plated onto LB agar 
plates containing 50μg/ml kanamycin. Plates were incubated overnight at 37°C. 
A single colony was isolated and incubated overnight in 5ml LB-Broth containing 
50μg/ml kanamycin. Cultures were incubated shaking at 150 rpm and 37°C. 
1.4ml of the overnight culture was added to 200ml LB-Broth containing 50μg/ml 
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kanamycin in a conical flask. Cultures were grown shaking at 150rpm and 37°C 
for 3 hours. Before induction, a 200μl aliquot was mixed with 200μl of 2X sodium 
dodecyl sulphate (SDS) loading buffer (buffer composition listed in Table 2-19), 
boiled for 5 minutes at 95°C and stored at -20°C (uninduced sample). Cultures 
were induced with 0.5mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
incubated for 3 hours shaking 150rpm at 37°C. Following induction, a 200μl 
aliquot was prepared as explained above for uninduced sample. Cultures were 
centrifuged at 18,000g for 25 minutes at 4°C. Pellets were frozen at -20°C for 30 
minutes. Pellets were transferred to 50ml tubes and frozen at -80°C. Pellets 
were thawed on ice and resuspended in 35ml of cold lysis buffer supplemented 
with two complete, mini, EDTA-free protease inhibitor cocktail tablets (Roche 
Diagnostics GmbH) (for buffer composition see Table 2-17). The resuspended 
pellet was sonicated for 25 minutes with 15 second pulses, and 45 second rest 
between each pulse (Soniprep 150 MSE SANYO). Lysates were cleared by 
centrifugation at 15,000g for 30 minutes at 4°C (Sigma Laboratory Centrifuges, 
4K15). Supernatant was transferred to a cold 50ml tube. 200μl of supernatant 
was added to 200μl 2X SDS loading buffer, boiled at 95°C for 5 minutes and 
stored at -20°C (crude lysate). GSTrap high performance (HP) column (GE 
Healthcare, Bioscience AB) was used to purify the GST recombinant p65. The 
column was firstly equilibrated with 5 volumes of binding buffer at a flow rate of 
5ml/min (for buffer composition see Table 2-17). The cleared supernatant was 
added to the column at a flow rate of 0.5ml/min and the flow through (FT) was 
collected. A 200μl aliquot of FT was prepared as previously described for the 
uninduced sample. Collected FT was re-run through the column at the same 
rate. The column was washed by the addition of 10 volumes of binding buffer at 
a flow rate of 5ml/min. First and last washes were collected and prepared as the 
uninduced sample described above. Protein was eluted by the addition of 10 
volumes of elution buffer at a flow rate of 3ml/min (for buffer composition see 
Table 2-17). Six elution samples were collected and prepared as describe above 
for the uninduced sample. Elutions were snap frozen and stored at -80°C. All 
prepared samples were analysed by SDS polyacrylamide gel electrophoresis 
(PAGE). Afterwards, column was washed and kept on storage buffer (for buffer 
composition see Table 2-18). 
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2.3.2 Protein extraction 
2.3.2.1 Non- denaturing whole cell extracts (HEK293T and RAW 264.7 cells) 
Cell culture media was aspirated from the plates and cells were gently washed 
with PBS 4°C. Cells were detached from the plate with PBS 4°C and pelleted at 
11,000g 4°C for 1 minute. Pellets were resuspended in 20μl-500μl 
radioimmunoprecipitation assay (RIPA) buffer (see Table 2-10 for RIPA buffer 
volumes and Table 2-21 for RIPA buffer composition). Resuspended pellets were 
incubated on ice for 30 minutes and the lysates were cleared by centrifugation 
at 16,000g for 10 minutes at 4°C. Supernatants were collected and quantified as 
explained in section 2.3.3 (Bradford Assay). 
Table 2-10 Non-denaturing lysis conditions 
 
Plate/dish RIPA buffer volume 
24 well plate 20μl 
12 well plate 50μl 
6cm dish 200μl 
10cm 500μl 
 
2.3.2.2 Denaturing whole cell extracts (HEK293T cells) 
Cells were incubated with 10mM N-ethylmaleimide (NEM) for 30 seconds prior to 
harvest. Cell culture media was aspirated from the plates and cells were gently 
washed with 4°C PBS containing 10mM NEM. Cells were detached from the 
pellets using 4°C PBS containing 10mM NEM and pelleted at 11,000g for 1 minute 
at 4°C. Pellets were resuspended in 100μl 1% SDS and boiled for 5 minutes at 
95°C. Cell pellets were disrupted by sonication, 5 cycles of 30 seconds at 30% 
amplitude, using Bandelin Sonopuls ultrasonic homogeniser HD 2070 with MS 73 
microtip. Lysates were cleared by centrifugation at 16,000g for 10 minutes at 
4°C. 
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2.3.3 Quantification 
Cellular protein extracts were quantified by Bradford Assay technique. 1μl of 
protein extracts was diluted in 1ml of 1X Bradford assay reagent (Protein Assay 
Dye Reagent Concentrate, Bio-Rad, 500-0006). A triplicate of each sample was 
measured using a spectrophotometric 96 well plate reader at 595nm absorbance 
(Tecan Sunrise, Magellan Software). An 8-point standard curve between 0-
10.5μg/ml of bovine serum albumin (BSA) was generated to determine unknown 
sample protein concentrations. 
2.3.4 SDS-PAGE protein gels 
Protein samples were denatured and separated by SDS-PAGE using the 
miniProtean Tetra Cell System from Bio-Rad. Cell extracts were diluted in 2X or 
4X SDS loading buffer and boiled for 5 minutes at 95°C to be denatured and 
samples were resolved in 8% acrylamide gels (see Table 2-23). Gels were run at 
120V for 60-100 minutes in 1X Tris-glycine running buffer (for buffer composition 
see Table 2-22). Resolved proteins were then detected by Western Blot (WB) 
(explained in section 2.3.5). 
2.3.5 Western blotting 
Proteins were denatured and separated as explained above in sections 2.3.2 and 
2.3.4. Resolved proteins were transferred to Amersham Protan 0.45μm NC 
Nitrocellulose Blotting membrane (GE Healthcare, Life Science, Amersham, 
10600007) using the Mini Trans-Blot Electrophoretic Transfer System from Bio-
Rad and 1X Tris-glycine Transfer Buffer (for buffer composition see Table 2-22). 
Nitrocellulose membranes were incubated in Ponceau solution (Sigma Aldrich, 
P7170) and washed with PBS-Tween-20 0.05% (PBS-T) to confirm proper transfer 
of the proteins from the gel to the nitrocellulose membrane. Membranes were 
incubated in 5% non-fat milk (Marvel)/PBS-T solution to block any non-specific 
binding of the antibodies to the membrane. Nitrocellulose membranes were then 
probed with primary antibodies in 5% milk/PBS-T overnight at 4°C and secondary 
antibodies in 5% milk/PBS-T for 1 hour at room temperature. After each 
antibody’s incubation, membranes were washed 3 times for 5 minutes in PBS-T. 
Secondary antibodies used were horse radish peroxidase (HRP) conjugated. 
Protein was detected with Western Bright ECL (Advansta, K12045-D50) or 
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Western Bright Sirius (Advansta, K12043-D20) chemiluminescent substrates. 
Membranes were scanned using the LI-COR c-Digit Model 3600 (USA). When 
multiple antibody reprobes for protein of the same or similar size was required, 
membranes were stripped using Restore Plus Western Blot Stripping Buffer 
(Thermo Scientific, 46430) as manufacturer’s instructions. Protein sizes were 
confirmed by the addition of a protein ladder (Thermo Scientific, 26616) and 
subsequent use of a chemiluminescent marker from Li-cor or a biotinylated 
protein ladder (Cell Signalling Technologies, 07/2017) and the addition of an 
anti-biotin antibody (Cell Signalling, 02/2017). 
2.4 Functional assays 
2.4.1 GST pulldown 
HEK293T cells were transiently transfected with the appropriate plasmid and 
transfection reagent amount (see Table 2-2). DMEM 10% FBS supplemented with 
glutamine and penicillin/streptomycin media was discarded from the dishes and 
cells were washed with cold PBS. Cells came off from the dish by the addition of 
cold PBS and pelleted by centrifugation for 1 minute at 11,000g at 4°C. Pellets 
were resuspended in 500μl pulldown lysis and binding buffer and incubated for 
30 minutes on ice. Cells were extracted by centrifugation for 10 minutes at 
16,000g at 4°C. Protein amount was quantified by the Bradford method 
described in section 2.3.3. Equal amounts of samples were transferred into a 
clean eppendorf and were diluted to a final volume of 1ml with pulldown lysis 
and binding buffer (see Table 2-21 for buffer composition). Diluted samples were 
precleared with 50μl of glutathione (GSH) agarose beads (Sigma Aldrich, G4510) 
for 2 hours in a rotator at 4°C and centrifuged at 14,000g 4°C for 2 minutes.  
Cleared samples were incubated for 2 hours with 50μl of GSH agarose beads and 
150nM of the purified recombinant GST-p65 or with 5μg of the commercially 
available GST-p65 (Enzo, BML UW9990-0050). Pulled down proteins were washed 
three times for 5 minutes on PBS-T and eluted by the addition of 30μl 2X SDS 
loading buffer, boiled for 5 minutes at 95°C. Samples were frozen at -20°C or 
subsequently analysed by WB. 
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2.4.2 Immunoprecipitation 
Non-denaturing whole cell extracts were prepared as explained in section 
2.3.2.1 and quantified as explained in section 2.3.3. Equal amount of protein 
(60μg) was diluted in RIPA buffer (0.1% Igepal) up to 20μl and 20μl of 2X SDS 
loading buffer, boiled at 95°C for 5 minutes and kept frozen for subsequent 
analysis. To immunoprecipitate the desired protein, equal amounts of proteins 
(1mg) were diluted in a final volume of 1ml with RIPA buffer (0.1% Igepal). 
Samples were precleared for 1 hour at the rotator at 4°C by the addition of 20μl 
of protein G agarose beads (EMD Millipore 16-266). Beads were discarded by 
centrifugation of the samples at 14,000g 4°C for 2 minutes. Samples were 
incubated with 20μl of protein G agarose beads and 1μl of the respective 
antibody, overnight on the rotator at 4°C. Immunoprecipitated proteins were 
washed three times with 1ml RIPA buffer and centrifugation at 11,000g 4°C for 1 
minute. Proteins were eluted from the beads by the addition of 30μl of 2X SDS 
loading buffer and boiling at 95°C for 5 minutes, incubation on ice for 2 minutes 
and centrifugation at 14,000g 4°C for 2 minutes. Samples were kept at -20°C or 
analysed via WB. 
2.4.3 Cellular ubiquitination assay 
Denatured whole cell extracts were prepared as describe in section 2.3.2.2. 
Equivalent volumes of lysates (10μl) were diluted in 10μl of RIPA buffer (1% 
Igepal CA-630, 20mM NEM) and 20μl of 2X SDS loading buffer. Lysates were 
boiled for 5 minutes at 95°C, incubated on ice for 2 minutes and centrifuged for 
2 minutes at 14,000g 4°C. They were kept at -20°C for subsequent analysis. The 
remaining volume of lysates (90μl) was resuspended in 900μl of RIPA buffer (1% 
Igepal, 20mM NEM). Samples were precleared for 30 minutes at 4°C in a rotator 
by the addition of 20μl of Protein G agarose beads (EMD Millipore 16-266). After 
centrifugation for 2 minutes at 14,000g 4°C, supernatants were transferred to a 
clean eppendorf and 20μl protein G agarose beads and 1μl of p65 antibody was 
added. Samples were immunoprecipitated overnight at 4°C on a rotator. 
Immunoprecipitated protein was washed 3 times on 1ml RIPA buffer followed by 
centrifugation at 11,000g and 4°C for 1 minute. Protein was eluted by the 
addition of 30μl of 2X SDS loading buffer, boiling for 5 minutes at 95°C, 
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incubation on ice for 2 minutes and centrifugation for 2 minutes at 14,000g 4°C. 
Samples were analysed by WB. 
2.4.4 Enzyme-linked immunosorbent assay (ELISA) 
The TNFα ELISA assay (TNFα ELISA, BD Bioscience, BD OptEIA, set mouse TNFα, 
555268) was performed according to manufacturer’s protocol. Absorbance was 
read at 450nm using Tecan Sunrise Plate reader and Magellan software. See 
Table 2-24 for buffer composition. 
2.5 Bioinformatic tools 
2.5.1 Multiple sequence alignment 
Multiple sequence alignment of the family members of the NF-κB family was 
performed using multiple alignment tool from Geneious R9 (Biomatters Ltd) 
software. 
2.5.2 Protein prediction software 
Prediction of the full-length structure of the p65 NF-κB member was performed 
by ROBETTA Software from the Baker Lab (http://robetta.bakerlab.org/). 
2.5.3 Crystal structure analysis 
Crystal structures were analysed with Maestro Schrodinger software and MOE 
software. Full length p65 was modelled using 1VKX PDB file and ROBETTA models 
of full length p65 protein, with Maestro Schrodinger software. Full length USP7 
was modelled using the following PDB files 5J7T, 4YOC, 5JTJ, 2F1Z, 5JTV, with 
Maestro Schrodinger software and MOE software. Full complex of the interaction 
was modelled by the addition of the heterodimer of p50-p65 from 1VKX PDB file. 
2.5.4 Crystal structure alignment 
3D structural alignments of the different members of the NF-κB family as well as 
USP7 alignment of different PDB files, was performed by Maestro Schrodinger 
software and MOE software. 
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2.5.5 Docking 
Modelled docking of the complex was performed with the help of Dr Matti 
Lepistӧ and Dr Christian Tyrchan (AstraZeneca, Gothenburg, Sweden) using 
Maestro Schrodinger software and MOE software.  
2.5.6 Statistical analysis 
Shapiro Wilk normality test and Mann Whitney test were performed with 
GraphPad Software. 
2.6 Plasmids 
Table 2-11 List of plasmids 
 
Protein Species Backbone Tag Tag 
position 
Antibiotic 
resistance 
USP7 Human pRK5 Flag N-terminal Ampicillin 
USP7 ΔMath Human pRK5 Flag N-terminal Ampicillin 
USP7  
ΔHUBL 
Human pRK5 Flag N-terminal Ampicillin 
USP7 
ΔUBL2345 
Human pRK5 Flag N-terminal Ampicillin 
USP7 
ΔUBL345 
Human pRK5 Flag N-terminal Ampicillin 
USP7 Δ45 Human pRK5 Flag N-terminal Ampicillin 
USP7 Δ5 Human pRK5 Flag N-terminal Ampicillin 
USP7 Δ4 Human pRK5 Flag N-terminal Ampicillin 
USP7 Δ3 Human pRK5 Flag N-terminal Ampicillin 
USP7 Δ2 Human pRK5 Flag N-terminal Ampicillin 
USP7 Δ1 Human pRK5 Flag N-terminal Ampicillin 
USP7 ΔLoop Human pRK5 Flag N-terminal Ampicillin 
USP7 
LoopSubs 
Human pRK5 Flag N-terminal Ampicillin 
USP7 
P804A 
Human pRK5 Flag N-terminal Ampicillin 
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Protein Species Backbone Tag Tag 
position 
Antibiotic 
resistance 
USP7 
K869A 
Human pRK5 Flag N-terminal Ampicillin 
USP7 DE Human pRK5 Flag N-terminal Ampicillin 
USP7 DD Human pRK5 Flag N-terminal Ampicillin 
USP7 DEDD Human pRK5 Flag N-terminal Ampicillin 
USP7 LDEL Human pRK5 Flag N-terminal Ampicillin 
USP7 
LDELDD 
Human pRK5 Flag N-terminal Ampicillin 
p65 Human pEF Ha C-terminal Ampicillin 
p65 Human pCDNA3.1   Ampicillin 
p65 Mouse pCMV Flag N-terminal Ampicillin 
p65 Mouse pCDNA3.1 Flag N-terminal Ampicillin 
p65 Mouse pCDNA3.1   Ampicillin 
p65 267A Mouse pCDNA3.1 Flag C-terminal Ampicillin 
p65 267A Mouse pCDNA3.1   Ampicillin 
p65 269A Mouse pCDNA3.1 Flag C-terminal Ampicillin 
p65 269A Mouse pCDNA3.1   Ampicillin 
p65 269D Mouse pCDNA3.1 Flag C-terminal Ampicillin 
p65 269D Mouse pCDNA3.1   Ampicillin 
p65 K56R Mouse pCDNA3.1 Flag N-terminal Ampicillin 
p65 K56R Mouse pCDNA3.1   Ampicillin 
p65 K62R Mouse pCDNA3.1 Flag N-terminal Ampicillin 
p65 K62R Mouse pCDNA3.1   Ampicillin 
p65 K123R Mouse pCDNA3.1 Flag N-terminal Ampicillin 
p65 K123R Mouse pCDNA3.1   Ampicillin 
Empty  pCDNA3.1 Flag N-terminal Ampicillin 
Empty  pCDNA3.1   Ampicillin 
Empty  pRK5 Flag N-terminal Ampicillin 
Bcl3 Mouse pRK5 Flag N-terminal Ampicillin 
p50 Mouse pRK5 Flag N-terminal Ampicillin 
c-Rel Mouse pRK5 Flag N-terminal Ampicillin 
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Protein Species Backbone Tag Tag 
position 
Antibiotic 
resistance 
RelB Mouse pEF4 Flag N-terminal Ampicillin 
DAXX Mouse pRK5 Flag N-terminal Ampicillin 
EBNA1 H. Herpes 
Virus4 (EBV) 
MSCV Flag/Ha N-terminal Ampicillin 
p53 Human pCMV   Kanamycin 
Ubiquitin* Human  Ha N-terminal Ampicillin 
GST-p65 Mouse pET 42 a+ GST N-terminal Kanamycin 
*Ubiquitin Ha plasmid (Matt Walsh Lab). 
2.7 Primers 
2.7.1 qPCR 
Table 2-12 List of qPCR primers 
 
Primer Sequence Supplier Catalogue 
Number 
mTBP 1 TGTTGGTGATTGTTGGT Eurofins N/A 
mTBP 2 AACTGGCTTGTGTGGGAAAG Eurofins N/A 
TNFα Quantitect Primer Assay 
Hs_TNF_1_SG 
Qiagen QT00029162 
 
2.7.2 Site Directed Mutagenesis 
Table 2-13 List of mutagenesis primers 
 
Primer Sequence Supplier 
USP7 ΔUBL2345 F CGAGCTGGCTGCTAGTGGATGAACCTTACCCAA
G 
IDT 
USP7 ΔUBL2345 R CTTGGGTAAGGTTCATCCACTAGCAGCCAGCTC
G 
IDT 
USP7 ΔUBL345 F GATAACAGTGAATTACCCTGAGCAAAGGAGTAT
TTCCGAG 
IDT 
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Primer Sequence Supplier 
USP7 ΔUBL345 R CTCGGAAATACTCCTTTGCTCAGGGTAATTCAC
TGTTATC 
IDT 
USP7 Δ45 F CAGCTTAAGATGAAAATCACATGATTTGAGAAC
AGGCGAAG 
IDT 
USP7 Δ45 R CTTCGCCTGTTCTCAAATCATGTGATTTTCATCT
TAAGCTG 
IDT 
USP7 Δ5 F GAAATCCCTTTGGACCAGGTGTGAATAGACAAA
GAGAATGAGATG 
IDT 
USP7 Δ5 R CATCTCATTCTCTTTGTCTATTCACACCTGGTCC
AAAGGGATTTC 
IDT 
USP7 Δ4 F ATCCCTTTGGACCAGGTG IDT 
USP7 Δ4 R ACTTCGCCTGTTCTCAAAG IDT 
USP7 Δ3 F CTTAAGATGAAAATCACAGACTTTG IDT 
USP7 Δ3 R GTGGTAGAGATCTCGGAAATAC IDT 
USP7 Δ2 F GATGACCCTGAAAATGATAAC IDT 
USP7 Δ2 R ATGATCTTTATCAAACTTGGG IDT 
USP7 Δ1 F GTTGATCCCGAGCTGGCTG IDT 
USP7 Δ1 R GAGATGGGCTTCCTGCCG IDT 
USP7 ΔLoop F AGGCGAAGTTTTAAATGTATATG IDT 
USP7 ΔLoop R TTTCATCTTAAGCTGCTG IDT 
USP7 LoopSubs F GCTGCGGCCAGGCGAAGTTTTAAATGTATATG IDT 
USP7 LoopSubs R GGCTGCGGCTTTCATCTTAAGCTGCTG IDT 
USP7 P804A F CATTTTCTGTGATAAAACAATCGCTAATGATCCT
GGATTTGTGG 
IDT 
USP7 P804A R CCACAAATCCAGGATCATTAGCGATTGTTTTAT
CACAGAAAATG 
IDT 
USP7 K869A F GAGATCTTCTACAGTTCTTCGCGCCTAGACAAC
CTAAGAAAC 
IDT 
USP7 K869A R GTTTCTTAGGTTGTCTAGGCGCGAAGAACTGTA
GAAGATCTC 
IDT 
USP7 DE F TAAAGCCCTTGCTGCACTAATGGATG IDT 
USP7 DE R TCAAGAGACACGTCATAG IDT 
USP7 DD F TGCCATCATAGTATTTCAGAAGGATG IDT 
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Primer Sequence Supplier 
USP7 DD R CCAGCCATTAGTTCATCAAGGGC IDT 
USP7 DD (DEDD) F TAAAGCCCTTGATGAACTAATGGCTG IDT 
USP7 DD (DEDD) R TCAAGAGACACGTCATAGTC IDT 
USP7 DEDD F TGCCATCATAGTATTTCAGAAGGATGAC IDT 
USP7 DEDD R CCAGCCATTAGTGCAGCAAGGGC IDT 
USP7 LDEL F GCAGCAATGGATGGTGACATCATAG IDT 
USP7 LDEL R AGCAGCGGCTTTATCAAGAGACAC IDT 
USP7 LDELDD F GCAGCAATGGCTGGTGCCATCATA IDT 
USP7 LDELDD R AGCAGCGGCTTTATCAAGAGACACG IDT 
 
2.7.3 Cloning 
Table 2-14 List of cloning primers 
 
Primer Sequence Supplier 
P65 F CCCAAGCTTGGGGCCACCATGGACGATCTGTTTCCCCTC IDT 
P65 R GCTCTAGAGCTTAGGAGCTGATCTGACTCAAAAG IDT 
P65-
Flag F 
CCCAAGCTTGGGGCCACCATGGATTACAAGGATGACGACGATAAG 
GACGATCTGTTTCCCCTC 
IDT 
 
2.7.4 Sequencing 
Table 2-15 List of sequencing primers 
 
Primer Sequence Supplier 
T7 TAATACGACTCACTATAGGG GATC 
BGH-Reverse TAGAAGGCACAGTCGAGG GATC 
CMV-F CGCAAATGGGCGGTAGGCGTG GATC 
EBV-RP GTGGTTTGTCCAAACTCATC GATC 
hUSP7-300 GGTGATGCCACGCTTTTA GATC 
hUSP7-699 TTTCACGAATCAGCTACG GATC 
hUSP7-1396 GTGGTTTATCTAAACCC GATC 
hUSP7-2099 ATTACTGTGGGCATATC GATC 
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Primer Sequence Supplier 
hUSP7-2700 CAGCCAATTTAGGGAAGAGG GATC 
mp65-Cterminal GAGCCCATGCTGATGGAGTA GATC 
mp65-Nterminal GCATTTATAGCGGAATCGCA GATC 
 
2.8 Antibodies 
Table 2-16 List of antibodies 
 
Antibody Company Catalogue Number 
p65 Santa Cruz Biotechnologies Sc-8008 
p65 Bethyl A301-824A 
p65 Santa Cruz Biotechnologies Sc-372 
GST Sigma Aldrich G7781 
FLAG Sigma F1804 
USP7 Bethyl A300-033A 
p53 Santa Cruz Biotechnologies Sc-6243 
Ha Santa Cruz Biotechnologies Sc-805 
β-Actin Sigma SAB 1305567 
c-Rel Santa Cruz Biotechnologies Sc-71 
RelB Santa Cruz Biotechnologies Sc-226 
DAXX Santa Cruz Biotechnologies Sc-7152 
Mouse GE Healthcare NXA931V 
Rabbit GE Healthcare NA934V 
Biotin HRP Linked Cell Signalling Technologies 02/2017 
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2.9 Buffers 
2.9.1 GST-protein purification 
Table 2-17 GST-protein purification buffers 
 
Buffer Composition 
Lysis buffer Tris HCl 50mM pH 8.5 
NaCl 150mM 
DTT 10mM 
Binding buffer PBS pH7.3 {NaCl 140mM, KCl 2.7mM, 
Na2HPO4 1.8mM, KH2PO4 10mM} 
DTT 10mM 
Elution buffer Tris HCl 50mM pH 8 
Reduced Glutathione 10mM 
DTT 10mM 
 
2.9.1.1 Column wash and storage 
Table 2-18 GST-protein purification column wash and storage buffers 
 
Buffer Composition 
Removal of precipitated or 
denatured substances 
2 Volumes of 6M Guanidine Hydrochloride 
5 Volumes of PBS 
Removal of hydrophobically 
bound substances 
4 Volumes of EtOH 70% 
5 Volumes of PBS 
Storage EtOH 20% 
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2.9.2 Loading buffer 
Table 2-19 WB loading buffer 
 
Buffer Composition 
2X SDS loading buffer 20% Glycerol 
0.2% bromophenol blue 
4%SDS 
200mM β-mercaptoethanol 
100mM Tris/HCl pH6.8 
 H20 
4X SDS loading buffer 40% Glycerol 
240mM Tris/HCl pH 6.8 
8% SDS 
0.04% Bromophenol Blue 
5% β-mercaptoethanol 
H2O 
 
2.9.3 SPOT-synthesis of peptides and overlay analysis 
Table 2-20 SPOT-synthesis of peptides and overlay analysis buffers 
 
Buffer Composition 
10X TBS 1litre 1M Tris-Cl pH 7.5 100ml 
NaCl 87.8g 
H2O up to 1 litre 
TBS-T TBS 1X 
0.05% Tween20 
Peptide array stripping buffer 2% SDS 
62mM Tris pH6.8 
20mM DTT 
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2.9.4 Cell lysis buffers 
Table 2-21 Cell lysis buffers 
 
Buffer Composition 
Radioimmunoprecipitation assay 
(RIPA) 
50mM Tris/HCl pH7.4 
0.1-1% Igepal 
0.25% Sodium deoxycholate 
150mM NaCl 
1mM EDTA pH8 
1mM PMSF* 
1mM NaF* 
1mM Na3VO4* 
2μg/ml aprotinin* 
1μg/ml pepstatin* 
2μg/ml leupeptin* 
Pull down lysis and binding buffer 20mM Tris/HCl pH8 
200mM NaCl 
1mM EDTA pH8 
0.5% Igepal 
1mM PMSF* 
2μg/ml aprotinin* 
1μg/ml pepstatin* 
*Added to the buffer immediately prior to use. 
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2.9.5 Electrophoresis buffers for western blotting 
Table 2-22 Electrophoresis buffers for western blotting 
 
Buffer Components 
1X Tris-glycine running buffer 25mM Tris/HCl 
250mM glycine 
0.1% SDS 
H2O 
1X Tris-glycine transfer buffer 48mM Tris/HCl 
39mM glycine 
0.0375% SDS 
20% methanol 
H2O 
 
2.9.6 Tris-glycine SDS-polyacrylamide gels 
Table 2-23 Tris-glycine SDS-polyacrylamide gels 
 
Gel Volume Components  
5% Stacking 1ml H2O 
30% Acrylamide 
1M Tris/HCl pH6.8 
10% SDS 
10% ammoniumpersulfate 
TEMED 
680μl 
170μl 
130μl 
10μl 
10μl 
1μl 
8% Resolving 5ml H2O 
30% Acrylamide 
1.5M Tris/HCl pH8.8 
10% SDS 
10% ammoniumpersulfate 
TEMED 
2.3ml 
1.3ml 
1.3ml 
50μl 
50μl 
3μl 
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2.9.7 ELISA 
Table 2-24 ELISA buffers 
 
Buffer Composition 
Coating buffer 0.2M Na3PO4 pH6.5 
Assay diluent 10% FBS  
PBS, pH7 
Wash buffer PBS 
Tween-20 0.05% 
Stop solution 2N H2SO4 
 
2.10 Reagents 
Table 2-25 List of reagents 
 
Reagent Company Catalogue # 
Acrylamide/Bis-acrylamide 30% 
Solution 
Sigma A3574 
Agarose Ultrapure Invitrogen 
Life technologies 
16500 
Ammonium persulfate Sigma A3678 
Ampicillin sodium salt Sigma Aldrich A9518 
Aprotinin from bovine lung Sigma Life Science A1153 
Β-mercaptoethanol Sigma Aldrich M6250 
Bovine Serum Albumin Sigma Aldrich A7906 
Bromophenol Blue Sigma Aldrich B8026 
DMSO (Dimethyl sulfoxide)  Fisher chemical D/4120/PB08 
DPBS 1X Gibco 14190-094 
DTT (Dithiothreitol) Melford Biolaboratories MB1015 
Dulbecco’s Modified Eagle’s 
Medium-high glucose 
Sigma D6429 
EDTA (Ethylenediaminetetraacetic 
acid) 
Fisher chemical D/0700/60 
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Reagent Company Catalogue # 
Ethanol VWR AnalaR Normapur 20821-330 
GHS beads Sigma Aldrich G4510 
L-glutamine solution Sigma G7513 
L-Glutathione reduced Sigma Aldrich G4251 
Glycerol Fisher Scientific G/0650/17 
Glycine Fisher Chemical G/0800/60 
Guanidine Hydrochloride Sigma Life Science G3272 
Heat inactivated FBS Gibco 10500-064 
Hydrochloric acid S.G Fisher Chemical H/1200/PB17 
Igepal CA-630 Sigma 18896 
IPTG (Isopropyl beta-D-1-
thiogalactopyranoside) 
Sigma I6758 
Isopropanol Sigma 24137 
Kanamycin Melford Laboratories K0126 
Potassium chloride Analar Normapur 26764 
Leupeptin Sigma Life Science L2884 
Lipopolysaccharides from 
Escherichia Coli 055:B5 
Sigma Aldrich L2880 
Methanol Fisher chemical M/4000/PC17 
Nuclease free water Qiagen 1039480 
Penicillin-Streptomycin Sigma P0781 
Pepstatin A Sigma Life Science P5318 
Phenylmethanesulfonyl fluoride Sigma P7626 
Potassium dihydrogen phosphate Analar Normapur 26936 
Protease inhibitor cocktail tablets 
Complete 
Roche Diagnostics GmbH 11697498001 
Protein Assay Dye Reagent 
Concentrate 
Bio-Rad 500-0006 
Protein G agarose beads EMD Millipore 16-266 
Ponceau S Solution Sigma Aldrich P7170 
Restore Plus Western Blot Stripping 
Buffer 
Thermo Scientific 46430 
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Reagent Company Catalogue # 
Sodium chloride VWR BDH Prolabo 27810.295 
Sodium deoxycholate Sigma Aldrich D6750 
Sodium dihydrogen phosphate 
dihydrate 
Riedel de Haen 04269 
SDS (Sodium Dodecyl Sulphate) VWR UN1325 
Sodium fluoride Sigma Aldrich S7920 
Sodium hydrogen phosphate AnalaR Normapur 102494C 
Sodium hydroxide pellets Fisher chemicals S/4920/53 
Sodium orthovanadate Sigma S6508 
Sulfuric acid Sigma Aldrich 258105 
TEMED 
(Tetramethylethylenediamine) 
Sigma T9281 
TMB 1X Substrate Solution eBioscience 00-4201-56 
Tris HCl Fisher Scientific BP 152-1 
0.05% Trypsin-EDTA 1X Gibco 25300-054 
Tween-20 Sigma Life Science P2287 
Western Bright ECL Advansta K12045 
Western Bright Sirius Advansta K12043 
 
2.11 Mimetic peptides 
2.11.1 p65 mimetic peptides 
Table 2-26 List of p65 mimetic peptides 
 
Peptide Sequence Modification Supplier 
E4 YGRKKRRQRRPYADPSLQAPVRVSMQLR N/A GenScript 
E4 Control 1 YGRKKRRQRRPYADPSLQAPVAVSMQLR R267A GenScript 
E4 Control 2 YGRKKRRQRRQQPRDSLVPAVSMRLPYA Scrambled GenScript 
F4 YGRKKRRQRRSPFNGPTEPRPPTRRIAV N/A GenScript 
F4 Control YGRKKRRQRRSPFNGPTEPRPPTAAIAV R329A, R330R GenScript 
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2.11.2 USP7 mimetic peptides 
Table 2-27 List of USP7 mimetic peptides 
 
Peptide Sequence Supplier 
Upep1 GYRDGPGNPLR GenScript 
Upep2 LRHNYEGT GenScript 
Upep3 RDGPGNPLRHNYEGT GenScript 
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3 Characterisation of important sites of p65 
involved in USP7 deubiquitinase activity 
3.1 Abstract 
The NF-κB transcription factor family is fundamental for the regulation of 
inflammation and the response to infection by directly controlling the 
transcription of genes involved in these processes. Due to its key role in these 
processes, NF-κB activity is highly regulated. The balance between 
ubiquitination and deubiquitination is a critical factor in the control of NF-κB 
mediated responses. USP7 is a DUB known to deubiquitinate the p65 subunit of 
the NF-κB transcription factor family. However, the molecular determinants of 
p65 recognition as a substrate by USP7 are currently unknown.  Based on a 
peptide analysis of p65 and USP7 interaction, we generated two cell permeable 
peptides mimicking regions of p65 previously identified as mediating interaction 
with USP7. These p65 mimetic peptides were not able to inhibit the NF-κB 
response. Further investigation on the specific recognition of p65 by USP7 is 
needed in order to develop a mimetic peptide able to inhibit USP7 activity on 
p65. A recently discovered phosphorylation site on p65 at S269 is in close 
proximity to R267. R267 of p65 is known to inhibit the interaction when mutated 
to alanine. We studied the effect of the phosphorylation status of p65 S269 on 
the interaction with USP7. However, mutation of S269 does not interfere with 
USP7-p65 interaction. 
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3.2 Introduction 
The transcription factor NF-κB is a key regulator of the immune response.  
Aberrant NF-κB activity leads to the development of a number of human 
diseases; for instance, different types of cancer (for example leukaemia, 
lymphoma) [457–459], autoimmune diseases (such as, lupus, diabetes, arthritis, 
multiple sclerosis) [2, 457, 458], neurodegenerative diseases (like Alzheimer, 
Parkinson, Huntington) [458], and viral infection diseases (e.g. AIDS, infection 
skin diseases) [457, 458]. Therefore the tight regulation of the NF-κB response is 
important for human health.  
NF-κB activity is regulated by different PTMs such as phosphorylation and 
ubiquitination among others [42]. Phosphorylation of NF-κB subunits plays a key 
role controlling their stability, degradation, interaction with other factors and 
transcription activity [17]. Certain phosphorylation events regulate the NF-κB 
transcriptional activity in a gene specific manner [17]. p65 is the most studied 
subunit and the main focus has been placed on S276 and S536 phosphorylation 
sites. Phosphorylation of these sites leads to transactivation of the NF-κB 
response and K310 acetylation [17]. However, there are various phosphorylation 
sites like S269, whose function in p65 regulation is still unknown [68]. On the 
other hand, ubiquitination of NF-κB subunits is the major limiting factor of pro-
inflammatory genes expression [15]. USP7 DUB deubiquitinates p65 subunit of 
NF-κB, leading to the termination of the NF-κB response [287]. As explained in 
section 1.4.3.3, huge efforts have been made on the generation of USP7 
inhibitors. All the inhibitors developed are based on a catalytic inhibition of 
USP7 but are not substrate specific and would be expected to promote the 
ubiquitination of all USP7 substrates equally. Therapeutic targeting of USP7 to 
inhibit NF-κB in the context of inflammation will require much greater substrate 
selectivity in order to minimise the potential for toxicity. 
In this chapter we investigated the ability of p65 mimetic peptides to inhibit 
USP7-p65 interaction. In order to test these peptides, we used a peptide 
transduction strategy which is based on the ability of certain peptidic sequences 
to cross the cellular membrane and enter into the cell, as explained in section 
1.3.3. Cargo molecules can be attached to the CPPs by different methods; 
chemical crosslinking, cloning and chemical synthesis [116, 122]. Among these 
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cargoes are proteins, nanoparticles, oligonucleotides and small interfering RNAs 
(siRNAs) [118, 120–122]. Once the cargoes have been taken up, they are able to 
act on their cellular targets [116].  
CPPs can be classified by their origin or their physicochemical properties. 
According to their origin there are three groups of CPPs; natural CPPs, chimeric 
CPPs and synthetic CPPs (see Table 3-1) [119, 124, 460]. On the other hand, 
according to their physicochemical properties they are divided in 3 different 
groups; cationic CPPs, amphipathic CPPs and hydrophobic CPPs (See Table 3-1) 
[116, 118, 120].  
Table 3-1 CPPs classification 
 
Classified by Group Description 
Origin Natural 
CPPs 
Derived from natural proteins 
Origin Chimeric 
CPPs 
Fusion of two natural proteins or peptide 
sequences 
Origin Synthetic 
CPPs 
Peptides based on natural proteins designed 
to mimic their activity 
Physicochemical 
properties 
Cationic 
CPPs 
High content of positively charged residues 
e.g. NLS 
Physicochemical 
properties 
Amphipathic 
CPPs 
Chimeric peptides formed by the covalent 
bond of an hydrophobic patch to an NLS 
Physicochemical 
properties 
Hydrophobic 
CPPs 
Contain apolar residues 
 
CPPs enter into the cells through different mechanisms. These mechanisms are 
independent but can occur at the same time [118, 119]. Cellular uptake 
mechanisms can be classified as energy independent and energy dependent. 
Energy independent mechanisms are known as direct translocation and include  
inverted micelle formation, adaptive translocation, pore formation model, 
carpet like model and membrane thinning model [117, 119, 460]. Whereas CPPs 
entering the cells through energy dependent mechanisms, do so through 
endocytosis, including micropinocytosis, clathrin and/or caveolae mediated 
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endocytosis and clathrin and/or caveolae independent mediated uptake [117–
121]. See Table 3-2. All these mechanisms are based on interactions between 
positively charged residues in the CPP sequence and negatively charged 
components of the lipid bilayer, leading to rearrangements in the membrane 
which result is the uptake of the peptide into the cell.  
Table 3-2 CPPs cellular entry mechanisms 
 
Group Type 
Energy 
independent or 
direct 
translocation 
Inverted micelle formation, adaptive translocation, pore 
formation model, carpet-like model, membrane thinning 
model 
Energy 
dependent or 
endocytosis 
Micropinocitosis, clathrin and/or caveolae mediated 
endocytosis, clathrin and/or caveolae independent 
endocytosis 
 
The first CPP discovered was part of the TAT protein from human 
immunodeficiency virus 1 (HIV-1 TAT) [124, 461–464]. A basic region composed 
by 10 amino-acids containing 2K and 6R promotes HIV-1 TAT protein cellular 
uptake [118, 124, 461–463]. TAT protein when added exogenously to cells in 
culture is uptaken by adsorptive endocytosis [461, 464]. Once in the cell it 
localises predominantly in the nucleus and nucleoli [462, 463]. TAT protein is 
also able to carry other molecules into the cells [118, 124, 463, 464], an 
important fact for drug therapies. The ability of CPPs to deliver a wide variety of 
cargoes into the cells makes them a really interesting tool for researching 
purposes. The most important one is their ability of therapeutic drug delivery. 
CPPs have been used to target the NF-κB signalling pathway as explained in 
section 1.3.3. However, these CPPs are not totally NF-κB specific, and have also 
effects on other signalling pathways [116]. 
A peptide array and subsequent alanine scan analysis to determine the specific 
residues of p65 involved in the interaction with USP7 was previously performed 
[287]. Using these data we designed a mimetic peptide derived from the amino-
acids of p65 that interact with USP7. We hypothesised that a p65 mimetic 
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peptide may block the interaction of p65 and USP7, thereby promoting p65 
ubiquitination and proteasomal degradation, and inhibiting NF-κB mediated 
inflammatory responses. The mimetic peptide was fused to the TAT sequence of 
the HIV-1 TAT protein, in order to deliver the peptide to the nucleus. Several 
phosphorylation sites on p65 have been described to play an important role on 
the NF-κB response [17], including S536 and S468 which regulate p65 
ubiquitination through interaction with E3 ligases [17]. A recently described 
phosphorylation site at S269 is in close proximity to R267 a residue previously 
identified as critical for interaction with USP7 [287]. In this chapter we also 
investigated the potential role of S269 phosphorylation in regulating the 
interaction of p65 with USP7. 
3.3 Results 
3.3.1 Mutation of S269 of p65 does not affect interaction with p65 
S269 is located in close proximity to R267, which when mutated to alanine 
inhibits the interaction of p65 with USP7. In order to study the potential role of 
S269 phosphorylation in the interaction, two different mutants were created, 
S269D and S269A. S269D mimics the phosphorylation of WT p65 protein at S269 
by the presence of the negative charge contained by the aspartic acid, while 
S269A mimics the non-phosphorylated status by the absence of the negative 
charge. These mutants were previously created in the Carmody group. Original 
p65 mutants were C-terminal FLAG-tagged in a pCDNA3.1 vector, while WT p65 
was N-terminal FLAG-tagged in a pCMV vector. Firstly, p65 WT and mutants were 
sub-cloned into pCDNA3.1 vector. Cloning was performed in order to reduce the 
variability of the interaction due to the presence of the FLAG-tag in a different 
site and/or due to different expression of each expression vector. See appendix 
8.2. 
p65 WT, p65 R267A, p65 S269A and p65 S269D plasmids were co-transfected with 
USP7 FLAG-tagged plasmid in HEK293T cells. Cells were harvested and lysates 
were immunoprecipitated with anti-p65 antibody. Protein levels were analysed 
by western blotting with anti-p65 and anti-FLAG antibodies. R267A mutation is 
known to inhibit the interaction between USP7 and p65 [287], therefore, it was 
used as a negative control for the interaction. There are no visible differences in 
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the protein level of USP7 when immunoprecipitated with p65 S269A and p65 
S269D in comparison to WT p65 (see Figure 3-1). From these results, we can 
conclude that the phosphorylation status of p65 S269 has no effect on the 
interaction of p65 with USP7. 
 
Figure 3-1 Phosphorylation status of p65 S269 has no effect on the interaction with USP7. 
HEK293T cells were co-transfected with p65 WT, p65 R267A, p65 S269A and p65 S269D along 
with USP7 FLAG-tagged plasmids. Cells were lysed and immunoprecipitated with anti-p65 
antibody. The immunoprecipitations were immunoblotted with antibodies anti- p65 and anti-FLAG. 
The figure is a representative of three independent experiments. 
 
3.3.2 p65 derived peptides 
3.3.2.1 Design and synthesis 
Two p65 derived mimetic peptides, designated E4 and F4, were designed 
according to the results obtained from a p65 peptide array and subsequent 
alanine scan previously performed in the lab [287] (see Figure 3-2). Peptide E4 
contains amino acids 256-273 of p65 and includes R267 (see Figure 3-2). In 
addition to the inhibitory role of R267A mutation [287], substitution of R273 with 
an alanine highly decreases the interaction with USP7 in peptide array 
experiments, indicating that 273 residue is also important for interaction. The 
E4 peptide is contained within the available crystal structure of p65 subunit (PDB 
1VKX), where it corresponds to an accessible site for the interaction with USP7 
(see Figure 3-3). 
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Peptide F4 comprises amino-acids 316-333 of p65 (see Figure 3-2). This peptide 
contains two arginine residues (R328, R329) which when mutated to alanine 
highly reduce the interaction with USP7 in peptide array experiments [287]. We 
were not able to analyse F4 position in the crystal structure of p65 as the PDB 
1VKX model covers only amino acids 19-291. Transactivation domains are 
difficult to crystallise due to the instability of the domain, so we created a full 
length p65 structural model using ROBETTA software 
(http://robetta.bakerlab.org/) and the truncated p65 3D structure from 1VKX 
(see section 6.3.1). This software was developed by Baker Lab and it uses 
available X-Ray crystal structures to predict structures. As we can see in the 
model, the missing part of the subunit in 1VKX is formed by flexible loops, which 
are more likely to move than to stay immobile. According to this model both 
mimetic peptides, E4 and F4 are accessible for potential interaction with USP7 
(see Figure 3-4). 
The final peptides consisted of the selected p65 sequence with the addition of 
the cell permeable HIV-TAT cargo carrying peptide sequence (YGRKKRRQRR). 
This 10 amino acid HIV-TAT sequence mediates the cellular uptake and nuclear 
localisation of fused peptides [465]. Previous work in the group confirmed the 
cellular uptake and nuclear localisation of peptides fused to this HIV-TAT 
sequence with no transfection required [466]. 
 
Figure 3-2 Design of p65 derived cell permeable peptides. A) Schematic representation of p65 
subunit of NF-κB with the corresponding p65 derived mimetic peptides E4 and F4. Position of both 
peptides within the p65 protein is indicated. B) Schematic of the p65 derived mimetic peptides 
fused to the HIV-TAT cargo protein construct (YGRKKRRQRR). Sequences of each peptide are 
noted. R267, R273 and R329 and R330 are underlined in E4 and F4 respectively. 
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Figure 3-3 p65 derived mimetic peptides structural localisation in a known X-Ray (PDB 
1VKX). A) Ribbon of the crystal structure of p65 from PDB 1VKX (amino-acids 19-291, RHD 
{amino-acids 19-306}). E4 peptide is marked in green. F4 is not present in the in 1VKX. B) Surface 
of the crystal structure of p65 from PDB 1VKX (amino-acids 19-291, RHD {amino-acids 19-306}). 
E4 peptide is marked in green. F4 is not present in the X-Ray. All structures were analysed with 
Maestro Schrodinger software. 
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Figure 3-4 p65 derived peptides structural localisation in a full length model. A) Ribbon of the 
full length model of p65 created by ROBETTA Software. E4 peptide is marked in green. F4 is 
coloured in yellow. The RHD and TAD domains of p65 are labelled in each of the structure views. 
B) Surface of the full length model of p65 created by ROBETTA Software. E4 peptide is marked in 
green. F4 is coloured in yellow. The RHD and TAD domains of p65 are labelled in each of the 
structure views. All structures were analysed with Maestro Schrodinger software. 
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3.3.2.2 Peptide characterisation 
Two control peptides were also designed to be used as a negative control for the 
effects of E4 and F4 on signalling in vitro. These control peptides will confirm 
that the effects on the NF-κB response are due to the activity of the specific 
test peptide and not due to the presence of a CPP. The control peptides E4C1 
and F4C were based on the E4 and F4 sequence but containing alanine 
substitutions of essential p65 interacting amino-acids [467] previously identified 
by peptide array [287] (E4C1: YGRKKRRQRRPYADPSLQAPVAVSMQLR; F4C: 
YGRKKRRQRRSPFNGPTEPRPPTAAIAV) (see Figure 3-5). In the case of E4C1 R267 
was mutated to alanine and in the case of F4C R328 and R329 were mutated to 
alanine. The mutated amino acids on each peptide control are highlighted on the 
crystal structures of p65 (PDB 1VKX and ROBETTA p65 full length model) (see 
Figure 3-6 and Figure 3-7). In addition, a second control peptide was designed 
for E4 mimetic peptide (E4C2). The design was performed using the 
bioinformatic tool Scrambled from Mimotopes, The Peptide Company. This 
second peptide control consisted of a scrambled E4 peptide sequence and the 
addition of the HIV-TAT cargo protein (E4C2: 
YGRKKRRQRRQQPRDSLVPAVSMRLPYA) (see Figure 3-5). Previous work in the 
group confirmed that following 2 hours of peptide treatment, the mimetic 
peptides are effectively internalised by cells and translocated to the nucleus 
[466], where USP7 and p65 interaction takes place [287]. To investigate the 
effect of these peptides on TLR signalling regulation in vitro, ELISA and qPCR 
analysis were performed.  
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Figure 3-5 Design of p65 derived cell permeable control peptides. A) Schematic 
representation of p65 subunit of NF-κB. The corresponding p65 derived mimetic peptides E4 and 
F4. Position of both peptides within the molecule is indicated. B) Schematic of the p65 derived 
mimetic control peptides fused to the HIV-TAT cargo protein construct. Sequences of each peptide 
are noted. Residue sites mutated to alanine compared to the WT sequence are underlined and 
marked in bold. E4C2 is a scrambled peptide, designed from the WT sequence. 
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Figure 3-6 p65 derived mimetic control peptides localisation on a known crystal strucure. A) 
Ribbon of the crystal structure of p65 from PDB 1VKX (amino-acids 19-291, RHD {amino-acids 19-
306}). E4 peptide is marked in green. Amino-acids mutated to alanine are coloured in red. F4 is not 
present in the structure. B) Surface of the crystal structure of p65 from PDB 1VKX (amino-acids 19-
291, RHD {amino-acids 19-306}). E4 peptide is marked in green. Amino-acids mutated to alanine 
are coloured in red. F4 is not present in the structure. All structures were analysed with Maestro 
Schrodinger software. 
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Figure 3-7 p65 derived mimetic control peptides localisation on full length p65 structural 
model. A) Ribbon of the full length model of p65 created by ROBETTA Software. E4 peptide is 
marked in green. F4 is coloured in yellow. Amino-acids mutated to alanine are coloured in red. The 
RHD and TAD of p65 are labelled in each of the structure views. B) Surface of the full length model 
of p65 created by ROBETTA Software. E4 peptide is marked in green. F4 is coloured in yellow. 
Amino-acids mutated to alanine are coloured in red. The RHD and TAD of p65 are labelled in each 
of the structure views. All structures were analysed with Maestro Schrodinger software. 
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A TNFα ELISA assay was performed to detect the effect of the peptide on LPS 
induced TNFα production. Experiments were carried out in RAW 264.7 cells and 
BMDM. Cells were incubated with different peptide concentrations (3μM, 10μM, 
30μM and 100μM) for 2 hours and followed by 4 hours or 8 hours LPS stimulation 
(100ng/ml) (see Figure 3-8, Figure 3-9, Figure 3-10 and Figure 3-11). No 
statistically significant differences were shown between peptide and control 
peptide treatments (non-parametric Mann Whitney test), suggesting that the p65 
mimetic peptides E4 and F4 do not inhibit the interaction of USP7 on p65; and 
therefore, p65 mimetic peptides E4 and F4 are not able to inhibit the LPS 
induced TNFα production.  
qPCR analysis was performed to detect differences at TNFα gene transcription 
level. qPCR analysis was completed in RAW 264.7 cells. Cells were incubated for 
2 hours with increasing concentrations of the peptides (3μM, 10μM, 30μM and 
100μM) followed by a 2 hours LPS (100ng/ml) stimulation to activate the NF-κB 
pro-inflammatory response (see Figure 3-12 and Figure 3-13). No statistically 
significant differences were found between peptide and control peptide 
treatments (non-parametric Mann Whitney test), suggesting that the p65 
mimetic peptides E4 and F4 do not inhibit the interaction of USP7 with p65; and 
therefore, p65 mimetic peptides E4 and F4 are not able to inhibit p65 mediated 
TNFα expression. These results corroborate the results obtained in the ELISA 
assay. 
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Figure 3-8 F4 p65 mimetic peptide does not inhibit LPS induced RAW 264.7 cells TNFα 
production. A) F4 and F4 negative control (F4C) amino-acid sequences. Marked in red is the HIV-
TAT cargo protein sequence. Labelled in green, the amino-acids mutated in order to create the 
negative control. B) RAW 264.7 cells were left untreated or pre-treated for 2h with increasing 
concentrations (3μM-100μM) of either F4 or F4C peptide before stimulation with 100ng/ml of LPS. 
Supernatants were harvested 4h after stimulation and the concentration of TNFα was determined 
by ELISA. Data shown are the medians of the technical triplicates from different independent 
experiments with the corresponding standard deviation. C) RAW 264.7 cells were left untreated or 
pre-treated for 2h with increasing concentrations (3μM-100μM) of either F4 or F4C peptide before 
stimulation with 100ng/ml of LPS. Supernatants were harvested 8h after stimulation and the 
concentration of TNFα was determined by ELISA. Data shown are the medians of the technical 
triplicates from different independent experiments with the corresponding standard deviation. 
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Figure 3-9 E4 p65 mimetic peptide does not inhibit LPS induced RAW 264.7 cells TNFα 
production. A) E4 and E4 negative control (E4C1) amino-acid sequences. Marked in red is the 
HIV-TAT cargo protein sequence fused to the mimetic peptides. Labelled in green, the amino-acids 
mutated in order to create the negative control. B) RAW 264.7 cells were left untreated or pre-
treated for 2h with increasing concentrations (3μM-30μM) of either E4 or E4C1 peptide before 
stimulation with 100ng/ml of LPS. Supernatants were harvested 4h after stimulation and the 
concentration of TNFα was determined by ELISA. Data shown are the medians of the technical 
triplicates from different independent experiments with the corresponding standard deviation. C) 
RAW 264.7 cells were left untreated or pre-treated for 2h with increasing concentrations (3μM-
100μM) of either E4 or E4C1 peptide before stimulation with 100ng/ml of LPS. Supernatants were 
harvested 8h after stimulation and the concentration of TNFα was determined by ELISA. Data 
shown are the medians of the technical triplicates from different independent experiments with the 
corresponding standard deviation. 
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Figure 3-10 F4 p65 mimetic peptide has no effect on BMDM TNFα production upon LPS 
stimulation. A) F4 and F4 negative control (F4C) amino-acid sequences. Marked in red is the HIV-
TAT cargo protein sequence fused to the mimetic peptides. Labelled in green, the amino-acids 
mutated in order to create the negative control. B) Mouse BMDM were left untreated or pre-treated 
for 2h with increasing concentrations (3μM-100μM) of either F4 or F4C peptide before stimulation 
with 100ng/ml of LPS. Supernatants were harvested 4h after stimulation and the concentration of 
TNFα was determined by ELISA. Data shown are the medians of the technical triplicates from 
different independent experiments with the corresponding standard deviation. 
 
 129 
 
 
Figure 3-11 E4 p65 mimetic peptide does not inhibit BMDM TNFα production upon LPS 
stimulation. A) E4 and E4 negative control (E4C1 or E4C2) amino-acid sequences. Marked in red 
is the HIV-TAT cargo protein sequence fused to the mimetic peptides. Labelled in green, the 
amino-acids mutated in order to create the negative control. B) Mouse BMDMs were left untreated 
or pre-treated for 2h with increasing concentrations (3μM-100μM) of either E4 or E4C1 peptide 
before stimulation with 100ng/ml of LPS. Supernatants were harvested 4h after stimulation and the 
concentration of TNFα was determined by ELISA. Data shown are the medians of the technical 
triplicates from different independent experiments with the corresponding standard deviation. C) 
Mouse BMDM were left untreated or pre-treated for 2h with increasing concentrations (3μM-
100μM) of either E4 or E4C1 peptide before stimulation with 100ng/ml of LPS. Supernatants were 
harvested 4h after stimulation and the concentration of TNFα was determined by ELISA. Data 
shown are the medians of the technical triplicates from different independent experiments with the 
corresponding standard deviation. 
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Figure 3-12 F4 p65 mimetic peptide has no effect on RAW 264.7 cells TNFα gene expression 
upon LPS stimulation. A) F4 and F4 negative control (F4C) amino-acid sequences. Marked in red 
is the HIV-TAT cargo protein sequence fused to the mimetic peptides. In green are shown the 
amino-acid mutated in order to create the negative control are shown in green. B) RAW 264.7 cells 
were left untreated or pre-treated for 2h with increasing concentrations (3μM-100μM) of either E4 
or E4C1 peptide before stimulation with 100ng/ml of LPS. Cells were harvested 2h after stimulation 
and the TNFα gene expression was determined by qPCR. Data shown are the medians of the 
technical triplicates from different independent experiments with the corresponding standard 
deviation. 
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Figure 3-13 E4 p65 mimetic peptide has no effect on RAW 264.7 cells TNFα gene expression 
upon LPS stimulation. A) F4 and E4 negative control (E4C1) amino-acid sequences. Showing in 
red the HIV-TAT cargo protein sequence fused to the mimetic peptides. The amino-acids mutated 
in order to create the negative control are marked in green. B) RAW 264.7 cells were left untreated 
or pre-treated for 2h with increasing concentrations (3μM-100μM) of either E4 or E4C1 peptide 
before stimulation with 100ng/ml of LPS. Cells were harvested 2h after stimulation and TNFα gene 
expression was determined by qPCR. Data shown are the medians of the technical triplicates from 
different independent experiments with the corresponding standard deviation. 
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3.4 Discussion 
The NF-κB response is regulated by a number of PTMs of which, ubiquitination 
plays a key role in the nuclear regulation of the NF-κB family members. The 
balance between ubiquitination and deubiquitination is crucial for the NF-κB 
transcriptional response. A higher level of ubiquitination will lead to 
proteasomal degradation and thereby, reduced NF-κB activity; while a higher 
level of deubiquitination will lead to an increase in the NF-κB response. USP7 
binds to NF-κB at the promoters of NF-κB target genes, regulating p65 
ubiquitination and its stability at sites of transcription [287]. Thus, USP7 
deubiquitinase activity is critical in determining the duration and strength of the 
NF-κB transcriptional response by opposing promoter associated ubiquitination 
[287, 468]. Targeting USP7-NF-κB interaction provides a novel therapeutic 
opportunity in the treatment of chronic inflammatory diseases. The blockade of 
this interaction will inhibit the expression of pro-inflammatory effectors, key 
mediators of inflammation [287]. 
The mechanism by which USP7 recognises p65 as a substrate and interacts with 
it is still unknown. However, previous studies have identified important sites in 
p65 for the interaction with USP7, such as R267 and S536 phosphorylation [287]. 
R267 when mutated to alanine inhibits USP7-p65 interaction and decreases USP7 
deubiquitinase activity [287] and S536 when mutated to alanine decreases USP7-
p65 interaction [287]. 
Combining the importance of phosphorylation on p65 activation and 
ubiquitination on the termination of the NF-κB response, we studied the role of 
p65 S269 phosphorylation [68] on USP7 interaction. S269 is in close proximity to 
R267, thus we hypothesised the possibility of a crosstalk between 
phosphorylation and the UPS. The phosphorylation status of S269 was analysed 
by the creation of two different mutants S260D and S269A. These mutants are 
based on the forces generated by the presence of a negative charge when the 
amino-acid is phosphorylated and the absence of charge when is not 
phosphorylated. This is a common tool in research to study the interaction 
between proteins which considers the physicochemical properties of the 
interaction. The fact that both p65 S269 mutants do not inhibit the interaction 
with USP7 means that a disruption of the force field by the presence of a 
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negative charge in that area has no effect on the interaction with USP7. The 
phosphorylation itself could be important for the activation of p65, but our data 
show it is not important for the interaction with USP7.  
Previous work identified a number of amino-acids of p65 as important for the 
interaction with USP7 [287]. Due to the lack of a full length elucidated 3D 
structure of p65, we modelled a full length p65 structure using ROBETTA 
software (see Figure 3-4 and Figure 3-7) to gain more detail about location of 
the identified amino-acids. This model revealed that peptides of p65 that 
interact with USP7 are localised quite close together in the 3D structure of p65. 
On the one hand, conformational rearrangements which molecules undergo in 
nature after protein-protein interactions are one of the problems when trying to 
solve the full length p65 protein 3D structure. Proteins in nature are flexible, in 
a changing conformation; and when binding to their substrates, they change into 
a stable state. When purifying a protein, the resulting solved structure is the 
result of the properties applied and the stability of the protein in such 
conditions. It might be probable that full length p65 protein on its own is not 
stable enough to be crystallised and it would require of a protein interaction to 
stabilise it. However, even if the protein is stable enough to be solved; it is 
possible that in nature the protein is found in a different conformation able to 
recognised different parts of p65. For these reasons, structural models are a 
useful tool. Our p65 full length model is the first model covering the full length 
of p65 protein. The flexibility of the TAD domain makes it a very difficult target 
to model. Peptide E4 is present in the actual crystal structure PDB 1VKX, but 
that structure is missing the TAD of p65. The TAD of p65 is a really flexible part 
of p65, which is probably formed by a flexible loop. This loop could actually hide 
E4 peptide in nature. Whereas F4 is present on a flexible loop, models of this 
part vary quite a lot. From the ROBETTA model, the F4 peptide is accessible to 
be recognised by USP7 but it could be possible that another 3D structure is 
formed in nature.  
We hypothesised that a mimetic peptide containing R267 or a mimetic peptide 
containing R328 and R329 will compete with endogenous p65 in USP7 
interaction; and therefore decrease the NF-κB inflammatory response via the 
inhibition of USP7 deubiquitination of p65. Both peptides were attached to the 
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cargo carrying peptide sequence of TAT protein. The effect of the peptides on 
the NF-κB response was studied at target gene expression level by qPCR and pro-
inflammatory cytokines production level by ELISA. In both cases, the results 
were negative; the designed p65 mimetic peptides did not have any effect on 
the NF-κB response. There were no significant differences on gene expression or 
cytokine production, when comparing peptide treatment to untreated cells. This 
absence of significant differences in TNFα expression and production could be 
because the mutated amino-acids on p65 sequence are important and contribute 
to the interaction but are not enough to disrupt the interaction with USP7. In 
protein-protein interactions electrostatic intermolecular interactions are the 
strongest bond between proteins. When molecules are small, disruption of a few 
electrostatic interactions might be enough to abolish the interaction, but within 
two proteins we also encounter van der Waal forces. Van der Waal forces are the 
weakest interaction between two proteins, but are the most common attractive 
forces between two proteins. The force field created by the Van der Waal forces 
could be stronger than the electrostatic interaction and even disrupting the 
electrostatic interaction might not be sufficient to disrupt the Van der Waal 
force field. The mimetic peptide might be binding to USP7 but not inhibiting the 
interacting site with p65, which would explain why USP7 is still able to create an 
adequate attractive force field and bind to p65 even in the presence of the 
mimetic peptide. For this reason we suggest that the targeted area is important 
for the interaction but it is not sufficient to disrupt the interaction. Taking all 
these into account, further investigation on the molecular determinants involved 
in the interaction is needed to be able to create a p65 mimetic peptide able to 
inhibit specifically USP7’s activity on p65 subunit of NF-κB. 
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Chapter Four 
Investigation of the molecular 
determinants involved in p65 
recognition by USP7 
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4 Investigation of the molecular determinants 
involved in p65 recognition by USP7 
4.1 Abstract 
The NF-κB transcription factor family is a key regulator of inflammation and 
orchestrates the transcriptional response to infection by directing the 
transcription of genes involved in these processes.  Ubiquitination, and 
subsequent proteasomal degradation, of NF-κB subunits is a critical factor in the 
termination of NF-κB mediated responses. However, ubiquitin chains can be 
removed by DUBs. USP7 is a crucial DUB for NF-κB subunits deubiquitination. 
USP7 is known to deubiquitinate the p65 subunit of NF-κB; however, the 
molecular determinants of p65 recognition as a USP7 substrate are currently 
unknown. The blockade of this interaction inhibits the expression of pro-
inflammatory effectors. USP7 is involved in several biological processes, such as 
cell cycle, apoptosis, stress response, DNA repair, cell survival, tumourigenesis, 
epigenetic regulation and viral infection due to its interaction with substrates 
involved in those processes. For this reason, targeting the catalytic 
deubiquitinase activity of USP7 leads to a variety of effects in many different 
biological processes. Therefore, we need to study the molecular determinants 
involved in USP7-p65 interaction in order to target p65 specifically. To 
understand the binding interface of USP7-p65 interaction, we performed a 
peptide array and subsequent alanine scanning array to identify the amino-acids 
of USP7 required for p65 recognition. Amino-acids within the C-terminal 
UBL12345 of USP7 were identified, the majority of the amino-acids being 
localised in a non-conserved loop of UBL3. Most of the amino-acids identified 
were charged, which is crucial in the generation of electrostatics interactions 
between proteins. Further investigation on the specific contribution of each UBL 
domain is required to identify the interaction binding pocket.  
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4.2 Introduction 
USP7 has been identified as an NF-κB deubiquitinase, critical for NF-κB 
transcriptional activity [287]. Inhibition of USP7 deubiquitinase activity inhibits 
the NF-κB response and it also affects several different biological processes. 
USP7 acts in various biological processes; such as apoptosis, DNA damage repair, 
cell cycle, transcription regulation, neuronal development, tumourigenesis, viral 
infection, epigenetic regulation and stress response [300, 418, 422, 433]; 
through the stabilisation or cellular localisation of proteins involved in those 
processes, for example, DNMT1, p53, claspin [300, 422, 433] and ICP0 [300, 
422]. Knowledge of the specific binding site with each target would enable 
strategies to target specific substrates of USP7.  
USP7 contains an N-terminal MATH/TRAF domain involved in substrate 
recognition [408, 411]; a C-terminal domain containing five UBLs [300, 418, 422] 
essential for an effective catalytic activity [408]; and a conserved CD [406, 408, 
411]. p65 is known to be recognised by the C-terminal region of USP7 [287]. 
Nevertheless, the molecular determinants involved in USP7-p65 interaction are 
still unknown. Peptide arrays are a useful tool to study protein-protein 
interactions [469, 470]. The peptide array method consists in the synthesis of a 
library of overlapping peptides covering the whole target sequence.  The most 
common procedure to prepare the peptide library on a solid support is the SPOT-
synthesis technique. The SPOT-synthesis method is a rapid and inexpensive way 
of simultaneous chemical synthesis of large numbers of predefined peptides on a 
variety of solid supports [470–473]. SPOT-synthesis of peptide libraries for 
peptide arrays is commonly used to map protein-protein interactions [469, 471, 
474]. Other uses of peptide arrays are extensively described in Applications of 
peptide arrays prepared by the SPOT-technology [471]. 
Peptide arrays when used for protein-protein interaction mapping are incubated 
with the binding protein (cell extract or recombinant protein) and detected 
through different techniques. Typically a primary antibody against the binding 
protein or the recombinant tag and a secondary antibody coupled to HRP are 
used [287, 475]. 
 138 
 
Based on the knowledge that USP7 C-terminal region is essential for the 
recognition of p65 as a substrate, we performed a USP7 C-terminal region 
peptide array. Interacting peptides were selected for subsequent alanine 
scanning array to determine the important amino-acids involved in the 
interaction. Those amino-acids are located within the 5 UBLs but a great number 
of them are located in a loop on UBL3 not conserved in the other UBLs. Amino-
acids identified in UBL1 correspond to positively charged amino-acids, while 
amino-acids identified in UBL2 are located in a negatively charged patch. 
However, amino-acids identified within UBL3, 4 and 5 (UBL345) are not in an 
overall negative or positive patch. Charged amino-acids form electrostatic 
interactions between proteins and are potential targets for drug discovery 
strategies. 
4.3 Results 
4.3.1 GST-p65 protein purification 
A recombinant GST-p65 protein was purified in order to perform a peptide array 
analysis. Recombinant GST-p65 plasmid was synthesised by GenScript. The 
murine p65 protein sequence was cloned into pET42a(+) expression vector. 
pET42a(+) vector allows inducible expression of GST fusion proteins in E.coli. 
Expression of GST-p65 protein requires the addition of IPTG to induce the 
activation of the promoter controlling the protein expression. E.coli BL21 DE3 
cells were transformed with pET42a(+)-GST-p65. The recombinant protein was 
induced with an optimised concentration of 0.5mM IPTG for 3 hours at 37°C. 
GST-p65 protein was subsequently purified through a GSTrap HP column (GE 
Healthcare, Bioscience AB). See Figure 4-1. 
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Figure 4-1 GST-p65 recombinant protein purification. A) GST-p65 recombinant protein 
purification process through the GSTrap HP column schematic. Firstly, the GSTrap HP column is 
calibrated by the addition of binding buffer. Subsequently the sample goes through the column, and 
the GST-p65 binds to the GSH sepharose beads. Addition of the washing buffer clears the column 
just maintaining the GST-p65 protein bound to the GSH sepharose beads. Lastly, addition of 
glutathione to the column competes for the GST-p65 protein binding and elutes it from the column. 
B) E. coli BL21 DE3 were transformed with pET42a(+) GST-p65 plasmid.  GST-p65 protein 
expression was induced with the addition of 0.5mM IPTG. The induced recombinant protein was 
affinity purified with a GSTrap HP column. Samples of each step of the process were analysed by 
western blotting for GST and p65. 
 
4.3.2 p65 protein is recognised by the C-terminal region of USP7 
Previous studies discovered USP7 as a deubiquitinase enzyme of p65 [287]. p65 
protein is recognised as a substrate of USP7 by its HUBL [287]. In order to 
confirm these findings a immunoprecipitation assay in HEK293T cells transfected 
with USP7 WT, a USP7 mutant lacking the MATH/TRAF domain (USP7ΔMATH) and 
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a USP7 mutant with the C-terminal HUBL deleted (USP7ΔHUBL) FLAG-tagged 
plasmids along with p65-HA was performed. Following cellular lysis, USP7 was 
immunoprecipitated with anti-FLAG antibody. Immunoprecipitated proteins were 
immunoblotted with anti-p65 and anti-FLAG antibodies. This analysis confirmed 
that deletion of the C-terminal region of USP7 is sufficient to inhibit p65 
interaction, while deletion of the MATH/TRAF domain has no effect on the 
interaction. See Figure 4-2. 
 
Figure 4-2 p65 is recognised by the C-terminal region of USP7. HEK293T cells were 
transfected with USP7, USP7ΔMATH and USP7ΔHUBL FLAG-tagged plasmids along with p65-
HA. Cell lysates were immunoprecipitated with an anti-FLAG antibody and immunoblotted with anti-
FLAG and anti-p65 antibodies. Deletion of the C-terminal region of USP7 is sufficient to inhibit the 
interaction with p65, while deletion of the N-terminal MATH/TRAF domain has no effect on p65 
recognition. The figure is a representative of three independent experiments. 
 
4.3.3 p65 binds to distinct peptides on a USP7 C-terminal region 
peptide array 
C-terminal region of USP7 is essential for the interaction with p65 [287]. This C-
terminal region of USP7 is formed by 5 UBLs. In order to experimentally identify 
the molecular determinants of USP7 mediating the interaction with p65, an 
immobilised peptide array based technique was performed. The peptide array 
consisted on a library of overlapping (4 amino-acids overlap) peptides of 18 
amino-acids in length covering amino-acids 541-1101 of the C-terminal region of 
USP7 (see appendix 8.3). USP7 overlapping peptides were SPOT-synthesised on 
nitrocellulose membranes (see Figure 4-3 and Table 4-1). USP7 peptide arrays 
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were then probed with either GST (previously purified by Dr. Patricia Collins) or 
GST-p65 proteins. Bound protein was detected by immunoblotting with anti-GST 
antibody (see Figure 4-3).  
GST-p65 protein specifically binds to a number of USP7 peptides suggesting that 
p65 likely makes contacts throughout the C-terminal region of USP7, not just 
specifically in one of the UBLs (see Table 4-2). The majority of the peptides 
identified were located within UBL3 and 4 (UBL34), with peptides identified in 
UBL3 more positively charged due to the presence of K and R amino-acids, and 
peptides identified in UBL4 more negatively charged due to the presence of D 
and E amino-acids. These domains may interact extensively with p65 protein. On 
the other hand, peptides identified on UBL 1, 2 and 5 (UBL125) are not as 
numerous but contain charged amino-acids within their sequences. Electrostatic 
interactions are the basis of protein-protein interactions. From this data it 
appears that UBL34 form more contacts with p65 than the rest of the UBLs; but 
interactions formed within UBL125 may be due to electrostatic forces which 
have an important role in the interaction. Electrostatics interactions within any 
of the UBLs and the substrate proteins may be important in the interaction. It is 
important to take into account that a greater number of identified peptides does 
not mean that those identified amino-acids are more important than amino-acids 
identified on any of the other UBLs. Based on the presence of negatively or 
positively charged amino-acids in those binding peptides, various peptides were 
selected for subsequent alanine scan analysis. 
Table 4-1 Peptide location within the C-terminal region of USP7 
 
Peptides Amino-acids USP7 region 
A1-A2 541-562 N-terminal 
A3-A6 549-578 N-terminal-Ubl1 
A7-A27 565-662 Ubl1 
A28-B1 649-678 Ubl1-linker 
B2 665-682 Linker 
B3-B6 669-698 Linker-Ubl2 
B7-B24 685-770 Ubl2 
B25-B28 757-786 Ubl2-linker 
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Peptides Amino-acids USP7 region 
B29 773-790 Linker 
B30-C3 777-806 Linker-Ubl3 
C4-C21 793-878 Ubl3  
C22-C24 865-890 Ubl3-linker 
C25 877-894 Ubl3-linker-Ubl4 
C26-C29 881-910 Linker-Ubl4 
C30-D9+F1-F6 897-972 Ubl4 
F7+D14-D15 959-984 Ubl4-linker 
D16 971-988 Ubl4-linker-Ubl5 
D17-D19 975-1000 Linker-Ubl5 
D20-E9 987-1080 Ubl5 
E10-E13 1067-1096 Ubl5-C-terminal 
E14-E15 1083-1101 C-terminal 
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Figure 4-3 Identification of p65 interacting regions on USP7 using peptide arrays. A) Peptide 
array of immobilised 18-mer peptides overlapping by 4 amino-acids schematic. B) Peptide arrays 
of immobilised overlapping 18-mer peptides, each shifted to the right by 4 amino-acids 
encompassing the full C-terminal region of USP7 were generated. Arrays were probed with GST or 
GST-p65 and immunoblotted with anti-GST antibody. Each dot represents binding of the protein to 
the peptide arrays. Each peptide array is labelled by a letter followed by a number. Sequences of 
the peptides are shown on section 8.3. 
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Table 4-2 Peptide arrays identified within USP7 UBLs 
 
USP7 UBL Domain Identified peptide array 
UBL1 A20 
A23 
UBL2 B7 
B10 
B24 
UBL3 C13 
C15 
C17 
C20 
C23 
C24 
C25 
UBL4 C25 
D11 
D15 
F6 
F7 
UBL5 D25 
E11 
 
4.3.4 Alanine substitution arrays identify interacting residues on 
USP7 
In order to identify individual amino-acids essential for p65 binding within the 
regions of USP7 identified by the peptide array, a series of alanine-scanning 
arrays were generated.  Alanine scanning arrays were derived from the 18-mer 
nucleotides parent peptide by subsequent single alanine substitutions (see 
appendix 8.4); in other words, each amino-acid was sequentially mutated to an 
alanine, whereas alanine residues were not mutated to a different amino-acid.  
Protein interactions are more likely to happen through electrostatic interactions 
between opposite charges. Thus, peptides were selected based on the peptide 
array results and on their amino-acidic composition. Peptides containing a high 
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charged amino-acid content were selected for subsequent alanine scan (see 
Table 4-3). The alanine scanning array was incubated with GST-p65 and 
immunoblotted with anti-GST antibody. GST-p65 bound to the alanine scanning 
arrays was detected by HRP-conjugated antibody. For each alanine substitution, 
the binding of GST-p65 was calculated in comparison to the binding of the 
parent peptide. Substitutions with less than a 60% binding of the parent peptide 
were considered as important amino-acids for p65 recognition as a substrate (see 
Table 4-4). These data indicated a number of key amino-acids within all five 
UBLs, but mostly located on UBL3 (see Figure 4-4). Most of the amino-acids 
identified as important within all UBLs are K, R, D or E. Taking this into account, 
contribution of each UBL to the interaction must be studied; a greater number 
of contacts within a UBL does not mean that UBL drives the interaction, it may 
be important but not essential for the interaction. 
Table 4-3 Peptide arrays selected for alanine scanning 
 
Peptide Sequence 
A23 SNGTKRPAMLDNEADGNK 
B24 LDKALDELMDGDIIVFQK 
C13 RLNTDPMLLQFFKSQGYR 
C15 LQFFKSQGYRDGPGNPLR 
C17 YRDGPGNPLRHNYEGTLR 
C20 YEGTLRDLLQFFKPRQPK 
C25 YYQQLKMKITDFENRRSF 
C30 IWLNSQFREEEITLYPDK 
D25 FLLRIHQGEHFREVMKRI 
E10 PGNMSHPRPWLGLDHFNK 
E15 APKRSRYTYLEKAIKIH 
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Table 4-4 Amino-acids identified by the alanine scanning peptide array 
 
Amino-acid Position Domain Peptide 
K 633 UBL1 A23 
R 634 UBL1 A23 
K 646 UBL1 A23 
L 757 UBL2 B24 
D 758 UBL2 B24 
E 759 UBL2 B24 
L 760 UBL2 B24 
D 833 UBL3 C13 
M 835 UBL3 C13 
F 839 UBL3 C13 
G 844 UBL3 C15  
Y 845 UBL3 C13 
R 646 UBL3 C15/C17 
D 847 UBL3 C15/C17 
G 848 UBL3 C17 
P 849 UBL3 C15 
G 850 UBL3 C15/C17 
N 851 UBL3 C15/C17 
L 853 UBL3 C15/C17 
R 854 UBL3 C15/C17 
N 855 UBL3 C17 
Y 856 UBL3 C17 
E 857 UBL3 C17 
G 858 UBL3 C17 
T 859 UBL3 C17 
L 860 UBL3 C17 
R 861 UBL3 C17 
Q 872 UBL3 C20 
D 887 Linker C25 
F 888 Linker C25 
L 899 UBL4 C30 
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Amino-acid Position Domain Peptide 
F 903 UBL4 C30 
E 905 UBL4 C30 
K 914 UBL4 C30 
E 1019 UBL5 D25 
R 1023 UBL5 D25 
I 1024 UBL5 D25 
R 1074 UBL5 E10 
P 1075 UBL5 E10 
W 1076 UBL5 E10 
L 1079 UBL5 E10 
D 1080 UBL5 E10 
H 1081 C-terminal E10 
F 1082 C-terminal E10 
K 1084 C-terminal E10 
N 1102 C-terminal E15 
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Figure 4-4 Important amino-acids of USP7 involved in p65 binding. Selected 18 amino-acids 
length peptides from USP7 sequentially substituted with alanine, probed with GST-p65 and 
immunoblotted with anti-GST antibody. Binding of GST-p65 protein to each substituted alanine 
peptides was compared to the binding of the parent peptide. Each peptide is labelled on the left of 
the image, their sequences are marked under the peptide array. The first peptide in each array 
corresponds to the parent peptide. Amino-acids included in the array and their location within the 
C-terminal region is indicated in the right side of the image. Amino-acid substitutions leading to a 
40% reduction compared to parent peptides are marked with an asterisk. 
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4.3.5 Localisation of the p65 interacting amino-acids within the 
USP7 sequence and structure 
The C-terminal region of USP7 is formed by five UBLs which share the ubiquitin 
β-grasp fold [299, 408, 418]. Despite sharing the ubiquitin fold, they are not 
more similar to each other than to UBL domains from different proteins [408, 
418]. The 5 UBLs are very divergent in sequence [408, 418]. Here, we localised 
the important amino-acids identified by the peptide array and subsequent 
alanine scan in USP7 sequence and structure of USP7 C-terminal region (see 
Figure 4-5 and Figure 4-6). Most of the identified amino-acids are located on 
UBL3, specifically in a loop not conserved among the UBLs. Moreover, most of 
the identified amino-acids correspond to charged amino-acids (K, R, D, E), which 
are more likely to be important for protein-protein interactions through the 
formation of electrostatic interactions. Some of the amino-acids identified are 
located in an internal area of the protein, which is not able to interact with 
other proteins. Amino-acids identified on UBL1 are positively charged, creating a 
positive patch which might interact with a negative patch on p65. Whereas, 
amino-acids identified on UBL2 are in a negative patch and might be identified 
by a positive charged motif on p65. These amino-acids are also located on a 
groove which is suitable to form a binding pocket for protein recognition. In the 
case of UBL345, positive and negatively charged amino-acids are recognised in 
the same way, so their charges may be neutralised, not forming a positive or 
negative patch (see Figure 4-6). Besides amino-acids on UBL3 which are located 
in a non-conserved loop and amino-acids on UBL2 which are located on a 
possible binding pocket groove; amino-acids on UBL1, 4 and 5 (UBL145) are not 
located on a specific structural position which would indicate substrate 
recognition and binding. Contribution of each domain to the interaction is still 
unknown. 
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Figure 4-5 Sequence localisation of USP7 amino-acids identified by the peptide array and 
subsequent alanine scan. USP7 C-terminal region sequence. UBL1 is coloured in purple, UBL2 
in blue, UBL3 in green, UBL4 in yellow and UBL5 in brown. Identified amino-acids by the peptide 
array and subsequent alanine scanning are highlighted in bold and marked with an asterisk. 
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Figure 4-6 Structural localisation of USP7 amino-acids identified by the peptide array and 
subsequent alanine scan. A) 3D structure of the C-terminal region of USP7 in white with the 
identified amino-acids in red (PDB: 2YLM). B) UBL domains 3D structure from the front of the 
domain and from the top. UBLs are coloured in white and identified amino-acids in red. 
 
4.3.6 Suitability of the recombinant GST-p65 protein for functional 
GST-pull down assays 
GST-pull down assays can be used to detect protein complexes formation. We 
performed this technique in order to subsequently evaluate the effect of 
inhibitory peptides on USP7-p65 complex formation. GST or GST-p65 
recombinant proteins were incubated with a whole HEK293T cell lysate 
overexpressing FLAG-tagged USP7 and affinity purified with GSH agarose. USP7 
did not co-purify with either GST-p65 recombinant protein laboratory purified or 
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commercial one (see Figure 4-7). GST-p65 laboratory purified protein is a full 
length p65 murine protein, while commercial GST-p65 is a truncated version of 
p65 human protein, containing amino-acids 12-317. GST-p65 purified protein is 
very unstable and 2 hours at 4°C was sufficient for degradation of p65 protein 
(see Figure 4-7). On the other hand, commercial GST-p65 is a truncated version 
of p65 human protein. It might be possible that amino-acids interacting with 
USP7 are missing on the truncated version of the protein. Both experiments were 
carried out at the same time as a positive technical control with a GST-p50 
protein and an overexpressed Bcl-3 FLAG-tagged protein. GST-p50 is known to be 
able to pull down overexpressed Bcl-3 [466]. GST protein and GST-p50 
recombinant protein were previously purified by Dr Patricia Collins. See Figure 
4-7. To test the commercial GST-p65 truncated protein we added another 
control. p65 protein dimerises with p50 protein through the C-terminal region of 
their RHD domains which is contained in the truncated version of the GST-p65 
commercial protein. Thus, we overexpressed p50 FLAG-tagged protein in order 
to analyse the ability of GST-p65 truncated protein to bind to overexpressed p50 
protein. However, GST-p65 truncated protein is not able to interact with p50. 
These data indicate that recombinant p65 is not suitable for pulldown 
experiments to investigate interaction with USP7. 
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Figure 4-7 Functional GST-pulldown assay of the recombinant GST-p65 protein. A) GST or 
GST-p65 recombinant proteins were incubated with a whole HEK293T cell lysate overexpressing 
FLAG-tagged USP7 and FLAG-tagged p50 and affinity purified with GSH agarose.  Commercial 
GST-p65 is not able to bind USP7 or p50 protein. GST or GST-p50 recombinant proteins were 
incubated with a whole HEK293T cell lysate overexpressing FLAG-tagged Bcl3 and affinity purified 
with GSH agarose as a technical control. The technical control shows interaction between GST-
p50 and Bcl3. B) GST or GST-p65 recombinant proteins were incubated with a whole HEK293T 
cell lysate overexpressing FLAG-tagged USP7 and affinity purified with GSH agarose. Purified 
GST-p65 is not able to bind USP7. By the end of the experiment the recombinant protein is 
degraded. GST or GST-p50 recombinant proteins were incubated with a whole HEK293T cell 
lysate overexpressing FLAG-tagged Bcl3 and affinity purified with GSH agarose as a technical 
control. The technical control performed with a GST-p50 and Bcl3 FLAG-tagged protein shows 
interaction between GST-p50 and Bcl3. 
 154 
 
 
4.3.7 Testing the effects of USP7 mimetic peptides on USP7-p65 
interaction 
As most of the identified amino-acids are located in a non-conserved loop on 
UBL3 (amino-acids 844-860), we decided to design USP7 mimetic peptides to 
determine if these mimetic peptides could disrupt the interaction with p65. 
Three USP7 mimetic peptides were designed based on the USP7 sequence of 
UBL3, which were designated as Upep1, Upep2 and Upep3. Upep1 covers amino-
acids 844-854, Upep2 amino-acids 853-860, and Upep3 encompasses both of 
them (see Figure 4-8 and Table 4-5).  
 
Figure 4-8 UBL3 non-conserved loop. Sequence of the UBL3 non-conserved loop and structural 
location on USP7 UBL3 3D structure (PDB: 2YLM). 
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Table 4-5 USP7 mimetic peptides sequences. 
 
Peptide Sequence Amino-acids location 
Upep1 GYRDGPGNPLR 844-854 
Upep2 LRHNYEGT 853-860 
Upep3 RDGPGNPLRHNYEGT 846-860 
 
Since GST pulldown is not suitable to assess the interaction between USP7 and 
p65, we decided to perform a immunoprecipitation assay with the addition of 
the USP7 mimetic peptides. In order to study the ability of USP7 mimetic 
peptides to disrupt an already bound USP7-p65 complex, we co-transfected 
HEK293T cells with USP7-FLAG and p65-HA proteins. Lysates were 
immunoprecipitated with an anti-FLAG antibody in the presence of individual 
peptides (100μM) overnight at 4°C. Proteins were detected by western blotting 
and immunoblotted with anti-FLAG and anti-p65 antibodies. None of the 
peptides was able to disrupt the USP7-p65 complex (see Figure 4-9). To 
investigate the ability of the peptides to prevent USP7-p65 interaction, we 
transfected HEK293T cells with p65-HA plasmid and different HEK293T cells with 
USP7-FLAG. Cellular p65 lysates were combined with cellular USP7 lysates and 
immunoprecipitated with an anti-FLAG antibody in the presence of individual 
USP7 peptides (100μM) overnight at 4°C. However, USP7 and p65 when 
transfected separately and mixed are not able to form an interacting complex 
(see Figure 4-9). These data demonstrated that mutational approaches would be 
required to identify the role of UBL3 domain in the interaction. 
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Figure 4-9 Role of USP7 mimetic peptides disrupting the interaction. A) Co-transfection of 
HEK293T cells with USP7-FLAG and p65-HA plasmids. Lysates were immunoprecipitated with an 
anti-FLAG antibody in the presence of individual USP7 mimetic peptides (100μM). There is no 
disruption of the interaction due to the presence of any USP7 mimetic peptide. The figure is a 
representative of three independent experiments. B) Transfection of HEK293T cells with USP7-
FLAG and p65-HA plasmid separately. Cellular lysates were mixed and immunoprecipitated with 
an anti-FLAG antibody in the presence of individual USP7 mimetic peptides (100μM). Lysates 
containing USP7 and p65 separately are not able to form a USP7-p65 interacting complex. The 
figure is a representative of three independent experiments. 
 
4.4 Discussion 
The p65 subunit is recognised as a USP7 substrate by USP7 C-terminal region 
[287]. The C-terminal region of USP7 is composed of five UBLs which share the 
ubiquitin β-grasp fold [299, 300]. Despite very low sequence similarity their 
structures share homology [418]. These 5 UBLs are arranged in an elongated 
2+1+2 conformation (UBL12 + UBL3 + UBL45). UBL12 and UBL45 form stable 
dimers and are connected to UBL3 through small linkers. These linkers give some 
flexibility to the C-terminal region of USP7 [299, 300, 408, 418, 422]. We 
performed a peptide array and subsequent alanine scan analysis to further 
investigate the amino-acids in charge of the interaction. Most of the amino-acids 
identified are localised in UBL3, specifically in a loop not present in the other 
UBLs.  UBL45 are required for full deubiquitinase activity of USP7, while UBL123 
are in charge of substrate recognition [299, 300, 408, 418, 422]. Flexibility of 
UBL3 is required for the structural rearrangements of USP7 leading to its active 
state [299, 300, 408, 418, 422]. We hypothesised an important role of UBL3 in 
p65 recognition, which is supported by the presence of a non-conserved crystal 
structure formed by several positively charged amino-acids. The presence of 
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positively charged amino-acids gives the possibility of forming electrostatic 
interactions with a negatively charged area of p65 protein. 
To further assess the role of the non-conserved loop on UBL3 we tried to 
perform a functional analysis. Commonly, interaction of proteins is studied by a 
GST-pulldown. Recombinant protein of interest is incubated with a cellular 
lysate and pulldown by affinity binding. For p65 protein this approach was not 
possible due to the instability of the protein, which is degraded after 2h at 4°C. 
On the other hand, commercially available p65 is truncated; it lacks the TAD 
domain.  
We tested the contribution of UBL3 amino-acids 844-860 located in a non-
conserved loop to USP7-p65 interaction; by generation of USP7 mimetic peptides 
and immunoprecipitation assays but no inhibition of the interaction was found. 
These results may be due to the technique performed not being suitable enough 
to study the contribution of the UBL3 non-conserved loop, or due to that loop 
not being essential for the interaction. A protein may be recognised by a specific 
binding pocket, but that does not mean that region is the only region making 
contacts with the target protein. Proteins in nature are flexible, and upon 
binding, they undergo conformational rearrangements in order to form an stable 
complex [476]. It could be possible that the binding site is not localised on UBL3 
non-conserved loop, but those contacts are required upon recognition and 
binding to stabilise the complex.  
Amino-acids throughout the entire C-terminal sequence of USP7 were identified 
as important amino-acids for the interaction. Despite localising a very promising 
binding area on a non-conserved loop with several positively charged amino-
acids on UBL3; none of the methods used detected an effect on USP7-p65 
interaction. Further experiments to elucidate the contribution of each UBL 
domain to the interaction are required.  
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5 Identification of UBL2 domain of USP7 as 
essential for the interaction with p65 
5.1 Abstract 
USP7 deubiquitinase enzyme controls the deubiquitination of p65 subunit of NF-
κB. Inhibition of USP7 deubiquitinase activity blocks pro-inflammatory gene 
expression. USP7 has a broad range of substrates involved in different biological 
processes. Thus, selective inhibition of USP7 activity towards p65 is required in 
order to harness the therapeutic potential of USP7 inhibition in inflammatory 
disease. USP7 multidomain protein recognises substrates by different regions. 
The N-terminal MATH/TRAF domain recognises substrates such as EBNA1, p53 
and MDM2, while substrates like DNMT1, UHRF1, ICP0 and p65 are recognised by 
the C-terminal region. Within the C-terminal region a pocket in UBL2 generates 
the binding site for a number of substrates, as for example, ICP0, DNMT1 and 
UHRF1. This binding pocket located in UBL2 recognises a positively charged 
motif K/RxKxxxK in substrates like DNMT1 and UHRF1. We performed a series of 
mutational experiments followed by immunoprecipitation assays to study the 
role of each UBL in the interaction and the possibility of a binding pocket for p65 
recognition. Our data identified that deletion of UBL2 inhibits interaction of 
USP7 with p65 and thereby, USP7 deubiquitination of p65. However, UBL2 is not 
required for interaction with a series of substrates such as DAXX, p53, EBNA1 and 
RelB. These data suggest that substrate specific inhibition might be possible, 
which is crucial for therapeutic purposes as substrate selective inhibition of USP7 
activity enables the targeting of the pro-inflammatory effects of p65 while 
maintaining the biological roles of USP7 through different substrates.  
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5.2 Introduction 
As explained in section 1.2, NF-κB transcription factor family regulates 
inflammation and transcriptional response upon infection [287] and is tightly 
regulated. NF-κB nuclear regulation occurs by the balance between 
ubiquitination and deubiquitination. USP7 recognises the p65 subunit through its 
C-terminal region and deubiquitinates it [287]. Inhibition of the deubiquitinating 
activity of USP7 blocks pro-inflammatory gene transcription [287].  However, 
USP7 is involved in several biological processes in pathology and physiology such 
as inflammation, tumourigenesis, cell cycle, apoptosis, DNA repair and viral 
infection; through the stabilisation and localisation of proteins involved in those 
processes like DNMT1, p53, UHRF1, MDM2, ICP0, NF-κB family members [287, 
418, 431, 477]. Identification of the specific molecular determinants involved in 
p65 recognition by USP7 is required in order to develop specific inhibitors of the 
NF-κB response. 
Protein-protein interactions are defined by the structural arrangements of the 
proteins involved in the interaction [476]; thereby, USP7 structure plays a key 
role to understand substrate recognition. As explained in section 1.4.3.1, USP7 is 
composed of an N-terminal MATH/TRAF domain, a catalytic domain and a C-
terminal domain composed by 5 UBLs, the HUBL [287, 299, 418]. The N-terminal 
MATH/TRAF domain and UBL12 domains are involved in substrate recognition 
[41, 418]. USP7 is known to interact with all NF-κB members [287], but the 
interacting region has only been studied for p65. Interaction of USP7 with p65 
requires the C-terminal region but not the N-terminal region [287]. Homology 
between the NF-κB subunits might suggest similar mechanisms for recognition by 
USP7. The five NF-κB subunits share an N-terminal RHD but only p65, RelB and c-
Rel contain a C-terminal TAD domain. RelB also incorporates an N-terminal LZ 
domain. [1, 40, 52, 478–481]. These structural differences might lead to 
different interacting mechanisms with USP7. 
In this chapter, we investigated the contribution of each UBL domain of USP7 to 
the interaction with p65, identifying UBL2 of USP7 as the domain in control of 
p65 recognition. Furthermore, we studied the effect of UBL2 deletion on the 
recognition of different USP7 substrates such as DAXX, EBNA1, p53, c-Rel and 
RelB, detecting effects only on c-Rel recognition. To further analyse the 
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inhibition of USP7 deubiquitinase activity on p65 we explored the effect of USP7 
UBL2 deletion on its deubiquitinase activity, confirming that inhibition of the 
interaction correlates with inhibition of the deubiquitinase activity.  
5.3 Results 
5.3.1 USP7 UBL2 is required for interaction with p65 
To further analyse the binding site of USP7-p65 interaction we created a series 
of USP7 mutants through site directed mutagenesis (explained in section 2.2.6). 
In order to investigate the contribution of each UBL domain to the interaction 
with p65 we created a series of C-terminal truncated USP7 mutants lacking one 
or more UBLs. As a result, we obtained USP7ΔUBL5 in which UBL5 is deleted, 
USP7ΔUBL45 in which UBLs 4 and 5 are deleted, USP7ΔUBL345 in which UBLs 3, 4 
and 5 are deleted and USP7ΔUBL2345 in which UBLs 2, 3, 4 and 5 are deleted 
(see Figure 5-1). Mutant USP7ΔHUBL in which all five UBLs are deleted, was 
previously generated in the group [287]. HEK293T cells were co-transfected with 
USP7 WT, USP7ΔUBL5, USP7ΔUBL45, USP7ΔUBL345, USP7ΔUBL2345 and 
USP7ΔHUBL FLAG-tagged plasmids along with p65-HA plasmid. Cellular lysates 
were immunoprecipitated with an anti-FLAG antibody and immunoblotted with 
anti-FLAG and anti-p65 antibodies (see Figure 5-2). USP7ΔUBL2345 and 
USP7ΔHUBL totally abolish the interaction with p65, while USP7ΔUBL45 and 
USP7ΔUBL345 decrease the level of interacting p65 protein.  
As USP7ΔUBL45 and USP7ΔUBL345 demonstrated decreased interaction with p65, 
we decided to further study the effect of UBL4 and UBL3 by deletion of each 
domain (see Figure 5-1). HEK293T cells were co-transfected with USP7 WT, 
USP7ΔUBL4, USP7ΔUBL3, USP7ΔUBL45 and USP7ΔHUBL FLAG-tagged plasmids 
along with p65-HA plasmid. Cellular lysates were immunoprecipitated with an 
anti-FLAG antibody and immunoblotted with anti-FLAG and anti-p65 antibodies 
(see Figure 5-2). USP7ΔUBL4 and USP7ΔUBL3 are able to interact with p65, thus 
neither UBL3 nor UBL4 are required for p65 interaction. 
As mutant USP7ΔUBL45 decreases the interaction with p65, we decided to study 
the effect of the UBL3 and UBL4 linker. The peptide array analysis identified two 
amino-acids D887 and F888, which are located in an α-helix within the linker 
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between both domains (see Figure 5-3). Those amino-acids were not present in 
USP7ΔUBL45 mutant, so we decided to analyse the contribution of this linker to 
the interaction with p65, by deletion or mutation to alanine of the amino-acids 
forming the α-helix, 885-ITDFEN-890. HEK293T cells were co-transfected with 
USP7 WT, USP7ΔUBL3-4Linker, USP7 UBL3-4Linker to alanine, USP7ΔUBL45 and 
USP7ΔHUBL FLAG-tagged plasmids along with p65-HA plasmid. Cellular lysates 
were immunoprecipitated with an anti-FLAG antibody and immunoblotted with 
anti-FLAG and anti-p65 antibodies (see Figure 5-2). Both mutants were able to 
interact with p65, suggesting that the linker is not required for p65 interaction. 
Further investigation of possible structural models of the interacting USP7-p65 
complex was performed during a stay in AstraZeneca (described on section 
6.3.3). Based on these analyses we created two possible mutants located on 
UBL3 and UBL3-4 linker region which could affect the interaction with p65, USP7 
K869A and USP7 P884A respectively. K869 mutation to alanine could affect the 
potential formation of a salt bridge with D94 of p65 and P884 mutation to 
alanine could change the conformation of the loop coordinating the DNA-p65 
interaction. The model also suggested possible contacts with UBL1 and UBL2 (see 
appendix 8.5); thus we created two more mutants, USP7ΔUBL1 in which UBL1 is 
deleted and USP7ΔUBL2 in which UBL2 is deleted (see Figure 5-1). HEK293T cells 
were co-transfected with USP7 WT, USP7ΔUBL1, USP7ΔUBL2, USP7 K869A, USP7 
P884A and USP7ΔUBL2345 FLAG-tagged plasmids along with p65-HA plasmid. 
Cellular lysates were immunoprecipitated with an anti-FLAG antibody and 
immunoblotted with anti-FLAG and anti-p65 antibodies (see Figure 5-2). Deletion 
of UBL2 domain was sufficient to inhibit USP7-p65 interaction, while the rest of 
the mutations did not prevent interaction with p65.  
To study the contribution of amino-acids within UBL2 of USP7 to the interaction 
with p65, we designed several mutants. These mutants were based on the 
peptide array data (see section 4.3.5) and knowledge of the USP7 binding pocket 
for its interaction with ICP0, DNMT1 and UHRF1 [41]. The peptide array data 
identified amino-acids 757-LDEL-760 as potentially involved in p65 recognition 
(see Figure 4-4). D762 and D764 have previously been implicated as mediators of 
USP7 interaction with ICP0, UHRF1 and GMPS [41] .To investigate the role of 
these amino-acids in the interaction with p65 we created several mutants, USP7 
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DE758-759AA, USP7 D762A D764A, USP7 LDEL757-760AAAA, USP7 LDEL757-
760AAAA D762A D764A and USP7 DE758-759AA D762A D764A (denominated USP7 
DE, USP7 DD, USP7 LDEL, USP7 LDELDD and USP7 DEDD respectively) (see Table 
5-1). HEK293T cells were co-transfected with USP7 WT, USP7 DE, USP7 DD, USP7 
DEDD, USP7 LDEL, USP7 LDELDD and USP7ΔUBL2 FLAG-tagged plasmids along 
with p65-HA plasmid. Cellular lysates were immunoprecipitated with anti-FLAG 
antibody and immunoblotted with anti-FLAG and anti-p65 (see Figure 5-4). There 
are no significant differences in the interaction of the mutants with p65. 
 
Figure 5-1 USP7 mutants structural schematic. Schematic representation of USP7ΔUBL5, 
USP7ΔUBL45, USP7ΔUBL345, USP7ΔUBL2345, USP7ΔHUBL, USP7ΔUBL4, USP7ΔUBL3, 
USP7ΔUBL2 and USP7ΔUBL1 USP7 mutants used for the immunoprecipitation assays. 
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Figure 5-2 USP7 UBL2 deletion abolishes interaction with p65. A) HEK293T cells were co-
transfected with USP7 WT, USP7ΔUBL5, USP7ΔUBL45, USP7ΔUBL345, USP7ΔUBL2345 and 
USP7ΔC FLAG-tagged plasmids along with p65-HA plasmid. Cellular lysates were 
immunoprecipitated with an anti-FLAG antibody and immunoblotted with anti-FLAG and anti-p65 
antibodies. USP7ΔUBL2345 abolishes USP7-p65 interaction. The figure is a representative of 
three independent experiments. B) HEK293T cells were co-transfected with USP7 WT, 
USP7ΔUBL4, USP7ΔUBL3, USP7ΔUBL45 and USP7ΔC FLAG-tagged plasmids along with p65-
HA plasmid. Cellular lysates were immunoprecipitated with an anti-FLAG antibody and 
immunoblotted with anti-FLAG and anti-p65 antibodies. Deletion of UBL3 or UBL4 did not inhibit 
USP7-p65 interaction. The figure is a representative of three independent experiments. C) 
HEK293T cells were co-transfected with USP7 WT, USP7ΔUBL3-4Linker, USP7 UBL3-4Linker to 
alanine, USP7ΔUBL45 and USP7ΔHUBL FLAG-tagged plasmids along with p65-HA plasmid. The 
amino-acids mutated to alanine or deleted in the linker between UBL3 and UBL4, are 885-ITDFEN-
890. Cellular lysates were immunoprecipitated with an anti-FLAG antibody and immunoblotted with 
anti-FLAG and anti-p65 antibodies. The linker between UBL3 and UBL4 is not required for USP7-
p65 interaction. The figure is a representative of three independent experiments. D) HEK293T cells 
were co-transfected with USP7 WT, USP7ΔUBL1, USP7ΔUBL2, USP7 K869A, USP7 P884A and 
USP7ΔUBL2345 FLAG-tagged plasmids along with p65-HA plasmid. Cellular lysates were 
immunoprecipitated with an anti-FLAG antibody and immunoblotted with anti-FLAG and anti-p65 
antibodies. Deletion of UBL2 prevents USP7-p65 interaction. The figure is a representative of three 
independent experiments. 
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Figure 5-3 Location of the important amino-acids in the linker between UBL3 and UBL4 of 
USP7. A) C-terminal sequence of USP7 C-terminal UBLs. Important amino-acids identified in the 
peptide array analysis and subsequent alanine scan are underlined, in italics and marked in red. 
UBL1 is coloured in purple, UBL2 is coloured in blue, UBL3 is coloured in green, UBL4 in yellow 
and UBL5 in maroon. Amino-acids D887 and F888 are marked in an orange circle. B) USP7 C-
terminal region 3D structure with amino-acids ITDFEN 885-890 coloured in red. Amino-acids 885-
ITDFEN-890 were mutated to alanine or deleted in order to study the contribution of UBL3-UBL4 
linker to the interaction with p65. PDB: 2YLM. 
  
 166 
 
Table 5-1 USP7 UBL2 new mutants 
 
Mutant Name Mutation 
USP7 DE D758A 
E759A 
USP7 DD D762A 
D764A 
USP7 LDEL L757A 
D758A 
E759A 
L760A 
USP7 LDELDD L757A 
D758A 
E759A 
L760A 
D762A 
D764A 
USP7 DEDD D758A 
E759A 
D762A 
D764A 
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Figure 5-4 Mutation of USP7 757-LDEL-760 762D and 764D to alanine is not sufficient to 
abolish USP7-p65 interaction. HEK293T cells were co-transfected with USP7 WT, USP7 DE, 
USP7 DD, USP7 DEDD, USP7 LDEL, USP7 LDELDD and USP7ΔUBL2 FLAG-tagged plasmids 
along with p65-HA plasmid. Cellular lysates were immunoprecipitated with an anti-FLAG antibody 
and immunoblotted with anti-FLAG and anti-p65 antibodies. None of the mutations was sufficient to 
abolish USP7-p65 interaction. The figure is a representative of three independent experiments. 
 
5.3.2 USP7 ΔUBL2 does not reverse p65 ubiquitination. 
USP7ΔUBL2 mutant abolishes the interaction with p65, however, the ability of 
the mutant to inhibit p65 deubiquitination was still unknown. To study the effect 
of USP7ΔUBL2 deubiquitinase activity on p65 we performed a cellular 
ubiquitination assay with USP7 WT and USP7ΔUBL2 mutant. In order to be able to 
detect p65 ubiquitination status, we co-transfected HEK293T cells with USP7 WT 
and USP7ΔUBL2 FLAG-tagged plasmids along with p65 and ubiquitin-HA plasmids. 
In the first place we cloned human p65-HA plasmid into an empty pCDNA3.1 
expression vector (see appendix 8.2). Cellular lysates from the co-transfected 
HEK293T cells were denatured prior to immunoprecipitated with an anti-p65 
antibody and immunoblotted with anti-FLAG, anti-p65 and anti-HA antibodies 
(see Figure 5-5). In contrast to USP7 WT, which effectively blocked p65 
ubiquitination, USP7ΔUBL2 is not able to deubiquitinate p65 protein. These data 
further support the interaction with p65 in order to regulate p65 
deubiquitination. 
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Figure 5-5 USP7ΔUBL2 mutant is not able to deubiquitinate p65 protein. HEK293T cells were 
co-transfected with USP7 WT and USP7ΔUBL2 FLAG-tagged plasmids along with p65 and 
ubiquitin-HA plasmids. Cellular lysates were immunoprecipitated with p65 antibody and 
immunoblotted with anti-FLAG, anti-HA and anti-p65 antibodies. Deletion of UBL2 blocks the ability 
of USP7 to deubiquitinate p65 protein. The figure is a representative of three independent 
experiments. 
 
5.3.3 USP7 substrate specificity 
USP7 acts in several biological processes through the stabilisation or  regulation 
of cellular localisation of proteins involved in those processes [287, 418, 431, 
477]. In order to further study the role of UBL2 in regulating substrate 
interaction, we investigated the effect of USP7ΔUBL2 mutant on several 
different substrates interactions.  
USP7 is known to interact with all NF-κB members [287]. These NF-κB members 
contain a high sequence similarity and structural homology. However, only RelB, 
c-Rel and p65 contain a TAD domain so we decided to analyse the interaction of 
USP7ΔUBL2 only with RelB and c-Rel.  HEK293T cells were co-transfected with 
USP7 WT and USP7ΔUBL2 FLAG-tagged plasmids along with RelB and c-Rel 
respectively. Cellular lysates were immunoprecipitated with anti RelB and anti 
c-Rel respectively and immunoblotted for USP7 and c-Rel or RelB. RelB 
interaction with USP7 is not affected by the deletion of USP7 UBL2, while c-Rel 
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interaction is abolished when USP7 UBL2 is deleted (see Figure 5-6). Protein-
protein interactions are regulated by the 3D structure of proteins involved in the 
interaction; therefore, we performed a structural alignment of the five NF-κB 
members to detect structural differences. All NF-κB subunits when structurally 
aligned show clear differences between p50 (PDB: 1SVC), p52 (PDB: 3DO7), RelB 
(3DO7), c-Rel (PDB: 1GJI) and p65 (PDB: 1VKX). p50 and p52 contain an α-helix 
not present on RelB, c-Rel and p65 (see Figure 5-7). This α-helix is located in the 
N-terminal region, where the RHD domain is located. Analysis of the domain 
composition of all family members showed that p50 and p52 are formed by the 
RHD domain and a GRR region; while RelB, c-Rel and p65 are formed by the RHD 
domain and the TAD domain. RelB also contains a leucine zipper domain in the 
N-terminal region of the protein. These differences in the protein structure 
would be sufficient to determine a different mechanism for substrate 
recognition by USP7. 
One of the most studied substrates of USP7 is the p53 tumour suppressor 
protein. We decided to analyse the effect of USP7 UBL2 deletion on the 
interaction with p53 protein. HEK293T cells were co-transfected with USP7 WT 
or USP7ΔUBL2 FLAG-tagged plasmids along with p53 plasmid. Cellular lysates 
were immunoprecipitated with anti-FLAG antibody and immunoblotted with 
anti-FLAG and anti-p53 antibodies (see Figure 5-6). This data demonstrated that 
interaction of USP7 with p53 was not disrupted by the deletion of USP7 UBL2.  
USP7 also interacts with several viral proteins including the Epstein Barr viral 
protein, EBNA1. HEK293T cells were co-transfected with USP7 WT or USP7ΔUBL2 
FLAG-tagged plasmids along with EBNA1-FLAG-HA-tagged plasmid. Cellular 
lysates were immunoprecipitated with anti-HA antibody and immunoblotted with 
anti-FLAG and anti-USP7 antibodies (see Figure 5-6). Similar to the interaction 
with p53 protein, deletion of UBL2 has no effect on EBNA1 interaction with 
USP7. 
We next analysed the ability of USP7ΔUBL2 to interact with DAXX. HEK293T cells 
were co-transfected with USP7 WT and USP7ΔUBL2 FLAG-tagged plasmids along 
with DAXX-FLAG tagged plasmid. Cellular lysates were immunoprecipitated with 
anti-DAXX antibody and immunoblotted with anti-FLAG and anti-DAXX antibodies 
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(see Figure 5-6). This revealed that deletion of UBL2 does not inhibit DAXX 
interaction with USP7. 
Together these results suggest that there is a selective requirement of UBL2 for 
the interaction of USP7 with its substrates. Deletion of UBL2 disrupts interaction 
with specific substrates like p65 and c-Rel; but has no effect on the interaction 
with other substrates such as RelB, DAXX, p53 and EBNA1. 
 
Figure 5-6 USP7 substrate recognition specificity. A) HEK293T cells were co-transfected with 
USP7 WT and USP7ΔUBL2 FLAG-tagged plasmids along with c-Rel. Cellular lysates were 
immunoprecipitated with anti-c-Rel and immunoblotted with anti-USP7 and anti-c-Rel antibodies. 
USP7ΔUBL2 inhibits c-Rel interaction. The figure is a representative of three independent 
experiments. B) HEK293T cells were co-transfected with USP7 WT and USP7ΔUBL2 FLAG-
tagged plasmids along with RelB. Cellular lysates were immunoprecipitated with anti-RelB and 
immunoblotted with anti-USP7 and anti-RelB antibodies. USP7ΔUBL2 has no effect on RelB 
recognition. The figure is a representative of three independent experiments. C) HEK293T cells 
were co-transfected with USP7 WT and USP7ΔUBL2 FLAG-tagged plasmids along with p53. 
Cellular lysates were immunoprecipitated with anti-FLAG antibody and immunoblotted for FLAG 
and p53 antibodies. USP7ΔUBL2 is not able to disrupt p53 interaction. The figure is a 
representative of three independent experiments. D) HEK293T cells were co-transfected with 
USP7 WT and USP7ΔUBL2 FLAG-tagged plasmids along with EBNA1-HA-FLAG-tagged plasmid. 
Cellular lysates were immunoprecipitated with anti-HA and immunoblotted with anti-USP7 and anti-
FLAG antibodies. USP7ΔUBL2 was not sufficient to disrupt EBNA1 recognition. The figure is a 
representative of three independent experiments. E) HEK293T cells were co-transfected with 
USP7 WT and USP7ΔUBL2 FLAG-tagged plasmids along with DAXX-FLAG plasmid. Cellular 
lysates were immunoprecipitated with anti-DAXX and immunoblotted with anti-DAXX and anti-
FLAG antibodies. USP7ΔUBL2 is still able to interact with DAXX. The figure is a representative of 
three independent experiments. 
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Figure 5-7 Structural alignment of the NF-κB subunits. A) 3D structures of the different 
subunits forming the NF-κB transcription factor family. p65 (1VKX) is coloured in blue, RelB (3DO7) 
in red, c-Rel (1GJI) in green, p50 (1SVC) in purple and p52 (3DO7) in yellow. B) Structural 
alignment of NF-κB subunits. 1) p65 (1VKX) is coloured in blue, RelB (3DO7) in red, c-Rel (1GJI) in 
green, p50 (1SVC) in purple and p52 (3DO7) in yellow. The black box marks the differences 
between NF-κB members. 2) Zoom-in of the α-helix present on p50 and p52 but missing on p65, 
RelB and c-Rel. p65 (1VKX) is coloured in blue, RelB (3DO7) in red, c-Rel (1GJI) in green, p50 
(1SVC) in purple and p52 (3DO7) in yellow. C) Structural alignment of NF-κB members based on 
the two different groups existing. 1) p50 and p52 alignment. p50 (1SVC) in purple and p52 (3DO7) 
in yellow. 2) p65, RelB and c-Rel structural alignment. p65 (1VKX) is coloured in blue, RelB (3DO7) 
in red, c-Rel (1GJI) in green. All structures were analysed with Maestro Schrodinger software. 
 
5.4 Discussion 
USP7 deubiquitinase enzyme interacts with and subsequently deubiquitinates a 
wide range of different substrates [287, 407, 431, 432]. The specific substrate 
recognition is required for a tight regulation of its deubiquitinase activity. Our 
results identified UBL2 of USP7 as essential for the interaction with p65. This 
domain has also been identified to play a key role in recognition of GMPS, UHRF1 
and ICP0 [41, 418]. On the other hand, substrates as p53 and EBNA1 have been 
identified to interact with a binding site on the N-terminal MATH/TRAF domain 
[41, 418]. Thus, we may classify USP7 substrates by N-terminal MATH/TRAF 
domain recognised substrates and C-terminal region recognised substrates. 
Mutations within the C-terminal region do not interfere with the interaction of 
substrates recognised by the N-terminal MATH/TRAF domain, same as deletion of 
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the MATH/TRAF domain is not able to abolish the interaction with p65. 
Consistently, our results show that EBNA1 and p53 interaction is not altered by 
the deletion of UBL2. Our data also demonstrates that other substrates such as 
DAXX and RelB, are not disrupted by UBL2 deletion which suggests that they are 
recognised by the N-terminal MATH/TRAF domain.  
Recent studies on the binding interface between USP7 and ICP0, UHRF1 and 
GMPS identified two aspartates (D762 and D764) in USP7 sequence, as important 
residues for the interaction [41]. UBL2 of USP7 recognises a positively charged 
motif (K/RxKxxxK) on substrates [41, 418], creating electrostatic intermolecular 
interactions between the carboxylate ion of D762 and D764, and the ammonium 
ion of the K or R present in K/RxKxxxK motif [41, 476]. Electrostatic interactions 
are the strongest non-covalent intermolecular interaction and the best potential 
target to disrupt the binding interface between two proteins [476]. Our peptide 
array data identified 757-LDEL-760 as amino-acids of USP7 that interact with 
p65. Combining our peptide array data and the crucial role of D762 and D764 on 
ICP0 recognition, we studied the interaction with p65 when those amino-acids 
are mutated; however, there is no inhibition of the interaction. One explanation 
could be that the negatively charged patch is involved in the interaction but is 
not essential for the interaction. Mutants D762R, D764R disrupt the interaction 
with GMPS, UHRF1 and ICP0 [41]. This probably occurs because the presence of 
two positively charged amino-acids instead of two negatively charged amino-
acids is creating a repulsion force between both proteins. As stated before, the 
UBL2 binding pocket recognises a positively charged motif on substrates. The 
interaction between two proteins is driven by steric complementarity and 
attractive intermolecular forces created between both proteins. When any of 
these characteristics is disrupted, so is the interaction. The mutation to alanine 
of D762 and D764 showed different levels of inhibition on GMPS, UHRF1 and ICP0 
[41]. This suggests that these amino-acids are involved in recognising the three 
substrates, but not with the same importance. This theory applies to the 
mutants created here. They might not include the key amino-acids which are 
essential for the interaction or a bigger disruption of the force field created in 
the protein interface might be needed to abolish the interaction. The possibility 
of different amino-acids being essential for different substrate recognition 
requires further investigation. Structural models of the interacting complexes 
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could be really useful to detect differences in the binding mechanism of each 
substrate. Another explanation for these results could be that the binding pocket 
containing D762 and D764 recognises different substrates; however, disruption of 
the electrostatic interactions within USP7 D762 and D764 and p65 is not 
sufficient to detect visible differences on the interaction levels. Thus, it should 
be taken into account that disruption of the binding interface of UBL2 not only 
would inhibit p65 interaction but also DNMT1, UHRF1, GMPS, ICP0 and some 
other substrates recognised by UBL2 domain as well. 
The NF-κB members are known to interact with USP7 but the mechanism by 
which each different NF-κB member is recognised is unknown [287]. The 
comparison of their domain composition and structural analysis show two clear 
groups. One group is formed by p50 and p52, which are not able to activate 
transcription and when forming homodimers act as repressors, are composed by 
the shared N-terminal RHD followed by a GRR. Whereas the second group is 
composed by RelB, c-Rel and p65; which are formed by the amino RHD and a C-
terminal TAD. RelB differs from p65 and c-Rel, by the additional presence of a 
LZ domain. This LZ and dimerisation with p50 or p52 is required to bind to the 
DNA and for its transactivation ability [1, 40, 52, 478–481]. These differences are 
reflected in the 3D structure of the proteins and in the interaction with USP7. 
RelB interacts with the USP7ΔUBL2 mutant while c-Rel, which contains the same 
structural domains as p65 is not able to interact with it. The presence of the LZ 
domain on RelB could affect the mechanism by which USP7 recognises RelB as a 
substrate. When comparing structural conformation of the proteins, RelB is not 
as similar to p65 as c-Rel is. There is a loop on the N-terminal region which is not 
aligned with p65 or c-Rel. On the other hand, c-Rel protein is organised in the 
same way as p65 protein, containing exactly the same domains. Structural 
alignment of both proteins shows almost perfect assembly between both 
proteins. These results reflect the importance of structure for protein-protein 
interactions. Different 3D structures will determine different protein interaction 
partners and mechanisms, which will finally determine the different biological 
role of each protein on the cell. The design of and anti-inflammatory drug based 
on USP7 deubiquitinase activity on NF-κB members would inhibit specifically p65 
and c-Rel activity, canonical activation of the NF-κB pathway, while the non-
canonical activation would be intact due to RelB being able to interact with 
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USP7. This drug would specifically target the expression of genes involved in 
inflammation, cell survival and innate immunity, while expression of genes 
involved in the lymphoid organogenesis, adaptive immunity, anti-inflammatory 
properties, B-cell maturation and osteoclastogenesis would be intact. p65 and c-
Rel subunits sharing a binding mechanism with USP7, highlights the pro-
inflammatory potential of a specific drug based on the disruption of the 
interaction. Further investigation of the effects of USP7ΔUBL2 on p50 and p52 is 
required to analyse that this strategy would not affect the repressive function of 
p50 and p52 homodimers. 
Deletion of UBL2 not only abolishes the interaction with p65 subunit but also 
USP7 deubiquitinase activity on p65. This lack of activity is hypothesised to be 
due to a lack of interaction, as USP7 is not able to interact with p65 it cannot 
deubiquitinate p65 subunit. However, the impact of UBL2 deletion of USP7 
deubiquitinase activity has not been assessed here and further investigation of 
the activity of USP7 UBL2 deletion on interacting substrates should be required. 
USP7 catalytic activity is regulated by conformational rearrangements upon 
substrate binding [408]. The location of UBL12 with respect to the CD has an 
effect on the ability of UBL45 to contact the catalytic domain and place the CTP 
of USP7 in the active cleft. When eliminating UBL2, flexibility between UBL 
domains is kept, but UBL45 might not be at a proper distance to be able to place 
the CTP on the active cleft. Therefore, further investigation on the effects of 
UBL2 deletion on USP7 activity is required. 
New therapeutic strategies are targeting the binding interface of interacting 
proteins [476]. Defining the specific binding site for p65 will reduce the 
potential side effects derived from a catalytic inhibition of USP7. In this chapter 
we discovered that the binding pocket of USP7 for p65 is located in UBL2 of 
USP7. However, not every USP7 substrate is recognised by UBL2; substrates such 
as p53, EBNA1, RelB and DAXX do not required the presence of UBL2 to interact 
with USP7. Supporting that the interaction is required for USP7 deubiquitinase 
activity on its substrates, USP7 UBL2 deletion inhibits USP7 deubiquitinase 
activity on p65. Our data suggest that design of a substrate specific inhibitory 
compound to inhibit p65 inflammatory response is possible, reducing the 
unwanted effects of USP7 catalytic inhibition.  
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Chapter Six 
Structural modelling of USP7-p65 
interaction 
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6 Structural modelling of USP7-p65 interaction 
6.1 Abstract 
3D structure of proteins is a key determinant of the biological function of 
proteins and regulates the possible interactions with other proteins. There has 
been a huge development of techniques to elucidate 3D structure of proteins 
and protein-protein complexes; but still, a high number of protein complexes 
and proteins are not solved. Molecular modelling is a series of computational 
techniques which helps to elucidate the 3D structure of proteins and protein 
complexes. There are different types of molecular modelling, including de novo 
modelling and template based modelling. As for protein complexes, the 
technique denominated docking has been developed. Molecular docking is the 
computational technique use to predict the 3D structure of a protein-protein 
complex from the 3D structures of the proteins involved in the interaction. In 
order to dock two proteins manually, knowledge of the amino-acids present in 
the binding site is required. Recent studies have identified a binding pocket 
located in UBL2 of USP7 which is important for recognising specific substrates. 
This binding pocket encompasses the amino-acids identified by our experimental 
data as important for the interaction with p65. In addition, a substrate pattern 
motif is recognised by USP7 consisting of positively charged amino-acids which 
can be found on p65 sequence. For this reason, we used the docking technique 
to generate models of the different possible USP7-p65 interactions leading to 
the generation of stable USP7-p65 complexes. These models were generated in 
order to elucidate the amino-acids regulating this interaction. Experimental 
investigation of the contribution of these residues to the interaction will in turn 
help to enlighten the accuracy of the model. 
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6.2 Introduction 
Inhibition of USP7 deubiquitinase activity on p65 leads to a termination of the 
NF-κB response [287]. However, inhibition of the catalytic activity of USP7 leads 
to a wide range of effects on different biological processes. Thus, new drug 
discovery strategies are focus on targeting binding interfaces, which are 
substrate specific [482–484]. To develop a compound able to inhibit the 
interaction between USP7 and p65, understanding of their 3D structures is 
required. 
The 3D structure of proteins plays a key role in the function and activity of a 
protein. The biological function of proteins is intimately related to their ability 
to interact with other proteins, and these interactions are determined by the 
protein 3D structure [476, 485–487]. Therefore, the forces controlling the 3D 
structure of a protein are key for its biological function [476]; and consist of 
intramolecular bonds. Amino-acid side chains interact with each other through 
an attractive or a repulsive force. Due to these interactions, proteins will 
rearrange their conformation in order to obtain their most stable structure 
[476]. Intramolecular interactions include; attraction forces as, electrostatic or 
ionic bonds, hydrogen bonds, Van der Waals interactions and dipoles; and 
repulsive forces [476]. Even though separately electrostatics or ionic bonds are 
the strongest interaction and Van der Waals the weakest; in the overall of a 
protein, Van der Waals are more important because there is a greater number of 
Van der Waals interactions in comparison to electrostatics or ionic bonds [476]. 
Protein interactions are regulated in a structurally specific way [485, 488, 489]. 
Protein recognition takes place in a crowded environment; hence, the specificity 
and regulation of the process is highly important [488]. Regulation of the 
interaction between proteins depends on the flexibility of the proteins involved 
and the conformational rearrangements underwent by those proteins, in order to 
get steric and physicochemical complementarity at the protein-protein interface 
[485, 488–490]. The 3D structure of a protein or a protein complex can be 
analysed experimentally and computationally [490–492]. The number of resolved 
protein 3D structures is increasing with the development of new methods for this 
purpose; but there are thousands of proteins still with no available 3D structure. 
In some cases getting the 3D structure of a protein through NMR or X-Ray 
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crystallography is impeded by experimental constraints and is also time 
consuming and cost expensive [491]. 
3D structure of USP7-p65 complex is important when studying the interaction 
interface. There is no available 3D structure of USP7-p65 complex, but there are 
a number of X-Ray structures from p65 protein sequence and USP7 protein 
sequence as explained in sections 1.2.2.1 and 1.4.3.1. When X-Ray 
crystallisation or NMR is not possible, computational molecular modelling is a 
useful tool. It can provide the experimental insights required for subsequent 
experiments such as site directed mutagenesis or co-immunoprecipitation assays 
in order to study the molecular determinants of two proteins involved in their 
interaction. Molecular modelling consists on all theoretical and computational 
methods used to describe the atomic and molecular interactions within 
molecules [493]. Thanks to the development of molecular modelling techniques, 
conformational flexibility and plasticity over a range of space and time scale can 
be simulated [491, 493]. Molecular modelling techniques can be divided into two 
groups; de novo modelling or template based modelling. De novo molecular 
modelling predicts the 3D structure of a protein from its primary amino acid 
sequence. It does not use a 3D structure of a homolog protein as a template. It is 
normally used to determine the folding of small molecules [491, 494]. Rosetta 
method is the method used by ROBETTA software (Baker Lab). ROBETTA 
software is able to design protein structural models with a given amino-acid 
sequence of a maximum of 600 amino-acids when a template structure is found 
on the PDB files. Rosetta is among the de novo methods but is not a truly de 
novo method [487, 491]. Rosetta combines different small peptide fragments 
obtained from the PDB and assembles them to get the complete protein 
structure following a relaxation process [491]. Template based modelling uses a 
known protein structure as the template for the structural modelling. The 
sequence identity between the target and the template has to be greater than 
30%. When the template used is from an homologous protein it is called 
homologous modelling [491, 494–498]. Once the proteins have been modelled a 
relaxation process of the model has to be performed in order to study the 
accuracy of the model. This process allows the molecules to move and find the 
most stable state. Molecular Dynamics (MD) program is usually used to mimic the 
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movement of atoms within the protein in space and time and looks for possible 
collisions [476, 490]. 
Protein-protein complex modelling is also possible. Molecular docking is the 
computational technique used to predict the 3D structure of a protein-protein 
complex from the 3D structures of the proteins involved in the interaction [476, 
488, 491, 499–501]. An accurate docking requires an optimal binding orientation 
with steric and physicochemical complementarity at the protein-protein 
interface [488, 491]. When the binding site is known, the more relevant docking 
method is the manual docking. The binding pocket is characterised 
conformationally and by its amino-acid composition [501]. The user manually 
pairs the binding site of the protein into the complementary binding pocket of 
the interacting protein and defines the ideal binding distance for each potential 
interaction [476]. 
The amino-acids forming the binding interface on USP7-p65 interaction are still 
unknown. However, USP7 ubiquitin recognition pocket has been identified and 
certain regions of USP7 bound to ubiquitin have been solved as for example PDB: 
5JTV and 5JTJ [299].  p65 protein is known to be ubiquitinated by several E3 
ligases such as PPARγ, ING4, SOCS1 [380, 383, 502, 503] at 10 different K 
residues in the human protein (K28, K56, K62, K79, K122, K123, K195, K310, 
K314 and K315) [372, 380, 381, 383, 388]. However, USP7 is the only known 
deubiquitinase enzyme in charge of p65 deubiquitination. This fact makes the 
modelling process even more difficult by the addition of more than one possible 
model in which different K residues could be ubiquitinated. These ubiquitinated 
lysines are supposed to be at close distance from USP7 catalytic triad so it can 
deubiquitinate p65. 
As Box and Draper said, “essentially all models are wrong, but some are useful” 
(Empirical Model Building and Response Surfaces, Box and Draper 1987). 
Modelling the interaction between USP7 and p65 is a useful tool for the design of 
subsequent experiments which will allow us to define the specific amino-acids 
involved in the interaction and the accuracy of the model as well. In this chapter 
we modelled a full length p65 protein and a full length USP7 protein 3D 
structure. Besides, we modelled the interaction between both proteins, 
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investigating the possible complexes for the interaction between USP7-p65 based 
on our biochemical data and previously determined interacting pockets. 
6.3 Results 
6.3.1 p65 full length protein 3D structure model 
There is no full length p65 available structure, hence we used the truncated p65 
structure from 1VKX (amino-acids 19-291 forming the RHD) (see Figure 6-1) and 
the ROBETTA software to design a full length p65 protein 3D structure. We 
submitted the murine amino-acid sequence of p65 to ROBETTA software 
(http://robetta.bakerlab.org/). As a result, we got 5 different models (see 
Figure 6-2 and Figure 6-3). From these 5 models, comparing them to the p65 
1VKX protein structure, we chose the more similar one and continue the full 
length p65 model with that one (ROBETTA model 1). 
For our full length p65 to be more consistent with the structure of the solved 
p65 on 1VKX, we structurally aligned the models to p65 1VKX (see Figure 6-4).  
Following the alignment, we spliced amino-acids 20-291 from 1VKX into the 
model. For amino-acids 1-20 splicing, we aligned structures manually and 
subsequently spliced amino-acids 1-20 into amino-acids 21-551 from 1VKX and 
p65 ROBETTA model 1, getting a full length p65 protein structure (see Figure 6-5 
and Figure 6-6). 
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Figure 6-1 1VKX PDB crystal structures. A) Ribbon of the crystal structure of the heterodimer 
p50-p65 (p50 amino-acids 39-364 and p65 amino-acids 19-291) in complex with the DNA helix 
from 1VKX.  p65 is coloured in blue, p50 in purple and the DNA helix in yellow and pink. B) 
Compact surface of the crystal structure of the heterodimer p50-p65 in complex with the DNA helix 
from 1VKX. p65 is coloured in blue, p50 in purple and the DNA helix in yellow and pink. C) Ribbon 
of the truncated p65 protein (RHD amino-acids 19-291) structure from 1VKX. D) Surface of the 
truncated p65 protein (RHD amino-acids 19-291) structure from 1VKX. All structures were 
analysed with Maestro Schrodinger software. 
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Figure 6-2 Ribbon structures of p65 protein modelled with ROBETTA software in 
comparison with p65 protein structure from 1VKX. Ribbon of the crystal structure of p65 from 
1VKX (RHD amino-acids 19-291) and full length models developed by ROBETTA software. Each 
structure is labelled on the figure. The view of all models tries to keep amino-acids 225-290 beta-
sheet secondary structure in the same place as p65 beta-sheet secondary structure in 1VKX. All 
3D structures were analysed with Maestro Schrodinger Software. 
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Figure 6-3 Surface structures of p65 protein modelled with ROBETTA software in 
comparison with p65 protein structure from 1VKX. Surface of the crystal structure of p65 from 
1VKX (RHD amino-acids 19-291) and full length models of full length p65 protein developed by 
ROBETTA software. Each structure is labelled on the figure. Colours are maintained for each 
structure. The view of all models tries to keep amino-acids 225-290 beta-sheet secondary structure 
in the same place as p65 beta-sheet secondary structure in 1VKX. All structures were analysed 
with Maestro Schrodinger software. 
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Figure 6-4 p65 full length protein model generation. A) Structural alignment of p65 structure 
from 1VKX (RHD amino-acids 19-291, coloured in blue) and p65 full length ROBETTA model 1 
(grey). The box in red highlights the aligned secondary structure from both structures; amino-acids 
225-290 (most conserved secondary structure among the models). Orange circles mark the 
homologous region between both proteins (amino-acids 20-190), which is not structurally aligned. 
B) Structure from the splicing of 1VKX protein structure (RHD amino-acids 19-291, coloured in 
blue) into amino-acids 292-551 of ROBETTA model 1 (grey). C) Manual structural alignment of 
amino-acids 20-26 from ROBETTA model 1 (grey) and the newly modelled amino-acids 21-551 
p65 structure. Parts of the model from 1VKX are coloured in blue (amino-acids 21-291), while parts 
from ROBETTA model 1 are coloured in grey (amino-acids 292-551). The red box highlights the 
structural alignment of amino-acids 20-26. D) p65 full length structural model resulting from the 
splicing of amino-acids 1-20 from ROBETTA model 1 (grey) into the previously modelled 21-551 
amino-acids p65 structure. Parts of the model from 1VKX are coloured in blue (amino-acids 21-
291), while parts from ROBETTA model 1 are coloured in grey (amino-acids 1-20 and 292-551). All 
structures were analysed with Maestro Schrodinger software.  
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Figure 6-5 Ribbon of p65 full length protein structural model. Different views of p65 protein 
modelled structure. The original amino-acid structure from 1VKX (amino-acids 20-291) is coloured 
in blue, while the original amino-acid structure from ROBETTA model 1 (amino-acids 1-19 and 292-
551) is coloured in grey. All 3D structures were analysed with Maestro Schrodinger Software. 
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Figure 6-6 Surface of p65 full length protein structural model. Surface of the full length p65 
protein model. Different views of the protein modelled structure. The original amino-acid structure 
from 1VKX (amino-acids 20-291) is coloured in blue, while the original amino-acid structure from 
ROBETTA model 1 (amino-acids 1-19 and 292-551) is coloured in grey. All structures were 
analysed by Maestro Schrodinger software. 
 
6.3.2 USP7 full length protein 3D structure model 
A full length USP7 protein has not been crystallised, however, a recent study 
proposed a full length structural model of USP7 using structures of smaller USP7 
regions or domains [299]. We modelled a full length USP7 3D structure following 
their model. Modelling of the full length USP7 was carried out in collaboration 
with Dr Matti Lepistӧ and Dr Christian Tyrchan (AstraZeneca, Sweden).  
The full length USP7 computational modelling was carried out with sequential 
structure alignments and splicing of different structures of USP7. The PDB files 
used were 5JTV, 5J7T, 4YOC, 5JTJ and 2F1Z (see Table 6-1, and Figure 6-7). 
Subsequently, atomic distances and any disrupted secondary structure were 
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repaired and the complex was minimised and relaxed by a molecular dynamics 
process.  
Table 6-1 Structures contained in each PDB file 
 
PDB File Structure 
5JTV USP7 CD and UBL45 and ubiquitin 
5J7T USP7 CD and UBL123 
4YOC USP7 UBL12345 and DNMT1 
5JTJ USP7 CD and CTP and Ubiquitin 
2F1Z USP7 NTD and  CD 
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Figure 6-7 Crystal structures of human USP7 used to develop a USP7 full length model. 
2F1Z contains the NTD and CD in its inactive form of USP7 and is coloured in purple. 4YOC 
encloses the five UBLs of USP7 and is coloured in violet. 5J7T comprises the CD and UBL123 
from USP7 and is coloured in yellow. 5JTJ is formed by the active CD (pink) and CTP (orange) of 
USP7 and a ubiquitin molecule (green). 5JTV encompasses the CD and UBL45 from USP7 (light 
grey) and a ubiquitin molecule (green). All structures were analysed with Maestro Schrodinger 
software. Each domain is labelled on the structures. 
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We started with 2F1Z, the only USP7 structure from the PDB files selected 
containing the NTD. 2F1Z lacks certain loops in its USP7 NTD 3D structure. For 
this task MOE software was used to model the loops from the real sequence of 
USP7 and a minimisation process was performed to look for possible 
rearrangements that would maximise the stability of the protein and to avoid 
atomic collisions, which were not found (see Figure 6-8).  
 
Figure 6-8 USP7 NTD modelling. A) Location of the missing loops on 2F1Z 3D structure. Red 
boxes highlight the location of the missing loops in the 3D structure. B) Alignment of the 2F1Z 
structure (dark purple) with the new modelled NTD-CD structure of USP7 containing the missing 
loops (light purple). The red boxes mark the overlap between the missing loops and the modelled 
loops. Loops were modelled with MOE software. C) Final modelled structure of USP7 NTD-CD. All 
structures were analysed with Maestro Schrodinger software. 
 
From structural analysis of USP7 in the absence and presence of ubiquitin, USP7 
is known to exist in an inactive and in an active state [299–301]. We structurally 
aligned the structures of the new modelled USP7 NTD-CD and 5JTJ (see Figure 
6-9). 5JTJ structure is in the active conformation of USP7, containing the CTP, 
which has an important role on USP7 deubiquitinase activity, in the correct 
location. The crystallised CD on 5JTJ is on the active conformation of USP7 due 
to its interaction with the ubiquitin molecule. On the other hand, the CD 
crystallised with the NTD is on its apo conformation (with no substrate 
interacting with USP7) (see Figure 6-9 and Figure 6-10). In order to create a 
functionally active model of USP7 3D structure, we required the protein to be on 
its halo conformation; that is, bound to its ligand. For this reason, we needed to 
splice the NTD into the active CD conformation. Once the NTD was spliced into 
the active CD-CTP we looked for possible collisions. There was a loop in the 
active CD colliding with the NTD (see Figure 6-10). We decided to sculpt the loop 
in order to avoid the collision. For this purpose, we splitted the new structural 
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model composed by the NTD-CD-CTP and ubiquitin molecule and continue only 
with the NTD-CD modelled structure, keeping the CTP and ubiquitin molecule for 
their addition later on. After sculpting the loop, the new structure was 
minimised to relax the molecule and look for possible atomic collisions (see 
Figure 6-11 and Figure 6-12). 
 
Figure 6-9 Structural alignment of the new modelled NTD-CD USP7 structure and 5JTJ. A) 
Active CD structure (pink) in complex with USP7 CTP (orange) and a ubiquitin molecule (green) 
from 5JTJ PDB file. B) Structure of the modelled NTD-CD USP7.  C) Structural alignment of 
modelled NTD-CD and 5JTJ. Ubiquitin molecule is coloured in green, 5JTJ active CD in pink, 5JTJ 
CTP in orange and 5JTJ ubiquitin in green. All structures were analysed on Maestro Schrodinger 
software. 
 
 194 
 
 
Figure 6-10 Differences between 2F1Z active CD and modelled NTD inactive CD structural 
conformation. A) General overview of the alignment of both 3D structures. The red circle marks 
differences in a loop, which collides with the NTD when present. The black box highlights the 
structural rearrangements on the CD of USP7 due to the conformational rearrangements upon 
activation. Modelled NTD-CD USP7 is coloured in purple, 2F1Z CD is coloured in pink, 2F1Z CTP 
in orange and 2F1Z ubiquitin in green. B) Zoom-in of the conformational rearrangements of the CD 
upon activation. Move of the switching loop from an in-conformation to an out-conformation, 
highlighted in red circles. Location of the CTP on the active cleft. Modelled NTD-CD USP7 is 
coloured in purple, 2F1Z CD is coloured in pink, 2F1Z CTP in orange and 2F1Z ubiquitin in green. 
All structures were analysed on Maestro Schrodinger software. 
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Figure 6-11 USP7 NTD active CD structure modelling. NTD splicing into active CD 
conformation. 1) Modelled NTD-CD structure coloured in purple. 2) 5JTJ 3D structure containing 
the active CD of USP7 (pink), the CTP of USP (orange) and a ubiquitin molecule (green). 3) 
Splicing of NTD (purple) into the active CD of USP7 from 2F1Z (pink). The black box marks the 
switching loop conformation. 4) Zoom-in of the switching loop out-conformation, active state of the 
CD of USP7. Active CD part from 2F1Z is coloured in pink, the CTP from 2F1Z is coloured in 
orange and the NTD-CD from the modelled NTD-CD is coloured in purple. All structures were 
analysed on Maestro Schrodinger software. 
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Figure 6-12 Reparation of the colliding loop from the active CD with the NTD. 1) General 
overview of the new modelled NTD active CD USP7. Red circle points the colliding loop present on 
the CD. Active CD part from 2F1Z is coloured in pink, the CTP from 2F1Z is coloured in orange and 
the NTD-CD from the modelled NTD-CD is coloured in purple. 2) Zoom-in of the colliding loop. 
Active CD part of 2F1Z is coloured in pink, the CTP from 2F1Z is coloured in orange and the NTD-
CD from the modelled NTD-CD is coloured in purple. 3) Loop sculpt, not colliding anymore. Each 
domain of USP7 is labelled. New modelled NTD active CD is coloured in red. All structures were 
analysed with Maestro Schrodinger software. 
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After the minimisation process we continued modelling the C-terminal region of 
USP7. Therefore, the next step was the addition of the UBLs to the NTD-CD USP7 
structure. We first added UBL123 to the model. 5J7T PDB file encompasses the 
CD of USP7 and UBL123. We aligned the new model NTD-CD with 5J7T structure 
and spliced the NTD-CD into UBL123 from 5J7T. The structure resulted was 
formed by USP7 NTD-CD-UBL123 (see Figure 6-13). After relaxing the newly 
formed structure and confirming no collisions between atoms, we continued 
modelling the full length USP7. Next step was to add the UBL45 region. For 
UBL45 we had two different conformations; an elongated arrangement (4YOC) 
and a more compact arrangement (5JTV). We aligned both structures with the 
new modelled USP7 NTD-CD-UBL123 (see Figure 6-14 and Figure 6-15). The 
alignment with 4YOC, kept UBL45 far away from the catalytic triad and the CTP. 
Moreover, alignment with 5JTV contained UBL45 in a compact form close to the 
CD but far away from UBL123. Following the model from Rouge et al [299], we 
spliced the new NTD-CD-UBL123 into UBL45 of 4YOC PDB structure and ran a 
minimisation process to relax the new structure (see Figure 6-16). Having USP7 
NTD-CD-UBL12345 the only part missing was the C-terminal region. PDB file 5JTJ 
contains the CTP in the active form, located in the activation cleft. The next 
step was to bond the newly created structure with the CTP from 5JTJ. There 
was a gap of 9 amino-acids (KAPKRSRYT) between the end of UBL5 and the CTP 
(see Figure 6-17). However, the distance between the end of UBL5 and the CTP 
was bigger than the distance covered by the addition of the nine amino-acids 
missing. For this reason, distance constraints were used to get UBL45 closer to 
the CD and a minimisation process was performed. During the process some 
secondary structures of UBL45 were disrupted (see Figure 6-17). The disrupted 
secondary structures of UBL45 were fixed through the addition of some distance 
and angles constraints, to maintain the appropriate helical turn, during a 
minimisation process. Once the distance was appropriate; the missing amino-
acids were added following the USP7 sequence and taking into account the 
presence of the ubiquitin molecule for CTP’s proper location within USP7 active 
structural conformation (see Figure 6-17). Then, the newly created structure 
was spliced into the CTP to give a full length (except the first 63 amino-acids) 
USP7 structural model (see Figure 6-17). To make sure the model was in a stable 
conformation with no atoms colliding; we run a minimisation process to relax the 
molecule. Subsequently, a molecular dynamics process was performed to 
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identify the most stable conformation for the new USP7 structure (see Figure 
6-18). After this process, full length USP7 structure was ready for future docking 
experiments. 
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Figure 6-13 USP7 NTD-CD-UBL123 structural modelling. A) Modelling steps to create USP7 
NTD-CD-UBL123 structure.  1) 5J7T structure containing the CD and UBL123 of USP7. 5JT7 
structure is coloured in yellow. 2) Modelled NTD active CD structure coloured in red. 3) Alignment 
of 5J7T structure (yellow) and modelled USP7 NTD active CD (red). 4) Splicing of modelled USP7 
NTD active CD (red) into UBL123 from 5J7T (yellow) to form the new USP7 NTD-CD-UBL123 
structure. B) Newly modelled USP7 NTD-CD-UBL123 structure with each USP7 domain labelled. 
All structures were analysed with Maestro Schrodinger software. 
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Figure 6-14 Modelled USP7 NTD-CD-UBL123 alignment with 5JTV. 1) Modelled USP7 NTD-
CD-UBL123 structure coloured in red. 2) 5JTV structure coloured in grey. It contains USP7 CD and 
UBL45. 3) Modelled USP7 NTD-CD-UBL123 (red) structural alignment with 5JTV (grey). Each 
domain of USP7 is labelled on the structure. All 3D structures were analysed with Maestro 
Schrodinger Software. 
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Figure 6-15 Modelled USP7 NTD-CD-UBL123 alignment with 4YOC. 1) Modelled USP7 NTD-
CD-UBL123 structure coloured in red. 2) 4YOC USP7 UBL12345 coloured in violet. 3) Modelled 
USP7 NTD-CD-UBL123 (red) structural alignment with 4YOC (violet). Each domain of USP7 is 
labelled on the structure. All structures were analysed with Maestro Schrodinger software. 
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Figure 6-16 USP7 NTD-CD-UBL12345 structural modelling. A) Modelling steps to create USP7 
NTD-CD-UBL12345 structure. 1) Structural alignment of 4YOC (USP7 UBL12345) structure (violet) 
and modelled NTD-CD-UBL123 (red). 2) Splicing of modelled USP7 NTD-CD-UBL123 (red) and 
4YOC USP7 UBL12345 (violet). B) Modelled USP7 NTD-CD-UBL12345 coloured in red. Each 
domain of USP7 is labelled. All structures were analysed with Maestro Schrodinger software. 
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Figure 6-17 USP7 CTP connection to modelled USP7 NTD, CD, UBL12345. A) UBL45 
approach to the CD. 1) Modelled NTD-CD-UBL12345 USP7 (red) among with the CTP (orange). 2) 
UBL45 converge to CD. USP7 NTD-CD-UBL12345 structure is coloured in blue and USP7 CTP in 
orange. 3) Comparison of the secondary structure differences between modelled USP7 NTD-CD-
UBL12345 before (red) and after (blue) the UBL45 approach to the CD. USP7 CTP is coloured in 
orange. B) Addition of the 9 missing amino-acids (KAPKRSRYT) to the molecule. 1) General 
overview of the addition of the 9 missing amino-acids. The box in black marks the distance 
between last added amino-acid (T) and the first amino-acid from the CTP (Y). USP7 NTD-CD-
UBL12345 is coloured in dark blue, the CTP in orange, the added amino-acids in light blue and 
ubiquitin in green. 2) Zoom-in of the distance between last added amino-acid (T) and the first 
amino-acid from the CTP (Y). USP7 NTD-CD-UBL12345 is coloured in dark blue, the CTP in 
orange, the added amino-acids in light blue and ubiquitin in green. All structures were analysed 
with Maestro Schrodinger software. 
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Figure 6-18 Molecular Dynamics of the full length USP7 model structure in complex with 
ubiquitin. A) Full length USP7 molecule. B) Relaxed full length USP7 molecule in complex with 
ubiquitin as the result of the molecular dynamics process. USP7 molecule is coloured in red and 
ubiquitin in green. Each domain of USP7 is labelled on the structure. All structures were analysed 
with Maestro Schrodinger software. 
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6.3.3 USP7-p65 complex model 
Considering the previous data about USP7 binding pockets and the number of 
possible p65 ubiquitinated lysines, we designed three different models. As the 
full length USP7 was modelled taking into account the 3D structure of a ubiquitin 
molecule (which in nature will correspond with the ubiquitin bound to the 
ubiquitinated substrate) located in the appropriate position for USP7 
deubiquitinase activity, we incorporated the ubiquitin molecule structure to 
USP7 full length model. For the first model, we incorporated the possible 
ubiquitinated lysines of p65; bonding the lysine to the ubiquitin molecule 
present on USP7 full length structural model. The other two models were based 
on the positively charged motif (R/KxR/KxxxR/K) of p65 and USP7 UBL2 binding 
pocket, forming part of the binding interface.  
6.3.3.1 No lysine specificity detected on USP7 deubiquitinase activity 
We studied the preference of USP7 to deubiquitinate various ubiquitinated 
lysines on p65 as K56, K62 and K123. p65 K56, K62 and K123 were selected 
according to sequence homology between NF-κB members of the homologous 
regions surrounding those lysines (see appendix 8.6). Mutation of these lysines to 
arginine maintains the physicochemical properties of the protein but prevents 
ubiquitination at those sites. If USP7 specifically recognises a ubiquitinated 
lysine, when that lysine is mutated to arginine the interaction between USP7 and 
p65 will be affected. 
We cloned murine p65 WT, p65K56R, p65K62R and p65K123R into pCDNA3.1 in 
order to remove the FLAG-tag from the original plasmids (see appendix 8.2). 
HEK293T cells were co-transfected with murine p65 WT, p65 K56R, p65 K62R and 
p65 K123R plasmids along with USP7 FLAG-tagged plasmid. Cellular extracts 
were immunoprecipitated with an anti-FLAG antibody and immunoblotted with 
antibodies anti-p65 protein and anti-FLAG tag. The interaction between USP7 
and p65 mutants is equivalent between WT and K56R, K62R and K123R mutants; 
there is no affinity for any of the lysines (see Figure 6-19). This result suggests 
that USP7 acts on several different ubiquitinated lysines on p65; therefore, USP7 
does not have a preference for interaction with p65 ubiquitinated at specific 
lysines. 
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Figure 6-19 USP7 has no specificity for K56, K62 or K123. HEK293T cells were co-transfected 
with murine p65 WT, p65 K56R, p65 K62R and p65 K123R plasmids along with FLAG-tagged 
USP7. Cellular lysates were immunoprecipitated with anti-FLAG antibody and immunoblotted with 
anti-FLAG and anti-p65 antibodies. USP7 has no preference for ubiquitinated K56, K62 or K123. 
The figure is a representative of three independent experiments. 
 
6.3.3.2 Model of USP7-p65 interaction when p65 is ubiquitinated at K62  
PDB files 5JTV and 5JTJ used in USP7 full length modelling contain a ubiquitin 
molecule. Merging both structures, the location of the possible ubiquitinated 
lysine is quite well defined. The lysine of p65 which would be ubiquitinated has 
to bind the G76 residue of ubiquitin molecule, and be at a feasible distance from 
the catalytic triad as it would happen when the ubiquitin bound to p65 locates in 
the appropriate location for USP7 deubiquitinase activity (see Figure 6-20). 
Based on the steric conformation of p65, K62 is the most accessible 
ubiquitinated site on p65 (see Figure 6-20). Hence, we decided to dock the p50-
p65-DNA complex structure on USP7 full length structure where p65 is 
ubiquitinated at K62. 
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Figure 6-20 Definition of the interacting site of USP7 with p65 ubiquitinated lysine. A) 
Location of the catalytic triad on USP7 and ubiquitin molecule. 1)  General overview of USP7 
catalytic triad and ubiquitin molecule location on USP7 full length molecule (coloured in red).  USP7 
catalytic triad (C223, H464, D481) is coloured in blue and ubiquitin molecule is coloured in green. 
The black box marks the location of the catalytic triad and ubiquitin G76.  Zoom-in of the catalytic 
triad and ubiquitin G76 location.  USP7 full length model is coloured in red, USP7 catalytic triad 
(C223, H464, D481) is coloured in blue and ubiquitin molecule is coloured in green. B) Different 
views of truncated p65 structure from PDB file 1VKX (amino-acids 19-291) with the known 
ubiquitinated lysines coloured in dark blue. C) Different views of p50-p65 heterodimer in complex 
with DNA structure from PDB file 1VKX (p50 amino-acids 39-364 and p65 amino-acids 19-291). 
p65 is coloured in light blue with the known ubiquitinated lysines coloured in dark blue. p50 is 
coloured in purple and the DNA helix in yellow and pink. All structures were analysed with Maestro 
Schrodinger software. 
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6.3.3.2.1 K62 
Lysine 62 of p65 is ubiquitinated by the E3 ligase ING4 promoting p65 
degradation [39]. Due to steric characteristics of the heterodimer in complex 
with the DNA helix, K62 is the most accessible lysine. As both binding interfaces 
were defined, we next performed manual docking. K62 has to form a bond with 
G76 of ubiquitin and be at an appropriate distance from the catalytic triad of 
USP7. One obstacle on the docking was the presence of the DNA helix. The DNA 
helix was elongated and bent into the appropriate conformation to fit in the 
model (see Figure 6-21). In this model, K62 forms a bond with G76 of ubiquitin 
and is located in the centre of the USP7 full length molecule (see Figure 6-22). 
We hypothesised that the DNA helix bends in a way that also goes in between 
the USP7 molecule (see Figure 6-23). We proposed a mechanism for this model in 
which the heterodimer in complex with the DNA binds to USP7 and USP7 
undergoes conformational rearrangements to locate the heterodimer in the 
centre. More specifically, USP7 molecule is in an open conformation and when 
p65 binds to the molecule it closes; getting UBL45 and the CTP closer to the CD, 
and surrounding the p50-p65-DNA complex which stays in the middle of USP7 
molecule. If the mechanism is correct, contacts between USP7 and the DNA may 
be important in the interaction. Structurally, this model is quite compact, with 
almost no gaps in between molecules (see Figure 6-23). The presence of gaps in 
the interaction interface leads to the presence of solvent molecules which could 
interfere with the interaction. One disadvantage of the model is the missing part 
of p65. The missing region of p65 contains K310, K314 and K315, three possible 
ubiquitination sites [468]. If we focus on the p65 structure, most of the contacts 
between USP7 and p65 are located on UBL1 and UBL3, while UBL45 is in contact 
with the DNA helix. The full complex, once modelled, was relaxed by a 
minimisation process. The minimisation process helped to detect the presence of 
any atomic collisions and select the most stable conformation of the structure of 
the complex. 
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Figure 6-21 DNA helix elongation and rearrangement. A) Comparison of the DNA helix solved 
in the crystal structure of 1VKX with the DNA helix modelled to fit in the model. The DNA helix is 
coloured in yellow and pink. The DNA helix was elongated to model possible interactions with 
USP7 molecule. In order to fit in the model, the DNA helix was bent. B) Comparison of p50-p65 
heterodimer (p50 amino-acids 39-364 and p65 amino-acids 19-291) in complex with the DNA helix 
solved in 1VKX and the heterodimer in complex with the modelled DNA helix. Different views of the 
complex. p65 protein is coloured in blue, p50 in purple and the DNA helix in yellow and pink. The 
DNA helix was elongated to model possible interactions with USP7 molecule. In order to fit in the 
model, the DNA helix was bent. All structures were analysed with Maestro Schrodinger software. 
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Figure 6-22 Interacting interface of the model based on K62-ubiquitination. A) General 
overview of the model. Catalytic triad and K62 are coloured in dark blue, USP7 molecule in red, 
DNA helix in yellow and pink, p65 in light blue, ubiquitin in green and p50 in purple. The black box 
marks the location of the catalytic triad and K62 from p65. B) Zoom-in of the interaction interface of 
K62 of p65 and catalytic triad of USP7 (C223, H464, D481).  Catalytic triad and K62 are coloured in 
dark blue, USP7 molecule in red, DNA helix in yellow and pink, p65 in light blue, ubiquitin in green 
and p50 in purple. 1) Catalytic triad amino-acids as well as p65 K62 backbone coloured in dark 
blue. 2) Catalytic triad amino-acids as well as p65 K62 and ubiquitin G76 residues side chains. 
Catalytic triad amino-acids and p65 K62 side chains are coloured in blue, while ubiquitin G76 side 
chain is coloured in green. All structures were analysed with Maestro Schrodinger software.   
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Figure 6-23 Surface model of the USP7-p65/p50/DNA complex based on ubiquitination of 
p65 K62. Different views of the complex. USP7 is coloured in red, p65 in blue, p50 in purple, 
ubiquitin in green and the DNA helix in yellow and pink. All structures were analysed with Maestro 
Schrodinger software. 
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6.3.3.3 Model of USP7-p65 interaction based on p65 R/KxR/KxxxR/K motif 
interaction with USP7 UBL2 binding pocket 
Recent studies on USP7 substrate recognition identified the binding site on UBL2 
of USP7 for substrates recognised by the C-terminal region [20, 21]. Pfoh et al 
described a peptidic sequence on ICP0 containing a KxxK motif required for USP7 
binding [41]. The complementary region identified on USP7 which form part of 
the binding site was composed by amino-acids 758-DELMDGD-764, being D762 
and D764 the amino-acids forming the interacting bonds with the lysines on 
KxxxK motif of ICP0 [41]. D762 and D764 when mutated to alanine or arginine 
are able to disrupt the interaction with ICP0, GMPS and UHRF1 [41]. Kim and 
Sixma investigated the positively charged motif present on the substrates 
binding to the C-terminal region of USP7 [418]. They identified a R/KxKxxxK 
motif on ICP0, DNMT1 and UHRF1 [418]. Using peptidic sequences of each 
substrate containing this motif they crystallised them in interaction with UBL2 of 
USP7 [418]. Comparing the interaction between the three substrate peptidic 
sequences with UBL12 we designed a binding pocket on USP7. This binding 
pocket is formed by amino-acids 627-ARSNGTK-633, 736-EEVKPNLTER-745 and 
757-LDELMDGD-764 (see Figure 6-24 and Figure 6-25). Comparing the amino-
acids forming the binding pocket to those identified as important by our 
experimental data from the peptide array and subsequent alanine scan, we 
found that the identified K633, L757, D758, E759 and L760 amino-acids are 
located within the binding pocket. From the co-immunoprecipitation assays 
data, we know that mutation on L757, D758, E759 and L760 does not inhibit the 
interaction. We modelled the interaction in that binding pocket in order to 
provide more details on the possibility of those amino-acids participating in the 
interaction.  
Having the binding pocket defined in USP7 we needed to define the interacting 
amino-acids on p65. As discovered by Pfoh et al and Kim and Sixma [41, 418], 
the interaction of USP7 with ICP0, DNMT1, UHRF1 and GMPS takes place through 
a positively charged region on the substrates. We analysed the p65 sequence for 
the presence of a similar motif on p65 (human and murine) sequence with 
Geneious software. This analysis identified two similarly positively charged 
motifs on p65. The first identified motif is 35-RYKCECR-41, and the second motif 
is 295-RHRIEEK-301 (see Figure 6-26). Using these motifs of p65 and the binding 
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pocket of USP7, we manually docked them in order to get a model of USP7-p65 
interaction which could help defining future experiments. Identification of these 
positively charged motifs within different USP7 substrates’ sequence is shown on 
appendix 8.7. 
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Figure 6-24 Binding pocket on USP7. A) Alignment of the crystal structures of USP7 co-
crystallised with the positively charged peptidic sequences of UHRF1 (amino-acids 652-664, PDB: 
5C6D), DNMT1 (amino-acids 1108-1115, PDB: 4Z96) and ICP0 (amino-acids 617-626, PDB: 
4WPI). 1) Structures of USP7 co-crystallised with the positively charged peptidic sequences of 
UHRF1 (5C6D), DNMT1 (4Z96) and ICP0 (4WPI). Each structure is coloured in a different grade of 
green (USP7) and red (substrate peptidic sequence). 2) Alignment of the three structures to 
visualise the binding pocket in which the peptides are bound. B)  Definition of the amino-acids 
forming the binding pocket (627-ARSNGTK-633, 736-EEVKPNLTER-745 and 757-LDELMDGD-
764). 1) General overview of the structural alignment. USP7 structures are coloured in different 
grades of green, substrate peptidic sequences in different grades of red and amino-acids forming 
the binding pocket are coloured in blue. The black box highlights the binding pocket location. 2) 
Zoom-in of the binding pocket on USP7. USP7 structures are coloured in different grades of green, 
substrate peptidic sequences in different grades of red and amino-acids forming the binding pocket 
are coloured in blue. All structures were analysed with Maestro Schrodinger software. 
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Figure 6-25 Binding pocket location in full length USP7 model. A) Alignment of the full length 
USP7 model with USP7 structures from 4Z96 (amino-acids 556-1083), 4WPI (amino-acids 538-
882) and 5C6D (amino-acids 560-881) PDB files. 1) General overview of the structural alignment of 
full length USP7 model with USP7 structures 4Z96, 4WPI, 5C6D. USP7 structures from 4Z96, 
4WPI, 5C6D are coloured in different grades of green, substrate peptidic sequences in different 
grades of red, amino-acids forming the binding pocket are coloured in blue and USP7 full length 
structure in red. The black box marks the location of the binding pocket. 2) Zoom-in on the binding 
pocket structural conformation. USP7 structures 4Z96, 4WPI, 5C6D are coloured in different 
grades of green, substrate peptidic sequences in different grades of red, amino-acids forming the 
binding pocket are coloured in blue and USP7 full length structure in red. The black box marks the 
location of the binding pocket. B) Binding pocket located in the full length USP7 model. Each 
domain is labelled on the structure. USP7 structure is coloured in red and binding pocket amino-
acids are coloured in blue. All structures were analysed with Maestro Schrodinger software. 
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Figure 6-26 R/KxR/KxxxR/K motif presence on p65 human and murine sequences. Location 
on the sequence of human p65 and murine p65 proteins of R/KxR/KxxxR/K motifs. Sequences 
were analysed with Geneius Software. 
 
6.3.3.3.1 p65 amino-acids 35-RYKCECR-41 as part of the binding interface 
This model was developed by a manual docking and subsequent minimisation 
process to relax the structure of the complex. The interface of the interaction 
was formed by amino-acids 627-ARSNGTK-633, 736-EEVKPNLTER-745 and 757-
LDELMDGD-764 of USP7 and amino-acids 35-RYKECR-41 from p65. Motif 35-
RYKECR-41 of p65 is present on the solved crystal structure of p65, 1VKX. Thus, 
we used the same p50-p65-DNA complex structure as it was used for the K62 
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model. The DNA helix in this model is also elongated and rearranged in 
comparison to the DNA helix solved in 1VKX. In this case, the binding site was 
defined but the need of a ubiquitinated lysine in close proximity to G76 of 
ubiquitin and the catalytic triad of USP7 was also considered. K28 is the most 
accessible ubiquitinated lysine in this model (see Figure 6-27). PPARγ promotes 
ubiquitination of p65 at K28 [380], and is also a substrate of USP7 [504]. K56 is 
also located in the area of the catalytic triad and the ubiquitin molecule; but 
some conformational rearrangements on p65 would be required for a proper 
interaction between K56, the catalytic triad and the ubiquitin molecule (see 
Figure 6-27). The study of the binding site in the model shows how amino-acids 
involved in the interaction are far from each other (see Figure 6-27). For this 
model to work properly, full length p65 structure and flexibility of the molecules 
should be taken into account. Conformational rearrangements of both proteins; 
USP7 and p65, after binding, will play an important role in the interactive 
complex structure. Another disadvantage of this model is that the model is not 
as compact as K62 model. Several gaps are observed, which would be filled with 
solvent molecules (see Figure 6-28). These solvent molecules may interfere with 
the interaction. On the other hand, a general overview of the model shows 
interactions between USP7 and p65 on UBL3 while the DNA helix interacts with 
the NTD and the α-helix connecting the CD with UBL1 (see Figure 6-28). In this 
case, the role of UBL45 may be to properly activate the deubiquitinase activity 
of USP7. 
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Figure 6-27 Model based on the interaction with the motif 35-RYKECR-41 of p65. A) Overall 
overview of the ribbon structure of the model. USP7 molecule is coloured in red, ubiquitin in green, 
p65 in blue, p50 in purple, DNA helix in yellow and pink, the binding site amino-acids in orange 
(amino-acids 627-ARSNGTK-633, 736-EEVKPNLTER-745 and 757-LDELMDGD-764 of USP7 and 
amino-acids 35-RYKECR-41 from p65) and the K-ubiquitinated accessible (K28 and K56) and 
catalytic triad (C223, H464 and D481) in dark blue. The black box marks the location of the binding 
interface. The black circle highlights the location of USP7 catalytic triad and possible p65 
ubiquitinated lysines. B) Zoom-in of the binding site region. USP7 molecule is coloured in red, 
ubiquitin in green, p65 in blue, p50 in purple, DNA helix in yellow and pink, the binding site amino-
acids in orange (amino-acids 627-ARSNGTK-633, 736-EEVKPNLTER-745 and 757-LDELMDGD-
764 of USP7 and amino-acids 35-RYKECR-41 from p65) and the K-ubiquitinated accessible (K28 
and K56) and catalytic triad (C223, H464 and D481) in dark blue. Black boxes show the location of 
USP7 binding pocket and p65 binding motif and their amino-acidic composition. 1) Amino-acids 
involved in the binding interface backbone coloured in orange. 2) Amino-acids involved in the 
binding interface backbone and side chains coloured in orange. C) Zoom-in of the catalytic triad 
(C223, H464 and D481) region. USP7 molecule is coloured in red, ubiquitin in green, p65 in blue, 
p50 in purple, DNA helix in yellow and pink, the binding site amino-acids in orange and the K-
ubiquitinated accessible and catalytic triad in dark blue. Catalytic triad, possible p65 ubiquitinated 
lysines amino-acids side chains are coloured in dark blue and ubiquitin G76 side chain coloured in 
green. All structures were analysed with Maestro Schrodinger software. 
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Figure 6-28 Surface of the USP7-p65/p50/DNA complex, modelled based on the interaction 
with motif 35-RYKECR-41. Different views of the complex. USP7 is coloured in red, p65 in blue, 
p50 in purple, ubiquitin in green, the DNA helix in yellow and pink and amino-acids involved in the 
interaction in orange. All structures were analysed with Maestro Schrodinger software. 
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6.3.3.3.2 p65 amino-acids 295-RHRIEEK-301 as part of the binding 
interface 
This model was also docked manually and subsequently relaxed by a 
minimisation process. The binding pocket on USP7 was the same as for motif 35-
RYKCECR-41 model, amino-acids 627-ARSNGTK-633, 736-EEVKPNLTER-745 and 
757-LDELMDGD-764 of USP7 and in this case, amino-acids 295-RHRIEEK-301 from 
p65. Amino-acids 295-RHRIEEK-301 are not present in the crystal structure of 
1VKX and so we used the full length p65 structure modelled with a combination 
of 1VKX structure and model 1 from ROBETTA software (see Figure 6-29). The 
motif 295-RHRIEEK-301 is located in an α-helix conformation followed by a 
flexible loop in this model. Comparing the five ROBETTA models, the α-helix 
containing the 295-RHRIEEK-301 motif is conserved, but the remaining flexible 
loop form a different rearrangement in each model. In order for the model to be 
more consistent, we used a truncated p65 structure, amino-acids 1-317, which 
contains the motif 295-RHRIEEK-301 in the conserved α-helix conformation 
within ROBETTA models (keeping K310, K314 and K315 as well in the model) (see 
Figure 6-29).  
We also added the p50 structure from 1VKX and the elongated and bent DNA 
helix as for the K62 model (see Figure 6-29). The location of the p65 motif on an 
α-helix in a flexible loop area facilitated a docking focusing only on the binding 
site. The motif sterically fits in the binding pocket allowing the p65 molecule to 
move (see Figure 6-30). This ability to move after binding, agrees with the 
notion of molecules going through conformational rearrangements upon binding. 
In this model, there is no single ubiquitinated lysine in close proximity to the 
catalytic triad, but most of them are facing the catalytic triad and the ubiquitin 
molecule as well (see Figure 6-30). We hypothesised that p65 and USP7 
conformational rearrangements will lead to the proximity of the target 
ubiquitinated lysine to the catalytic triad. This model fits the fact that USP7 is 
not specific for a certain ubiquitinated lysine (see Figure 6-30). 
This model works as follows. In the first place the motif 295-RHRIEEK-301 of p65 
will bind to the binding pocket present on USP7. Then both molecules will go 
through conformational rearrangements, accommodating the p65 molecule 
appropriately, depending on which lysine is ubiquitinated, allowing USP7 to 
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deubiquitinate p65 protein. This model has the same disadvantage as the model 
based on the interaction with 35-RYKCECR-41 motif on p65; it contains several 
gaps and is not as compact as the model based on K62 ubiquitination (see Figure 
6-31). Those gaps may be filled with solvent molecules which may interfere with 
the interaction. A general overview of the model shows interactions between 
USP7 and p65 through UBL12 and the N-terminal of p65 may interact with UBL3, 
but no interactions between DNA and USP7. UBL45 will likely be involved in the 
approximation of p65 molecule to the catalytic triad proximity in this model. 
See Figure 6-31. 
 
Figure 6-29 Model of p65 amino-acids 1-317 structure. A) Different views of the p65 molecule 
structure with the motif 295-301 coloured in orange. B) Heterodimer p50-p65 in complex with the 
elongated rearranged DNA helix 3D structure from 1VKX. p65 is coloured in blue, the motif 295-
301 is coloured in orange, p50 is coloured in purple and the DNA helix is coloured in yellow and 
pink. All 3D structures were analysed with Maestro Schrodinger Software. 
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Figure 6-30 Model based on the interaction with the motif 295-RHRIEEK-301 of p65. A) 
Overview of the ribbon structure of the model. USP7 is coloured in red, ubiquitin in green, p65 in 
blue, p50 in purple, DNA helix in yellow and pink, the binding site amino-acids in orange (amino-
acids 627-ARSNGTK-633, 736-EEVKPNLTER-745 and 757-LDELMDGD-764 of USP7 and amino-
acids 295-RHRIEEK-301 from p65) and the accesible K-ubiquitinated and catalytic triad (C223, 
H464 and D481) in dark blue. The black box marks the location of the binding interface. The black 
circle highlights the location of USP7 catalytic triad and possible p65 ubiquitinated lysines. p50 
protein structure is from 1VKX, p65 is from 1VKX and ROBETTA model 1, the DNA helix was 
elongated and rearranged from the DNA helix of 1VKZ, and full length USP7 and ubiquitin are from 
5JTV, 5J7T, 4YOC, 5JTJ and 2F1Z. B) Zoom-in of the binding site region. USP7 molecule is 
coloured in red, ubiquitin in green, p65 in blue, p50 in purple, DNA helix in yellow and pink, the 
binding site amino-acids in orange (amino-acids 627-ARSNGTK-633, 736-EEVKPNLTER-745 and 
757-LDELMDGD-764 of USP7 and amino-acids 295-RHRIEEK-301 from p65) and the accessible 
K-ubiquitinated and catalytic triad (C223, H464 and D481) in dark blue. 1) Amino-acids involved in 
the binding interface backbone coloured in orange. 2) Amino-acids involved in the binding interface 
backbone and side chains coloured in orange. C) Zoom-in of the catalytic triad region (C223, H464 
and D481). USP7 molecule is coloured in red, ubiquitin in green, p65 in blue, p50 in purple, DNA 
helix in yellow and pink and the accessible K-ubiquitinated (K28, K56, K62, K79, K122, K123, 
K195, K310, K314 and K315) and catalytic triad (C223, H464 and D481) in dark blue. Catalytic 
triad, possible p65 ubiquitinated lysines amino-acids side chains are coloured in dark blue and 
ubiquitin G76 side chain coloured in green. 1) Zoom-in of the catalytic triad and accessible K-
ubiquitinated on p65. 2) Zoom-out of the catalytic triad and accessible K-ubiquitinated on p65. All 
structures were analysed with Maestro Schrodinger software. 
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Figure 6-31 Surface of the USP7-p65/p50/DNA complex modelled based on the interaction 
with motif 295-RHRIEEK-301. Different views of the complex. USP7 is coloured in red, p65 in 
blue, p50 in purple, ubiquitin in green, the DNA helix in yellow and pink and amino-acids involved in 
the interaction in orange. All structures were analysed with Maestro Schrodinger software. 
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6.4 Discussion 
There are no available 3D structures of USP7 full length protein, p65 full length 
protein or the complex formed by USP7-p65, thus we modelled them with the 
help of computational chemistry softwares.  
p65 protein has been solved in a truncated version containing amino-acids 19-
291 from the RHD and missing the TAD. Normally, the flexible regions of a 
protein are less stable and a huge number of proteins are solved in a truncated 
version. NMR experiments of p65 TAD, shows a disordered region with some 
more conserved helical turns [27, 28], which correlates with the different 
rearrangements of p65 protein TAD domain when modelled with ROBETTA. 
Flexible loops do not have a conserved conformation, so this part might not have 
a defined structure, what makes really difficult to characterise the 3D structure 
of that area. Mutations stabilising the area would be a good approach to solve 
the crystal structure of that region. However, certain amino-acid mutations 
could totally disrupt the whole 3D structure of the protein. The p65 full length 
model helps to locate possible amino-acids involved in USP7 interaction. Within 
structural conformations, α-helices and β-sheets are conserved conformations, 
while loops are flexible and not conserved. The presence of the α-helix within 
the flexible loops identifies a conserved region which may be important for p65 
protein. The role of this α-helix, as it is formed by the positively charged motif 
R/KxR/KxxxR/K identified in USP7 substrates, may be essential to form the 
binding interface with USP7 protein. The full length p65 protein model helps us 
to identify possible interacting interfaces. 
On the other hand, USP7 is a 130KDa protein, which makes difficult the process 
of purification, the bigger the protein the more difficult to purify. In these 
cases, structural experiments are too cost expensive and time consuming [487]. 
For this reason, molecular modelling is the best option to combine all 
information from different techniques. The full length USP7 model takes into 
account the molecular rearrangements that USP7 undergoes upon substrate 
binding [299–301]. Therefore, it takes into account USP7 flexibility. As for p65 
protein full length model, USP7 full length model helps to identify possible 
protein-protein interaction interfaces. Furthermore, knowledge of the specific 
binding pocket identified in UBL2 makes the screening for potential inhibitory 
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compounds possible. A virtual compound screening is a useful tool in the design 
of new therapeutic drugs. Knowing the binding pocket structure, compounds can 
be identified by a steric filter and subsequently by its physicochemical 
properties. However, further research should be done on the determination of 
the amino-acids involved in the interaction and the actual structural model of 
the interaction for the development of new therapeutic specific drugs targeting 
the interface of the interaction between USP7-p65. 
The USP7-p65 models described in this chapter have been manually done. In the 
manual docking the flexibility of the molecules relies in the possible changes the 
user does on proteins. However, considering all the information about the 
interaction from the experimental data (UBL2 is required for the interaction, 
p65 is ubiquitinated, USP7 does not have specificity for a unique lysine, p65 
needs to be bound to the DNA [287]), one unique state of the interaction is not 
enough to explain the interaction mechanism with p65.  
UBL2 is involved in the substrate recognition not only of p65 but also of DNMT1, 
ICP0, UHRF1, GMPS [41, 418]. These USP7 substrates do not share a large 
homology on their sequences and subsequently on their structures. However, 
they are recognised by the same binding pocket on USP7, which recognises an 
amino-acidic pattern on substrates. For this reason the motif proposed as the 
motif recognised by USP7 is a general motif composed by a 7 amino-acids 
sequence containing 3 positively charge amino-acids in a conserved order [41, 
418]. To be a conserved pattern necessary for the interaction, the hypothesis 
would be that it is present in a conserved structural conformation. The 
crystallised structures used to understand USP7 binding pocket conformation, 
only used a peptidic sequence of each substrate. These peptidic sequences are 
rearranged as a flexible loop; thus, these 3D structures give insights on USP7 
binding pocket but not on any conserved 3D structure on substrates binding the 
pocket. Comparison of both motifs found on p65 detects a flexible loop structure 
for amino-acids 35-41 and an α-helix structure for amino-acids 295-301. It is 
more likely to form the binding site with motif 295-301 due to the presence of 
the conserved secondary structure on the motif. In this secondary structure 
positively charge amino-acids will face the binding pocket generating 
electrostatic interactions with the negatively charge amino-acids from USP7 
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binding pocket. If the motif is present in a flexible loop, flexibility of the 
molecule makes more than one conformation of the flexible loop possible to 
bind the pocket. Molecules are dynamic in nature, but the interaction interface 
is generally conserved. We hypothesised that the recognised motif is more likely 
to be present on a conserved stable structural conformation instead of being on 
a flexible loop. Therefore, we hypothesised that once the molecule forms the 
interaction, the rest of the molecule undergoes conformational rearrangements; 
flexibility would be required upon binding. 
As well as having substrate specificity, USP7 recognises ubiquitinated lysines 
within a protein. p65 protein is known to be ubiquitinated in 9 different lysines 
within its sequence [468] and USP7 is the only known DUB which deubiquitinates 
p65 [287]. This suggests a general mechanism in which USP7 is able to 
deubiquitinate different ubiquitination sites within p65. We studied the ability 
of USP7 to interact with three different ubiquitination sites of p65 when 
mutated to arginine. There is no specificity for any of the lysine, as the 
interaction level with all three mutants is the same as for the WT. Flexibility of 
USP7 C-terminal region correlates with this concept. USP7 might have a unique 
binding site for p65; once p65 binds USP7, the UBLs go through some 
conformational rearrangements to accommodate p65 K-ubiquitinated in the 
correct space to be deubiquitinated by the catalytic triad. This hypothesis 
should be studied with further experiments such as SDM to describe the unique 
binding site. This hypothesis fits with the motif 295-RHRIEEK-301 model. In the 
model the motif is bound to USP7 and most of the lysines are facing the catalytic 
triad in the area above UBL45. UBL45 have a specific role on USP7 
deubiquitinase activity. They could also have a role on accommodation of the 
specific ubiquitinated molecule in the exact site to be deubiquitinated. USP7 C-
terminal region is composed by the 5 UBL domains which form a dimeric-
monomeric-dimeric conformation. Flexibility of UBL12 is quite reduced, UBL3 
has more flexibility grades than UBL12, but it is the UBL45 dimer the one 
containing higher flexibility level. In the inactive state, UBL45 are in an open 
conformation and once the substrate binds, they get closer letting the CTP 
connect with the activation cleft. This movement could be in charge of the 
appropriate movements needed by p65 to properly fit the ubiquitinated lysine on 
the catalytic triad. Further investigation in the activation mechanism of USP7 
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should be done to surely confirm the conformational changes suffered upon p65 
binding like hydrogen/deuterium exchange experiments followed by mass 
spectrometry analysis. Hydrogen/deuterium experiments have been used to 
detect binding interfaces between two interacting proteins [505]. Besides, it has 
been described that hydrogen/deuterium exchange experiments followed by a 
mass spectrometry analysis detected structural rearrangements on viral capsids 
[506]. Thus, hydrogen/deuterium exchange experiments followed by mass 
spectrometry analysis of USP7 full length alone, p65 full length alone and USP7 
and p65 together in order to form the USP7-p65 complex could help elucidating 
the interacting mechanism of both proteins. 
Lastly, the interaction with USP7 of a DNA binding defective mutant of p65 is 
reduced [287]; however, the role of DNA on USP7-p65 binding is still unknown. 
The DNA helix could have a proper job in the interaction as it is proposed in the 
first model (ubiquitination of K62). According to this model, the double stranded 
DNA helix would make contacts with USP7 molecule and stabilise the complex. 
Or this reduction could be due to a reduction on p65 ubiquitination level on that 
DNA binding defective mutant. Further investigation on the role of DNA helix 
should be performed to confirm its active role on the interaction or its indirect 
effect.  
To summarise, we designed three different models for USP7-p65 interaction. The 
first model designed was the one based on K62 ubiquitination. This model 
identifies the DNA helix forming contacts with USP7 as well. Further 
investigation on the contribution of the DNA helix is required. This model also 
helps us to study the specificity of USP7 on ubiquitinated lysines. If USP7 
deubiquitinase activity was specific of only a ubiquitinated lysine, the model 
should be performed using that lysine as the one bound to the ubiquitin 
molecule. As we expected, USP7 has no specificity for lysines, therefore a 
binding pocket on USP7 may recognise a binding motif on p65. The last two 
models are based on two possible interactive motifs on p65, and give us more 
information for subsequent mutational experiments. Mutation of both motifs of 
p65 could give us information on the molecular determinants of p65 involved in 
the interaction. Mutational experiments on the binding pocket amino-acids of 
USP7, would allow the identification of the amino-acids involved in p65 binding. 
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Molecular modelling is a helpful tool for subsequent experiments. It gives a 
different point of view of the same question; which are the amino-acids involved 
in this interaction?  
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Chapter Seven 
General discussion  
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7 General discussion 
The main aim of this thesis was to investigate the recognition of p65 by USP7 
towards the ultimate goal of developing a p65 specific USP7 deubiquitinase 
activity inhibitor. We identified USP7 UBL2 as essential for p65 recognition and 
subsequent USP7 deubiquitinase activity in a substrate specific way.  
USP7 interacts with a wide variety of substrates by different mechanisms [418]. 
However, the main focus developing a USP7 inhibitor is based on inhibition of 
USP7 catalytic activity [445, 453]. Hence, these inhibitors would have effects in 
a plethora of biological processes [287, 407, 418]. The potential of a substrate 
based compound inhibitor means that USP7 inhibition of p65 would not affect its 
deubiquitinating activity of substrates like p53, EBNA1, DAXX and RelB. This 
significates that the pro-inflammatory role of USP7 through its p65 
deubiquitinase activity would be suppressed while its roles on viral infection 
through EBNA1 [429, 430], its roles on apoptosis, cell survival and tumourigenesis 
through p53 and DAXX [417, 423] and its anti-inflammatory properties through 
RelB would be intact. On the opposite side, targeting the interaction with p53 
for anti-cancer therapies would not affect the pro-inflammatory role of USP7. 
This new generation of USP7 inhibitors will be targeting specific roles of USP7 
instead of targeting the catalytic activity of USP7. USP7 deletion in mice has a 
lethal effect on embryos [444]; therefore, the catalytic inhibition of USP7 
activity may potentially lead to undesired consequences.  
These data also implicate that p53, EBNA1, DAXX and RelB are recognised by 
USP7 in a different way to p65 and c-Rel. p53 and EBNA1 have been identified as 
N-terminal interacting substrates [418] while p65 has been identified as a C-
terminal interacting substrate [287]. The recognition domain for RelB, DAXX and 
c-Rel has not yet been identified; however, our data suggest that RelB and DAXX 
are recognised by the N-terminal MATH/TRAF domain and c-Rel is recognised by 
the C-terminal UBL2. The majority of the structural work on USP7-substrate 
binding has been performed with peptide sequences of the substrates [41, 418]. 
These peptide sequences acquire a flexible loop conformation; hence, they are 
useful tools for USP7 binding pocket recognition, although no structural 
information on USP7 substrates is described.  
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RelB, c-Rel and p65 are members of the NF-κB family of proteins sharing high 
structural homology on their RHDs [1, 15]. Protein-protein interactions are 
driven by the different 3D structures of the proteins involved in the interaction 
[476, 485–487]; the data from this thesis show that RelB uses a different 
recognition mechanism than p65 and c-Rel in the interaction with USP7. RelB 
structurally differs from p65 and c-Rel by the presence of a LZ domain in its N-
terminal domain and a more prominent linker between the two immunoglobulin 
like domains of the RHD [1, 31]. Besides, RelB is only transcriptionally active 
when bound to p50 or p52, and drives the NF-κB transcriptional response through 
the non-canonical pathway [1]. These structural differences on its RHD might be 
the reason why RelB has a different USP7 interaction mechanism than p65 and c-
Rel. Taking this into account, USP7 might be able to distinctly regulate the pro-
inflammatory and anti-inflammatory effects of NF-κB. 
From our data, we showed that USP7ΔUBL2 does not deubiquitinate p65 as USP7 
WT does, correlating interaction inhibition with deubiquitinase activity 
inhibition. Nonetheless, the majority of the structural experiments performed on 
USP7 suggested that the flexibility of the HUBL is a requirement for its full 
catalytic activity [408]. The CD and HUBL of USP7 are connected through a 
helical turn which when shortened decreases the catalytic activity of USP7 
[300]. This helical turn is crucial for proper UBL12 location and subsequently, 
UBL45 and CTP location on the active cleft [300]. UBL3 is bound to UBL12 and 
UBL45 through flexible linkers that permit USP7 to undergo conformational 
rearrangements on the HUBL and accommodate each UBL in the correct 
structural conformation for a proper deubiquitinase activity [300, 418, 422]. 
According to these experiments, deletion of the whole UBL2 might have the 
same effect as shortening the helical turn connecting the CD and HUBL. UBL3 
would locate closer to the helical turn and the flexibility of its linkers might not 
be sufficient to accommodate the CTP on the active cleft. To further investigate 
if the deubiquitinase activity of USP7ΔUBL2 on p65 was inhibited by the 
inhibition of the interaction between USP7 and p65 or by the disruption of the 
HUBL proper structural conformation, a cellular ubiquitination assay of RelB was 
performed by Jennifer Mitchell (Carmody Group) which is described on appendix 
8.8. The data show that USP7ΔUBL2 mutant deubiquitinates RelB protein, 
confirming that p65 deubiquitination inhibition was due to an inhibition of the 
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interaction with p65. It is important to keep in mind that our data have been 
obtained from in vivo experiments, in other words from a functional cellular 
environment. This means that USP7 HUBL might be more flexible than it was 
thought, and might be able to accommodate UBL45 and the CTP to gain a full 
catalytic activity even when UBL2 is removed. 
On the other hand, we also encountered some surprising results. Most of the 
amino-acidic contacts identified on the peptide array and subsequent alanine 
scan experiments take part through USP7 UBL3 although UBL3 is not crucial for 
the interaction. This suggests that UBL3 plays a role stabilising USP7-substrate 
complexes. Previous studies identified UBL12 as the region of HUBL needed for 
substrate recognition and a functional role for UBL45, which when deleted, 
reduces the catalytic activity of USP7 [408, 418]; however, the role of UBL3 has 
not yet been defined. Our data suggest that UBL3 is important for the 
interaction of USP7 with p65, to stabilise the complex between both proteins. 
Moreover, USP7 has no specificity for any of the possible ubiquitination sites on 
p65, meaning that there is not a unique USP7-p65 complex. Depending on which 
lysine is ubiquitinated, once USP7 and p65 interact, they will undergo the 
necessary conformational rearrangements to accommodate the ubiquitinated 
lysine in the proper location for the catalytic triad to be able to deubiquitinate 
it. These data suggest that USP7 has a unique p65 recognition mechanism and 
depending on the structural rearrangements undertaken by the complex, USP7 
would deubiquitinate each specific lysine. Following this result, we defined USP7 
amino-acids 627-ARSNGTK-633, 736-EEVKPNLTER-745 and 757-LDELMDGD-764 as 
a potential USP7 binding pocket for p65 recognition, which recognises a 
positively charged pattern on p65 (R/KxR/KxxxR/K). In this way, we discovered 
two possible motifs on p65 sequence. The first motif, 35-RYKCECR-41, is 
composed by a flexible loop, and the second motif, 295-RHRIEEK-301, is not 
present on available 3D structures. If the interaction mechanism is conserved by 
different substrates as our data suggest, the binding interface has to be 
composed by conserved structural regions. When modelling the  full length p65 
protein, the disordered TAD 295-RHRIEEK-301 was placed on a conserved α-helix 
secondary structure. This location suggests that 295-RHRIEEK-301 is more likely 
to be the pattern recognised by USP7 binding pocket. Besides, the α-helix 
conformation will face the positively charged amino-acids on the pattern 
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towards the USP7 binding pocket and the negatively charged amino-acids facing 
the opposite direction. These unexpected results have important implications on 
the explanation of USP7-p65 interaction. This mechanism is in turn more 
complicated than we initially thought, and likely explains why a p65 mimetic 
peptide strategy was not sufficient to inhibit the interaction. 
Although we identified UBL2 as the UBL regulating p65 interaction, further 
investigation is required to develop a p65-specific USP7 inhibitor. Based on our 
binding pocket identification, a virtual compound screening could be performed. 
The compound screening would firstly filter compounds by their steric 
conformation, and those who fit in the binding pocket would then be filtered 
according to their physicochemical properties. The selected compounds could be 
tested in in vivo inflammatory models to study their effect on the pro-
inflammatory role of NF-κB. At the same time, mutational analysis on both p65 
and USP7 proteins would be useful to identify the contribution of USP7 binding 
pocket (627-ARSNGTK-633, 736-EEVKPNLTER-745 and 757-LDELMDGD-764) and 
p65 motifs (35-RYKCECR-41 and 295-RHRIEEK-301) to the interaction. On the 
other hand, immunoprecipitation assays with different substrates, which have 
not been tested already, could be performed to analyse the possibility of 
substrate specificity. As for the role of USP7 inhibition on different NF-κB 
members, repression of the transcriptional activity of NF-κB members could be 
tested by a promoter activity reporter assay. 
Together the data presented in this thesis demonstrate that USP7 specific roles 
on different biological processes could be specifically targeted. In addition to 
identification of USP7 UBL2 as the domain regulating p65 interaction, we 
described substrate selectivity even between NF-κB members. Deletion of USP7 
UBL2 targets p65 along with c-Rel; therefore, it just inhibits the pro-
inflammatory role of the NF-κB response. Furthermore, the identification of a 
potential USP7 binding pocket provides an excellent basis for a virtual compound 
screening to identify inhibitors specific for the inhibition of p65 deubiquitination 
by USP7.  
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8 Appendixes 
8.1 Amino-acids abbreviations 
Alanine  Ala A  
Arginine  Arg R  
Asparagine  Asn N  
Aspartic acid  Asp D  
Cysteine  Cys C  
Glutamine  Gln Q  
Glutamic acid Glu E  
Glycine  Gly G  
Histidine  His H  
Isoleucine  Ile I  
Leucine  Leu L  
Lysine   Lys K  
Methionine  Met M  
Phenylalanine Phe F  
Proline  Pro P  
Serine   Ser S  
Threonine  Thr T  
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Tryptophan  Trp W  
Tyrosine  Tyr Y  
Valine   Val V   
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8.2 Cloning 
Primers amplifying p65 protein were designed (see Table 2-14). p65 protein 
cDNA was amplified by PCR, gel extracted and purified. Amplified cDNA 
following digestion by the correspondent restriction enzymes was ligated into 
the new empty vector (see section 2.2.7). To study the success of the cloning 
strategy, several colonies resulted from the transformation of the ligation 
product were amplified by PCR and subsequently sequenced. Successful cloned 
plasmids were selected for subsequent experiments. See Figure 8-1. 
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Figure 8-1 p65 WT and mutants cloning into an empty pCDNA3.1 expression vector. A) 
pCDNA3.1 expression vector map (Plasmid map from Addgene, Cambridge, USA). B) PCR 
amplification of p65 protein (WT (human and mouse) and mutants (mouse)). B) p65 protein PCR 
amplification product. C) p65 protein and pCDNA3.1 empty vector digestion product by the 
enzymes XbaI and HindIII. D) Ligation product colony PCR for each of the new cloned plasmids. 
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8.3 Peptide array sequences 
Sequences of the peptide arrays used for USP7 C-terminal peptide array 
experiment (see Table 8-1). 
Table 8-1 Peptide array sequences. 
 
Name Sequence Location 
A1 VERLQEEKRIEAQKRKER 541-558 
A2 QEEKRIEAQKRKERQEAH 545-562 
A3 RIEAQKRKERQEAHLYMQ 549-566 
A4 QKRKERQEAHLYMQVQIV 553-570 
A5 ERQEAHLYMQVQIVAEDQ 557-574 
A6 AHLYMQVQIVAEDQFCGH 561-578 
A7 MQVQIVAEDQFCGHQGND 565-582 
A8 IVAEDQFCGHQGNDMYDE 569-586 
A9 DQFCGHQGNDMYDEEKVK 573-590 
A10 GHQGNDMYDEEKVKYTVF 577-594 
A11 NDMYDEEKVKYTVFKVLK 581-598 
A12 DEEKVKYTVFKVLKNSSL 585-602 
A13 VKYTVFKVLKNSSLAEFV 589-606 
A14 VFKVLKNSSLAEFVQSLS 593-610 
A15 LKNSSLAEFVQSLSQTMG 597-614 
A16 SLAEFVQSLSQTMGFPQD 601-618 
A17 FVQSLSQTMGFPQDQIRL 605-622 
A18 LSQTMGFPQDQIRLWPMQ 609-626 
A19 MGFPQDQIRLWPMQARSN 613-630 
A20 QDQIRLWPMQARSNGTKR 617-634 
A21 RLWPMQARSNGTKRPAML 621-638 
A22 MQARSNGTKRPAMLDNEA 625-642 
A23 SNGTKRPAMLDNEADGNK 629-646 
A24 KRPAMLDNEADGNKTMIE 633-650 
A25 MLDNEADGNKTMIELSDN 637-654 
A26 EADGNKTMIELSDNENPW 641-658 
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Name Sequence Location 
A27 NKTMIELSDNENPWTIFL 645-662 
A28 IELSDNENPWTIFLETVD 649-666 
A29 DNENPWTIFLETVDPELA 653-670 
A30 PWTIFLETVDPELAASGA 657-674 
B1 FLETVDPELAASGATLPK 661-678 
B2 VDPELAASGATLPKFDKD 665-682 
B3 LAASGATLPKFDKDHDVM 669-686 
B4 GATLPKFDKDHDVMLFLK 673-690 
B5 PKFDKDHDVMLFLKMYDP 677-694 
B6 KDHDVMLFLKMYDPKTRS 681-698 
B7 VMLFLKMYDPKTRSLNYC 685-702 
B8 LKMYDPKTRSLNYCGHIY 689-706 
B9 DPKTRSLNYCGHIYTPIS 693-710 
B10 RSLNYCGHIYTPISCKIR 697-714 
B11 YCGHIYTPISCKIRDLLP 701-718 
B12 YTPISCKIRDLLPVMCD 706-722 
B13 ISCKIRDLLPVMCDRAGF 709-726 
B14 IRDLLPVMCDRAGFIQDT 713-730 
B15 LPVMCDRAGFIQDTSLIL 717-734 
B16 CDRAGFIQDTSLILYEEV 721-738 
B17 GFIQDTSLILYEEVKPNL 725-742 
B18 DTSLILYEEVKPNLTERI 729-746 
B19 ILYEEVKPNLTERIQDYD 733-750 
B20 EVKPNLTERIQDYDVSLD 737-754 
B21 NLTERIQDYDVSLDKALD 741-758 
B22 RIQDYDVSLDKALDELMD 745-762 
B23 YDVSLDKALDELMDGDII 749-766 
B24 LDKALDELMDGDIIVFQK 753-770 
B25 LDELMDGDIIVFQKDDPE 757-774 
B26 MDGDIIVFQKDDPENDNS 761-778 
B27 IIVFQKDDPENDNSELPT 765-782 
B28 QKDDPENDNSELPTAKEY 769-786 
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Name Sequence Location 
B29 PENDNSELPTAKEYFRDL 773-790 
B30 NSELPTAKEYFRDLYHRV 777-794 
C1 PTAKEYFRDLYHRVDVIF 781-798 
C2 EYFRDLYHRVDVIFCDKT 785-802 
C3 DLYHRVDVIFCDKTIPND 789-806 
C4 RVDVIFCDKTIPNDPGFV 793-810 
C5 IFCDKTIPNDPGFVVTLS 797-814 
C6 KTIPNDPGFVVTLSNRMN 801-817 
C7 NDPGFVVTLSNRMNYFQV 805-822 
C8 FVVTLSNRMNYFQVAKTV 809-826 
C9 LSNRMNYFQVAKTVAQRL 813-830 
C10 MNYFQVAKTVAQRLNTDP 817-834 
C11 QVAKTVAQRLNTDPMLLQ 821-838 
C12 TVAQRLNTDPMLLQFFKS 825-842 
C13 RLNTDPMLLQFFKSQGYR 829-846 
C14 DPMLLQFFKSQGYRDGPG 833-850 
C15 LQFFKSQGYRDGPGNPLR 837-854 
C16 KSQGYRDGPGNPLRHNYE 841-858 
C17 YRDGPGNPLRHNYEGTLR 845-862 
C18 PGNPLRHNYEGTLRDLLQ 849-866 
C19 LRHNYEGTLRDLLQFFKP 853-870 
C20 YEGTLRDLLQFFKPRQPK 857-874 
C21 LRDLLQFFKPRQPKKLYY 861-878 
C22 LQFFKPRQPKKLYYQQLK 865-882 
C23 KPRQPKKLYYQQLKMKIT 869-886 
C24 PKKLYYQQLKMKITDFEN 873-890 
C25 YYQQLKMKITDFENRRSF 877-894 
C26 LKMKITDFENRRSFKCIW 881-898 
C27 ITDFENRRSFKCIWLNSQ 885-902 
C28 ENRRSFKCIWLNSQFREE 889-906 
C29 SFKCIWLNSQFREEEITL 893-910 
C30 IWLNSQFREEEITLYPDK 897-914 
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Name Sequence Location 
D1 SQFREEEITLYPDKHGCV 901-918 
D2 EEEITLYPDKHGCVRDLL 905-922 
D3 TLYPDKHGCVRDLLEECK 909-926 
D4 DKHGCVRDLLEECKKAVE 913-930 
D5 CVRDLLEECKKAVELGEK 917-934 
D6 LLEECKKAVELGEKASGK 921-938 
D7 CKKAVELGEKASGKLRLL 925-942 
D8 VELGEKASGKLRLLEIVS 929-946 
D9 EKASGKLRLLEIVSYKII 933-950 
D10 GKLRLLEIVSYKIICLSP N/A 
D11 LLEIVSYKIICLSPATSR N/A 
D12 VSYKIICLSPATSRTFRI N/A 
D13 IICLSPATSRTFRIEEIP N/A 
D14 SPATSRTFRIEEIPLDQV 963-980 
D15 SRTFRIEEIPLDQVDIDK 967-984 
D16 RIEEIPLDQVDIDKENEM 971-988 
D17 IPLDQVDIDKENEMLVTV 975-992 
D18 QVDIDKENEMLVTVAHFH 979-996 
D19 DKENEMLVTVAHFHKEVF 983-1000 
D20 EMLVTVAHFHKEVFGTFG 987-1004 
D21 TVAHFHKEVFGTFGIPFL 991-1008 
D22 FHKEVFGTFGIPFLLRIH 995-1012 
D23 VFGTFGIPFLLRIHQGEH 999-1016 
D24 FGIPFLLRIHQGEHFREV 1003-1020 
D25 FLLRIHQGEHFREVMKRI 1007-1024 
D26 IHQGEHFREVMKRIQSLL 1011-1028 
D27 EHFREVMKRIQSLLDIQE 1015-1032 
D28 EVMKRIQSLLDIQEKEFE 1019-1036 
D29 RIQSLLDIQEKEFEKFKF 1023-1040 
D30 LLDIQEKEFEKFKFAIVM 1027-1044 
E1 QEKEFEKFKFAIVMMGRH 1031-1048 
E2 FEKFKFAIVMMGRHQYIN 1035-1052 
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Name Sequence Location 
E3 KFAIVMMGRHQYINEDEY 1039-1056 
E4 VMMGRHQYINEDEYEVNL 1043-1060 
E5 RHQYINEDEYEVNLKDFE 1047-1064 
E6 INEDEYEVNLKDFEPQPG 1051-1068 
E7 EYEVNLKDFEPQPGNMSH 1055-1072 
E8 NLKDFEPQPGNMSHPRPW 1059-1076 
E9 FEPQPGNMSHPRPWLGLD 1063-1080 
E10 PGNMSHPRPWLGLDHFNK 1067-1084 
E11 SHPRPWLGLDHFNKAPKR 1071-1088 
E12 PWLGLDHFNKAPKRSRYT 1075-1092 
E13 LDHFNKAPKRSRYTYLEK 1079-1096 
E14 NKAPKRSRYTYLEKAIKI 1083-1100 
E15 APKRSRYTYLEKAIKIH 1085-1101 
F1 ASGKLRLLEIVSYKIIGV 935-952 
F2 LRLLEIVSYKIIGVHQED 939-956 
F3 EIVSYKIIGVHQEDELLE 943-960 
F4 YKIIGVHQEDELLECLSP 947-964 
F5 GVHQEDELLECLSPATSR 951-968 
F6 EDELLECLSPATSRTFRI 955-972 
F7 LECLSPATSRTFRIEEIP 959-976 
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8.4 Alanine scanning peptide array sequences 
Sequences of the peptide arrays used for the alanine scanning peptide array 
experiment (see Table 8-2). 
Table 8-2 Alanine scanning peptide array sequences. 
 
Peptide Location Sequence 
A11 1 NDMYDEEKVKYTVFKVLK 
A11 2 ADMYDEEKVKYTVFKVLK 
A11 3 NAMYDEEKVKYTVFKVLK 
A11 4 NDAYDEEKVKYTVFKVLK 
A11 5 NDMADEEKVKYTVFKVLK 
A11 6 NDMYAEEKVKYTVFKVLK 
A11 7 NDMYDAEKVKYTVFKVLK 
A11 8 NDMYDEAKVKYTVFKVLK 
A11 9 NDMYDEEAVKYTVFKVLK 
A11 10 NDMYDEEKAKYTVFKVLK 
A11 11 NDMYDEEKVAYTVFKVLK 
A11 12 NDMYDEEKVKATVFKVLK 
A11 13 NDMYDEEKVKYAVFKVLK 
A11 14 NDMYDEEKVKYTAFKVLK 
A11 15 NDMYDEEKVKYTVAKVLK 
A11 16 NDMYDEEKVKYTVFAVLK 
A11 17 NDMYDEEKVKYTVFKALK 
A11 18 NDMYDEEKVKYTVFKVAK 
A11 19 NDMYDEEKVKYTVFKVLA 
A20 1 QDQIRLWPMQARSNGTKR 
A20 2 ADQIRLWPMQARSNGTKR 
A20 3 QAQIRLWPMQARSNGTKR 
A20 4 QDAIRLWPMQARSNGTKR 
A20 5 QDQARLWPMQARSNGTKR 
A20 6 QDQIALWPMQARSNGTKR 
A20 7 QDQIRAWPMQARSNGTKR 
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Peptide Location Sequence 
A20 8 QDQIRLAPMQARSNGTKR 
A20 9 QDQIRLWAMQARSNGTKR 
A20 10 QDQIRLWPAQARSNGTKR 
A20 11 QDQIRLWPMAARSNGTKR 
A20 12 QDQIRLWPMQARSNGTKR 
A20 13 QDQIRLWPMQAASNGTKR 
A20 14 QDQIRLWPMQARANGTKR 
A20 15 QDQIRLWPMQARSAGTKR 
A20 16 QDQIRLWPMQARSNATKR 
A20 17 QDQIRLWPMQARSNGAKR 
A20 18 QDQIRLWPMQARSNGTAR 
A20 19 QDQIRLWPMQARSNGTKA 
A23 1 SNGTKRPAMLDNEADGNK 
A23 2 ANGTKRPAMLDNEADGNK 
A23 3 SAGTKRPAMLDNEADGNK 
A23 4 SNATKRPAMLDNEADGNK 
A23 5 SNGAKRPAMLDNEADGNK 
A23 6 SNGTARPAMLDNEADGNK 
A23 7 SNGTKAPAMLDNEADGNK 
A23 8 SNGTKRAAMLDNEADGNK 
A23 9 SNGTKRPAMLDNEADGNK 
A23 10 SNGTKRPAALDNEADGNK 
A23 11 SNGTKRPAMADNEADGNK 
A23 12 SNGTKRPAMLANEADGNK 
A23 13 SNGTKRPAMLDAEADGNK 
A23 14 SNGTKRPAMLDNAADGNK 
A23 15 SNGTKRPAMLDNEADGNK 
A23 16 SNGTKRPAMLDNEAAGNK 
A23 17 SNGTKRPAMLDNEADANK 
A23 18 SNGTKRPAMLDNEADGAK 
A23 19 SNGTKRPAMLDNEADGNA 
B24 1 LDKALDELMDGDIIVFQK 
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Peptide Location Sequence 
B24 2 ADKALDELMDGDIIVFQK 
B24 3 LAKALDELMDGDIIVFQK 
B24 4 LDAALDELMDGDIIVFQK 
B24 5 LDKALDELMDGDIIVFQK 
B24 6 LDKAADELMDGDIIVFQK 
B24 7 LDKALAELMDGDIIVFQK 
B24 8 LDKALDALMDGDIIVFQK 
B24 9 LDKALDEAMDGDIIVFQK 
B24 10 LDKALDELADGDIIVFQK 
B24 11 LDKALDELMAGDIIVFQK 
B24 12 LDKALDELMDADIIVFQK 
B24 13 LDKALDELMDGAIIVFQK 
B24 14 LDKALDELMDGDAIVFQK 
B24 15 LDKALDELMDGDIAVFQK 
B24 16 LDKALDELMDGDIIAFQK 
B24 17 LDKALDELMDGDIIVAQK 
B24 18 LDKALDELMDGDIIVFAK 
B24 19 LDKALDELMDGDIIVFQA 
C13 1 RLNTDPMLLQFFKSQGYR 
C13 2 ALNTDPMLLQFFKSQGYR 
C13 3 RANTDPMLLQFFKSQGYR 
C13 4 RLATDPMLLQFFKSQGYR 
C13 5 RLNADPMLLQFFKSQGYR 
C13 6 RLNTAPMLLQFFKSQGYR 
C13 7 RLNTDAMLLQFFKSQGYR 
C13 8 RLNTDPALLQFFKSQGYR 
C13 9 RLNTDPMALQFFKSQGYR 
C13 10 RLNTDPMLAQFFKSQGYR 
C13 11 RLNTDPMLLAFFKSQGYR 
C13 12 RLNTDPMLLQAFKSQGYR 
C13 13 RLNTDPMLLQFAKSQGYR 
C13 14 RLNTDPMLLQFFASQGYR 
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Peptide Location Sequence 
C13 15 RLNTDPMLLQFFKAQGYR 
C13 16 RLNTDPMLLQFFKSAGYR 
C13 17 RLNTDPMLLQFFKSQAYR 
C13 18 RLNTDPMLLQFFKSQGAR 
C13 19 RLNTDPMLLQFFKSQGYA 
C15 1 LQFFKSQGYRDGPGNPLR 
C15 2 AQFFKSQGYRDGPGNPLR 
C15 3 LAFFKSQGYRDGPGNPLR 
C15 4 LQAFKSQGYRDGPGNPLR 
C15 5 LQFAKSQGYRDGPGNPLR 
C15 6 LQFFASQGYRDGPGNPLR 
C15 7 LQFFKAQGYRDGPGNPLR 
C15 8 LQFFKSAGYRDGPGNPLR 
C15 9 LQFFKSQAYRDGPGNPLR 
C15 10 LQFFKSQGARDGPGNPLR 
C15 11 LQFFKSQGYADGPGNPLR 
C15 12 LQFFKSQGYRAGPGNPLR 
C15 13 LQFFKSQGYRDAPGNPLR 
C15 14 LQFFKSQGYRDGAGNPLR 
C15 15 LQFFKSQGYRDGPANPLR 
C15 16 LQFFKSQGYRDGPGAPLR 
C15 17 LQFFKSQGYRDGPGNALR 
C15 18 LQFFKSQGYRDGPGNPAR 
C15 19 LQFFKSQGYRDGPGNPLA 
C17 1 YRDGPGNPLRHNYEGTLR 
C17 2 ARDGPGNPLRHNYEGTLR 
C17 3 YADGPGNPLRHNYEGTLR 
C17 4 YRAGPGNPLRHNYEGTLR 
C17 5 YRDAPGNPLRHNYEGTLR 
C17 6 YRDGAGNPLRHNYEGTLR 
C17 7 YRDGPANPLRHNYEGTLR 
C17 8 YRDGPGAPLRHNYEGTLR 
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Peptide Location Sequence 
C17 9 YRDGPGNALRHNYEGTLR 
C17 10 YRDGPGNPARHNYEGTLR 
C17 11 YRDGPGNPLAHNYEGTLR 
C17 12 YRDGPGNPLRANYEGTLR 
C17 13 YRDGPGNPLRHAYEGTLR 
C17 14 YRDGPGNPLRHNAEGTLR 
C17 15 YRDGPGNPLRHNYAGTLR 
C17 16 YRDGPGNPLRHNYEATLR 
C17 17 YRDGPGNPLRHNYEGALR 
C17 18 YRDGPGNPLRHNYEGTAR 
C17 19 YRDGPGNPLRHNYEGTLA 
C20 1 YEGTLRDLLQFFKPRQPK 
C20 2 AEGTLRDLLQFFKPRQPK 
C20 3 YAGTLRDLLQFFKPRQPK 
C20 4 YEATLRDLLQFFKPRQPK 
C20 5 YEGALRDLLQFFKPRQPK 
C20 6 YEGTARDLLQFFKPRQPK 
C20 7 YEGTLADLLQFFKPRQPK 
C20 8 YEGTLRALLQFFKPRQPK 
C20 9 YEGTLRDALQFFKPRQPK 
C20 10 YEGTLRDLAQFFKPRQPK 
C20 11 YEGTLRDLLAFFKPRQPK 
C20 12 YEGTLRDLLQAFKPRQPK 
C20 13 YEGTLRDLLQFAKPRQPK 
C20 14 YEGTLRDLLQFFAPRQPK 
C20 15 YEGTLRDLLQFFKARQPK 
C20 16 YEGTLRDLLQFFKPAQPK 
C20 17 YEGTLRDLLQFFKPRAPK 
C20 18 YEGTLRDLLQFFKPRQAK 
C20 19 YEGTLRDLLQFFKPRQPA 
C25 1 YYQQLKMKITDFENRRSF 
C25 2 AYQQLKMKITDFENRRSF 
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Peptide Location Sequence 
C25 3 YAQQLKMKITDFENRRSF 
C25 4 YYAQLKMKITDFENRRSF 
C25 5 YYQALKMKITDFENRRSF 
C25 6 YYQQAKMKITDFENRRSF 
C25 7 YYQQLAMKITDFENRRSF 
C25 8 YYQQLKAKITDFENRRSF 
C25 9 YYQQLKMAITDFENRRSF 
C25 10 YYQQLKMKATDFENRRSF 
C25 11 YYQQLKMKIADFENRRSF 
C25 12 YYQQLKMKITAFENRRSF 
C25 13 YYQQLKMKITDAENRRSF 
C25 14 YYQQLKMKITDFANRRSF 
C25 15 YYQQLKMKITDFEARRSF 
C25 16 YYQQLKMKITDFENARSF 
C25 17 YYQQLKMKITDFENRASF 
C25 18 YYQQLKMKITDFENRRAF 
C25 19 YYQQLKMKITDFENRRSA 
C30 1 IWLNSQFREEEITLYPDK 
C30 2 AWLNSQFREEEITLYPDK 
C30 3 IALNSQFREEEITLYPDK 
C30 4 IWANSQFREEEITLYPDK 
C30 5 IWLASQFREEEITLYPDK 
C30 6 IWLNAQFREEEITLYPDK 
C30 7 IWLNSAFREEEITLYPDK 
C30 8 IWLNSQAREEEITLYPDK 
C30 9 IWLNSQFAEEEITLYPDK 
C30 10 IWLNSQFRAEEITLYPDK 
C30 11 IWLNSQFREAEITLYPDK 
C30 12 IWLNSQFREEAITLYPDK 
C30 13 IWLNSQFREEEATLYPDK 
C30 14 IWLNSQFREEEIALYPDK 
C30 15 IWLNSQFREEEITAYPDK 
253 
 
Peptide Location Sequence 
C30 16 IWLNSQFREEEITLAPDK 
C30 17 IWLNSQFREEEITLYADK 
C30 18 IWLNSQFREEEITLYPAK 
C30 19 IWLNSQFREEEITLYPDA 
D15 1 SRTFRIEEIPLDQVDIDK 
D15 2 ARTFRIEEIPLDQVDIDK 
D15 3 SATFRIEEIPLDQVDIDK 
D15 4 SRAFRIEEIPLDQVDIDK 
D15 5 SRTARIEEIPLDQVDIDK 
D15 6 SRTFAIEEIPLDQVDIDK 
D15 7 SRTFRAEEIPLDQVDIDK 
D15 8 SRTFRIAEIPLDQVDIDK 
D15 9 SRTFRIEAIPLDQVDIDK 
D15 10 SRTFRIEEAPLDQVDIDK 
D15 11 SRTFRIEEIALDQVDIDK 
D15 12 SRTFRIEEIPADQVDIDK 
D15 13 SRTFRIEEIPLAQVDIDK 
D15 14 SRTFRIEEIPLDAVDIDK 
D15 15 SRTFRIEEIPLDQADIDK 
D15 16 SRTFRIEEIPLDQVAIDK 
D15 17 SRTFRIEEIPLDQVDADK 
D15 18 SRTFRIEEIPLDQVDIAK 
D15 19 SRTFRIEEIPLDQVDIDA 
D25 1 FLLRIHQGEHFREVMKRI 
D25 2 ALLRIHQGEHFREVMKRI 
D25 3 FALRIHQGEHFREVMKRI 
D25 4 FLARIHQGEHFREVMKRI 
D25 5 FLLAIHQGEHFREVMKRI 
D25 6 FLLRAHQGEHFREVMKRI 
D25 7 FLLRIAQGEHFREVMKRI 
D25 8 FLLRIHAGEHFREVMKRI 
D25 9 FLLRIHQAEHFREVMKRI 
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Peptide Location Sequence 
D25 10 FLLRIHQGAHFREVMKRI 
D25 11 FLLRIHQGEAFREVMKRI 
D25 12 FLLRIHQGEHAREVMKRI 
D25 13 FLLRIHQGEHFAEVMKRI 
D25 14 FLLRIHQGEHFRAVMKRI 
D25 15 FLLRIHQGEHFREAMKRI 
D25 16 FLLRIHQGEHFREVAKRI 
D25 17 FLLRIHQGEHFREVMARI 
D25 18 FLLRIHQGEHFREVMKAI 
D25 19 FLLRIHQGEHFREVMKRA 
E10 1 PGNMSHPRPWLGLDHFNK 
E10 2 AGNMSHPRPWLGLDHFNK 
E10 3 PANMSHPRPWLGLDHFNK 
E10 4 PGAMSHPRPWLGLDHFNK 
E10 5 PGNASHPRPWLGLDHFNK 
E10 6 PGNMAHPRPWLGLDHFNK 
E10 7 PGNMSAPRPWLGLDHFNK 
E10 8 PGNMSHARPWLGLDHFNK 
E10 9 PGNMSHPAPWLGLDHFNK 
E10 10 PGNMSHPRAWLGLDHFNK 
E10 11 PGNMSHPRPALGLDHFNK 
E10 12 PGNMSHPRPWAGLDHFNK 
E10 13 PGNMSHPRPWLALDHFNK 
E10 14 PGNMSHPRPWLGADHFNK 
E10 15 PGNMSHPRPWLGLAHFNK 
E10 16 PGNMSHPRPWLGLDAFNK 
E10 17 PGNMSHPRPWLGLDHANK 
E10 18 PGNMSHPRPWLGLDHFAK 
E10 19 PGNMSHPRPWLGLDHFNA 
E15 1 APKRSRYTYLEKAIKIH 
E15 2 APKRSRYTYLEKAIKIH 
E15 3 AAKRSRYTYLEKAIKIH 
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Peptide Location Sequence 
E15 4 APARSRYTYLEKAIKIH 
E15 5 APKASRYTYLEKAIKIH 
E15 6 APKRARYTYLEKAIKIH 
E15 7 APKRSAYTYLEKAIKIH 
E15 8 APKRSRATYLEKAIKIH 
E15 9 APKRSRYAYLEKAIKIH 
E15 10 APKRSRYTALEKAIKIH 
E15 11 APKRSRYTYAEKAIKIH 
E15 12 APKRSRYTYLAKAIKIH 
E15 13 APKRSRYTYLEAAIKIH 
E15 14 APKRSRYTYLEKAIKIH 
E15 15 APKRSRYTYLEKAAKIH 
E15 16 APKRSRYTYLEKAIAIH 
E15 17 APKRSRYTYLEKAIKAH 
E15 18 APKRSRYTYLEKAIKIA 
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8.5 Structural model of USP7-p65 complex based 
mutants 
Structural model designed during a stay at AstraZeneca Sweden with the help 
and in collaboration with Dr Matti Lepistӧ and Dr Christian Tyrchan. In this model 
UBL1 and UBL2 from USP7 make direct contacts with p65 protein (see Figure 
8-2). 
 
Figure 8-2 USP7-p65 complex structural model. Structural model of the interaction generated 
during a stay at AstraZeneca Sweden with the help of Dr Christian Tyrchan and Dr Matti Lepistӧ. 
Direct contacts between UBL1 and UBL2 of USP7 with p65. USP7 is coloured in red, ubiquitin in 
green, p65 in blue, p50 in purple and the DNA helix in yellow and pink. 
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8.6 NF-κB members sequence homology for K56, K62 
and K123 of p65 
Sequence homology in the amino-acids surrounding K56 residue shared by the 
NF-κB members (see Table 8-3), K62 residue (see Table 8-4) and K123 residue 
(see Table 8-5). Amino-acids coloured in red represents homology within 
subunits; amino-acids in blue, homology between some subunits but no with p65; 
amino-acids in green, homology between negatively charged amino-acids; and 
maroon, homology between positively charged amino-acids. 
Table 8-3 p65 K56 sequence homology within NF-κB members. 
 
Subunit      K56     
p65 S T F T T K T H P T 
c-Rel S T D N N K T F P S 
RelB S T E A S K T Q P A 
p52 S E K G R K T Y P T 
p50 S E K N K K S Y P Q 
 
Table 8-4 p65 K62 sequence homology within NF-κB members. 
 
Subunit      K62    
p65 T H P T I K I N G 
c-Rel T F P S I Q I L N 
RelB T Q P A I E L R D 
p52 T Y P T V K I C N 
p50 S Y P Q V K I C N 
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Table 8-5 p65 K123 sequence homology within NF-κB members. 
 
Subunit     K123     
p65 Q C V K K R D L E 
c-Rel Q C V K K K D L K 
RelB Q C V R K K E I E 
p52 L H V T K K N M M 
p50 L H V T K K K V F 
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8.7 R/KxR/KxxxR/K motif identification within different 
USP7 substrates’ sequences 
Identification of R/KxR/KxxxR/K positively charged motifs within different USP7 
substrates’ sequence through Geneious software (see Figure 8-3).  
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Figure 8-3 R/KxR/KxxxR/K motif presence on USP7 different substrates’ sequences. Location 
on the sequence of UHRF1, ICP0 and DNMT1 proteins of R/KxR/KxxxR/K motifs. Sequences were 
analysed with Geneius Software. 
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8.8 RelB ubiquitination assay 
RelB ubiquitination assay was performed by Jennifer Mitchell (Carmody Group). 
To study the effect of UBL2 deletion of USP7 deubiquitinase activity on a 
different substrate than p65 we selected RelB NF-κB member. RelB shares 
homology with p65 but is still able to interact with USP7ΔUBL2. A cellular 
ubiquitination assay with USP7 WT and USP7ΔUBL2 mutant was performed. In 
order to be able to detect RelB ubiquitination status, HEK293T cells were co-
transfected with USP7 WT and USP7ΔUBL2 FLAG-tagged plasmids along with RelB 
and ubiquitin-HA plasmids. 
Cellular lysates from the co-transfected HEK293T cells were denatured prior to 
immunoprecipitated with an anti-RelB antibody and immunoblotted with anti- 
RelB and anti-HA antibodies (see Figure 8-4). In contrast to USP7ΔUBL2 inability 
to deubiquitinate p65, USP7ΔUBL2 deubiquitinates RelB protein (see Figure 8-4). 
These data further support the requirement of interaction with the substrate in 
order to regulate substrate deubiquitination. 
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Figure 8-4 USP7ΔUBL2 mutant deubiquitinates RelB protein. HEK293T cells were co-
transfected with USP7 WT and USP7ΔUBL2 FLAG-tagged plasmids along with RelB and Ubiquitin-
HA plasmids. Cellular lysates were immunoprecipitated with RelB antibody and immunoblotted with 
HA-tag and USP7 and RelB proteins antibodies. Deletion of UBL2 has no impact on USP7 ability to 
deubiquitinate RelB protein. The figure is a representative of three independent experiments. RelB 
ubiquitination assay was performed by Jennifer Mitchell (Carmody Group). 
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